Cystic fibrosis gene repair: correction of ΔF508 using ZFN and CRISPR/Cas9 guide RNA gene editing tools by Hollywood, Jennifer A.
Title Cystic fibrosis gene repair: correction of ΔF508 using ZFN and
CRISPR/Cas9 guide RNA gene editing tools
Author(s) Hollywood, Jennifer
Publication date 2013
Original citation Hollywood, J. 2013. Cystic fibrosis gene repair: correction of ΔF508
using ZFN and CRISPR/Cas9 guide RNA gene editing tools. PhD
Thesis, University College Cork.
Type of publication Doctoral thesis
Rights © 2013, Jennifer Hollywood
http://creativecommons.org/licenses/by-nc-nd/3.0/
Item downloaded
from
http://hdl.handle.net/10468/1407
Downloaded on 2017-02-12T06:54:29Z
 Thesis submitted for the degree of Ph.D. to the National University of Ireland, Cork 
 
 
 
 
 
 
 
 
 
Department of Physiology & Department of Microbiology 
Heads of Department: Prof. Ken O‟ Halloran, Prof. Ger Fitzgerald 
Research Supervisors: Dr. Patrick Harrison, Dr. Martina Scallan 
Submitted October 2013
 
Cystic fibrosis gene repair: Correction of 
ΔF508 using ZFN and CRISPR/Cas9 guide 
RNA gene editing tools 
 
Jennifer Hollywood B.Sc. 
 i 
 
 
Table of Contents 
 
Abstract ..................................................................................................................... x 
Abbreviations .......................................................................................................... xi 
1 Introduction ....................................................................................................... 1 
1.1 Cystic Fibrosis ............................................................................................. 1 
1.1.1 A brief history ...................................................................................... 1 
1.1.2 Cloning of the gene .............................................................................. 2 
1.1.3 Cystic Fibrosis Transmembrane Regulator .......................................... 3 
1.1.4 Airway Surface Liquid (ASL) regulation ............................................ 5 
1.1.5 CF today ............................................................................................... 6 
1.1.6 Diagnosis .............................................................................................. 7 
1.1.7 Bacterial Infections and Inflammation ................................................. 7 
1.2 CF Mutations ............................................................................................. 10 
1.2.1 Mutations and classification ............................................................... 10 
1.2.2 Mutations and disease severity........................................................... 12 
1.2.3 ΔF508 ................................................................................................. 14 
1.3 Mutation Specific Therapies ..................................................................... 14 
1.3.1 Aminoglycosides for Premature Stop Codons ................................... 14 
1.3.2 Correctors ........................................................................................... 15 
1.3.3 Potentiators ......................................................................................... 16 
1.3.4 Lung tissue engineering ..................................................................... 17 
1.4 Gene Therapy for CF ................................................................................. 18 
1.4.1 CF: A good and bad candidate for gene therapy ................................ 18 
1.4.2 Which cells/ part of the lung to target? .............................................. 20 
 ii 
 
1.4.3 Efficacy is difficult to detect .............................................................. 21 
1.4.4 Animal models to study the disease ................................................... 21 
1.4.5 CF gene therapy to date...................................................................... 22 
1.5 Gene addition vs Gene repair .................................................................... 27 
1.6 Genome editing ......................................................................................... 29 
1.6.1 DNA repair mechanisms .................................................................... 29 
1.6.2 Homologous Recombination .............................................................. 31 
1.6.3 Single Strand Annealing .................................................................... 32 
1.6.4 Non-Homologous End Joining ........................................................... 32 
1.6.5 Regulation of repair pathway choice ................................................. 33 
1.6.6 Homology-directed repair (HDR) ...................................................... 34 
1.7 ZFN, TALEN and CRISPR/Cas-based tools for genome editing ............. 37 
1.7.1 Zinc Finger Proteins (ZFPs) ............................................................... 37 
1.7.2 Zinc finger nucleases: designer nucleases for HDR .......................... 40 
1.7.3 Zinc Finger Protein Design ................................................................ 42 
1.7.4 Modular Design .................................................................................. 43 
1.7.5 Rational Design .................................................................................. 44 
1.7.6 ZFP Oligomerised Pool Engineering “OPEN” Selection .................. 45 
1.7.7 Context-dependent assembly (CoDA) ............................................... 46 
1.7.8 Transcription Activator-like effectors (TALE) .................................. 46 
1.7.9 CRISPR/Cas system ........................................................................... 48 
1.8 Gene modifications using programmable and RNA-guided nucleases ..... 51 
1.8.1 Gene Disruption ................................................................................. 52 
1.8.2 Gene Correction ................................................................................. 54 
1.8.3 Gene Correction and iPs cells ............................................................ 55 
1.9 Off-Target activity ..................................................................................... 59 
1.9.1 FokI heterodimerisation ..................................................................... 59 
 iii 
 
1.9.2 Nickases ............................................................................................. 61 
1.10 Aims: ......................................................................................................... 62 
1.11 Objectives: ................................................................................................. 62 
2 Materials and Methods ................................................................................... 63 
2.1 Cell Lines .................................................................................................. 63 
2.2 Cell Culture Reagents ................................................................................ 63 
2.2.1 Cell Culture Medium ......................................................................... 63 
2.2.2 Other reagents .................................................................................... 64 
2.3 Bacterial Strains ........................................................................................ 64 
2.4 Bacterial Growth Media and Antibiotics ................................................... 65 
2.4.1 Growth Media .................................................................................... 65 
2.4.2 Antibiotics .......................................................................................... 65 
2.5 Buffers, solutions and drugs ...................................................................... 66 
2.6 Molecular biology reagents ....................................................................... 67 
2.7 Chemical Reagents .................................................................................... 68 
2.8 Other Reagents .......................................................................................... 68 
2.9 Plasmids ..................................................................................................... 69 
2.9.1 Plasmids provided .............................................................................. 69 
2.9.2 Plasmids constructed .......................................................................... 69 
2.10 Kits ............................................................................................................ 70 
2.11 Oligonucleotides ........................................................................................ 71 
2.12 Equipment ................................................................................................. 74 
2.13 Software ..................................................................................................... 74 
2.14 Cell culture protocols ................................................................................ 75 
2.14.1 Subculturing cells ............................................................................... 75 
2.14.2 Cell quantification and seeding density ............................................. 75 
2.15 Bacterial protocols ..................................................................................... 76 
 iv 
 
2.15.1 Inoculation of LB broth ...................................................................... 76 
2.15.2 Bacterial transformation ..................................................................... 76 
2.16 DNA and RNA isolation ........................................................................... 76 
2.16.1 Plasmid extraction (Qiagen Plasmid Plus Purification Kit) ............... 76 
2.16.2 Plasmid extraction (Qiagen Miniprep Kit) ......................................... 77 
2.16.3 Plasmid extraction (Qiagen Maxiprep Kit) ........................................ 77 
2.16.4 Measuring DNA concentration .......................................................... 78 
2.16.5 RNA extraction .................................................................................. 78 
2.16.6 Measuring RNA concentration .......................................................... 79 
2.17 DNA and RNA manipulation .................................................................... 79 
2.17.1 Restriction digests .............................................................................. 79 
2.17.2 Preparing DNA agarose gels .............................................................. 79 
2.17.3 Loading and running agarose gels ..................................................... 80 
2.17.4 RNA gel ............................................................................................. 80 
2.17.5 Gel purification .................................................................................. 80 
2.17.6 Annealing oligonucleotides ................................................................ 81 
2.17.7 Ligation .............................................................................................. 81 
2.17.8 De-phosphorylation ............................................................................ 81 
2.17.9 Golden gate cloning ........................................................................... 81 
2.17.10 Site-directed mutagenesis ............................................................... 81 
2.17.11 Reverse Transcription ..................................................................... 82 
2.17.12 Polymerase chain reaction .............................................................. 83 
2.17.13 High Fidelity Polymerase Chain Reaction ..................................... 83 
2.17.14 PCR purification ............................................................................. 83 
2.17.15 Cel-1 (Surveyor) Nuclease Assay .................................................. 84 
2.17.16 T7E1 assay ..................................................................................... 84 
2.17.17 In vitro transcription translation reaction ....................................... 84 
 v 
 
2.18 Transfection ............................................................................................... 85 
2.18.1 Transfection of cell lines .................................................................... 85 
2.19 Fluorescence Microscopy .......................................................................... 85 
2.20 Flow Cytometry ......................................................................................... 85 
2.21 Genotyping ................................................................................................ 85 
2.22 Immuno-staining ....................................................................................... 85 
2.23 Enrichment of GFP positive cells .............................................................. 86 
2.24 Next Generation Sequencing ..................................................................... 87 
2.25 Miscellaneous methods ............................................................................. 88 
2.25.1 Dual-luciferase reporter assay ............................................................ 88 
3 Design and construction of pITR-donor and pITR-donor-XC donor repair 
plasmids, and correction of ΔF508 mutation in the CFTE cell line .................. 89 
3.1 Aims: ......................................................................................................... 89 
3.2 Objectives: ................................................................................................. 89 
3.3 Design and construction of pITR-donor and pITR-donor-XC .................. 89 
3.3.1 Cloning of CFTR into AAV backbone .............................................. 89 
3.3.2 Site-Directed Mutagenesis on pITR-donor to yield pITR-donorXC . 92 
3.4 Development of a wild type specific RT-PCR assay to detect homology 
directed repair with pITR-donor ........................................................................... 94 
3.5 CFi9-L
EL
/CFi9-R
KK
 ZFNs mediate HDR in the presence of pITR-donor or 
pITR-donor-XC .................................................................................................... 94 
3.6 Quantification of the level of repair .......................................................... 97 
3.6.1 XhoI/ClaI digests: .............................................................................. 97 
3.6.2 Genotyping ......................................................................................... 98 
3.6.3 Next generation sequencing (NGS) data ............................................ 99 
3.7 Conclusions ............................................................................................. 100 
 
 vi 
 
4 Mini-gene Repair Strategy using ZFNs ...................................................... 103 
4.1 Aims: ....................................................................................................... 103 
4.2 Objectives: ............................................................................................... 103 
4.3 Design and construction of three NheI donor plasmids with homology 
arms of 4.3, 1.5 and 1 kb. ................................................................................... 104 
4.3.1 pITR-CFTE and pITR-CFTE-NheI.................................................. 105 
4.3.2 Construction of pUC-CFTE-NheI-1 kb and pUC-CFTE-NheI-1.5 kb 
donors.............................................................................................................. 107 
4.4 Development of detection assays to determine if NheI is introduced into 
the genome following ZFN mediated HDR with NheI donor plasmids ............. 109 
4.4.1 NheI-specific primer reaction .......................................................... 110 
4.4.2 NheI quantification assay ................................................................. 111 
4.5 Successful incorporation of NheI tag into CFTR using CFi9-LEL/CFi9-RKK 
ZFNs and pUC-CFTE-NheI-1.5 kb donor .......................................................... 112 
4.6 Design and construction of mini-gene construct to correct >80% of CF-
causing mutations by ZFN mediated HDR ........................................................ 115 
4.6.1 Design of mini-gene donor............................................................... 115 
4.6.2 Construction of mini-gene donor ..................................................... 116 
4.7 Detection of HDR with CFi9-LEL/CFi9-RKK ZFNs and pUC-mini-gene 
donor............ ....................................................................................................... 121 
4.7.1 Transfection with ZFNs and mini-gene donor produce GFP positive 
cells.............. ................................................................................................... 121 
4.7.2 Enrichment of GFP positive cells .................................................... 123 
4.7.3 Fluorescent Activated Cell Sorting (FACs) analysis ....................... 124 
4.7.4 Does addition of SAHA increase HDR as determined by FACs 
analysis?. ......................................................................................................... 125 
4.7.5 PCR-based assays to determine if HDR occurred at the correct 
location............................................................................................................ 126 
 vii 
 
4.7.6 Next Generation Sequencing sheds light on mini-gene HDR .......... 127 
4.8 Conclusions ............................................................................................. 127 
5 CRISPR/Cas9/gRNA system as an alternative to ZFNs to mediate HDR in 
the presence of donor plasmids ........................................................................... 132 
5.1 Aims: ....................................................................................................... 132 
5.2 Objectives: ............................................................................................... 132 
5.3 Design of two CRISPR gRNAs to target and cleave CFTR ................... 133 
5.3.1 One-step cloning of CRISPR IN9 and CRISPR EX10 .................... 134 
5.4 Determination of cleavage efficiency of CRISPR IN9 and CRISPR 
EX10................ ........................................................................................... ........135 
5.4.1 NGS data for CRISPR cleavage ....................................................... 137 
5.5 CRISPR/Cas9 system can mediate HDR in the presence of appropriate 
donor plasmids. .................................................................................................. 138 
5.5.1 CRISPR EX10 can mediate HDR with pITR-donor-XC ................. 139 
5.5.2 NGS data for CRISPR ex10 and pITR-donor-XC ........................... 141 
5.5.3 CRISPR IN9 gRNA HDR with the pUC-mini-gene donor ............. 142 
5.6 Conclusions: ............................................................................................ 143 
6 Discussion: ..................................................................................................... 145 
7 Bibliography .................................................................................................. 152 
8 Appendix: ...................................................................................................... 171 
8.1 Functional Assay: Immunofluorescence for detection of CFTR protein 
trafficking ........................................................................................................... 171 
8.2 Transfection of CFTE cells with pCEP-CFTR and pEGFP .................... 172 
 viii 
 
Declaration: 
 
This thesis is the candidate‟s own work and has not been submitted for another 
degree, either at University College Cork or elsewhere. 
 
Signed: __________________________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
Peer Reviewed Publications generated from this work: 
 C.M. Lee, R. Flynn, J.A. Hollywood, M.F. Scallan, P.T. Harrison 
(2012). Correction of the ΔF508 mutation in the cystic fibrosis 
transmembrane conductance regulator gene by zinc-finger nuclease 
homology-directed repair. BioResearch Open Access 1(3): 99-108. 
 
Manuscript in preparation: 
 J.A. Hollywood, CM. Lee, MF. Scallan, PT. Harrison. Genome editing 
of cystic fibrosis cells using gRNA-Cas9 system to correct the ΔF508 
mutation 
 
Abstracts and Poster Presentations: 
 J.A. Hollywood, K. Kaschig, C.M. Lee, M.F. Scallan, P.T. Harrison 
(September 2010). ctns gene repair using AAV mutagenesis. 6
th
 International 
Cystinosis Conference, Lignano, ITALY. Poster presentation. 
 
 J.A. Hollywood, C.M. Lee, K. Kaschig, M.F. Scallan, P.T. Harrison (October 
2011). Correction of the DF508 mutation in the CFTR gene in Epithelial Cells 
using Zinc Finger Nuclease Homology-Directed Repair. European Society of 
Gene and Cell Therapy conference in Brighton Poster presentation. 
 
 J.A. Hollywood, C.M. Lee, K. Kaschig, M.F. Scallan, P.T. Harrison (July 
2011). Correction of the DF508 mutation in the CFTR gene in Epithelial Cells 
using Zinc Finger Nuclease Homology-Directed Repair. Physiological Society 
Annual Meeting, Oxford 201.1 Poster presentation. (Shortlisted for poster 
prize) 
 
 J.A. Hollywood, C.M. Lee, K. Kaschig, M.F. Scallan, P.T. Harrison (April 
2012). Correction of the DF508 mutation in the CFTR gene in Epithelial Cells 
using Zinc Finger Nuclease Homology-Directed Repair. 9th European CF 
Basic Science meeting, Paris 2012. Poster presentation and invited 2 min talk. 
 
 J.A. Hollywood, C.M. Lee, K. Kaschig, M.F. Scallan, P.T. Harrison (May 
2012). Correction of the DF508 mutation in the CFTR gene in Epithelial Cells 
using Zinc Finger Nuclease Homology-Directed Repair. 6
th
 European CF 
Young Investigator Meeting, Paris 2012. Oral presentation. 
 
 J.A. Hollywood, C.M. Lee, K. Kaschig, M.F. Scallan, P.T. Harrison (June 
2013). Correction of >80% CF-causing mutations by ZFN Homology-Directed 
Repair. 37
th
 European Cystic Fibrosis Society Meeting, Lisbon, 2013.   
 
 
 x 
 
Abstract 
 
Cystic Fibrosis (CF) is an autosomal recessive monogenic disorder caused by 
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
with the ΔF508 mutation accounting for approximately 70% of all CF cases 
worldwide.  This thesis investigates whether existing zinc finger nucleases designed 
in this lab and CRISPR/gRNAs designed in this thesis can mediate efficient 
homology-directed repair (HDR) with appropriate donor repair plasmids to correct 
CF-causing mutations in a CF cell line. 
Firstly, the most common mutation, ΔF508, was corrected using a pair of existing 
ZFNs, which cleave in intron 9, and the donor repair plasmid pITR-donor-XC, 
which contains the correct CTT sequence and two unique restriction sites. HDR was 
initially determined to be <1% but further analysis by next generation sequencing 
(NGS) revealed HDR occurred at a level of 2%.  
This relatively low level of repair was determined to be a consequence of distance 
from the cut site to the mutation and so rather than designing a new pair of ZFNs, 
the position of the existing intron 9 ZFNs was exploited and attempts made to 
correct >80% of CF-causing mutations. The ZFN cut site was used as the site for 
HDR of a mini-gene construct comprising exons 10-24 from CFTR cDNA (with 
appropriate splice acceptor and poly A sites) to allow production of full length 
corrected CFTR mRNA.  
Finally, the ability to cleave closer to the mutation and mediate repair of CFTR 
using the latest gene editing tool CRISPR/Cas9 was explored. Two CRISPR gRNAs 
were tested; CRISPR ex10, which targets within exon 10, 85 bp upstream of the 
ΔF508, was shown to cleave at an efficiency of 15% and CRISPR in9 targets intron 
9 and cleaved at 3%. Both CRISPR gRNAs mediated HDR with appropriate donor 
plasmids at a rate of ~1% as determined by NGS. This is the first evidence of 
CRISPR induced HDR in CF cell lines.          
 xi 
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1 Introduction 
1.1 Cystic Fibrosis 
1.1.1 A brief history 
“Woe to the child which when kissed on the forehead tastes salty. He is bewitched 
and soon must die”. This proverb from early English folklore is the first reference to 
the disease known today as Cystic Fibrosis (CF). The disease was first recognised in 
modern times by Dr. Dorothy H. Anderson in 1939, who from studying the 
autopsies and case histories of children, described the symptoms and organ changes 
that occurred (Anderson, 1938). She noted that most destruction occurred in the 
pancreas and so called it “cystic fibrosis of the pancreas”. During the 1940s 
physicians were becoming more aware of the clogging of ductal systems, such as 
the pancreas, with thick secretions which would impair the body‟s ability to break 
down food and absorb nutrients. They also became more aware of the impaired 
breathing of CF patients due to these mucus secretions and inflammation caused by 
bacterial infections living in the lungs. By 1946 researchers had deduced from 
studying the pattern of disease inheritance in families that CF was a recessive 
disease whereby two copies of the mutant gene were needed to cause the disease. 
Then during a heat wave in New York in 1949, hospitals saw a huge increase in the 
treatment of children with CF for dehydration compared to other children. Paul di 
Saint‟Agnese and colleagues (including Dr. Dorothy Anderson) noticed that 
children with CF lost an excessive amount of salt in sweat. Even though the reason 
for this increase in saltiness would not be discovered for many years, the 
observation was of great clinical benefit and resulted in the development of the first 
method of CF diagnosis: measurement of Cl
-
 in sweat which remains today the 
cornerstone of diagnosis (see section 1.1.6). During the 1970s scientists began to 
realise that a malfunction in the epithelial cells was at the heart of every tissue in CF 
patients. In 1973 Paul M. Quinton found that the CF epithelia lining the sweat 
glands failed to take up chloride ions efficiently which led to the salty skin of 
patients. This was the first indication that it was a Cl
-
 flux problem; however, the 
underlying cause was still not known (Quinton and Philpott, 1973). 
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1.1.2 Cloning of the gene 
The 1980‟s was a time when researchers were trying to map the genetic location of 
the CF-causing gene. A number of novel molecular techniques were used such as 
restriction fragment length polymorphism (RFLP) analysis. This tool had been used 
to map the β-globin gene and led to predictions of variants which caused sickle cell 
anaemia (Kan & Dozy, 1978). In 1985, the CF locus was mapped using this 
technique to human chromosome 7q31 (White et al., 1985). This chromosomal 
mapping provided a guide for locating the gene and the methods of chromosomal 
walking and jumping, and complementary DNA (cDNA) hybridisation were used to 
isolate DNA sequences from the CF region to create a physical map of the gene, a 
sequence of 250,000 base pairs (bp) (Rommens et al., 1989). cDNA clones from the 
sequence were used to probe a cDNA library created from colon carcinoma cell 
lines, CF sweat gland cells and adult lung tissue leading to the isolation of 18 
further cDNA clones and prediction of a 1480 amino acid protein (Riordan et al., 
1989). This group went on to name the gene the cystic fibrosis transmembrane 
conductance regulator (CFTR). Finally the cause of CF was known to be linked to 
mutations in this protein. The first mutation to be identified was the ΔF508 class II 
mutation (Kerem et al, 1989), (Riordan et al., 1989), (Rommens et al., 1989). In 
1990, Drumm et al. used retroviruses to transduce a functional CFTR cDNA into a 
CF cell line. Agents that increase intracellular cAMP stimulated 
125
I efflux in clones 
exposed to CFTR expressing virus but not in those transduced with control. Patch-
clamping analysis of whole cell clones showed that the anion efflux responses were 
due to cAMP stimulation of Cl
- 
conductance (Drumm et al., 1990). That same year 
Rich et al. showed that delivery of wild-type (WT) CFTR cDNA but not mutant 
corrected the channel defect, demonstrating a causal relationship between mutations 
in the CFTR gene and defective Cl
-
 transport was the cause of the disease (Rich et 
al., 1990). With the developments in gene discovery and the indication that cDNA 
addition could resolve the ion flux defect in CF cell lines, people were excited that 
possible gene-based treatments were not far away. However, as discussed below, 
the path to CF-gene based treatments has proved difficult to navigate and has still 
not succeeded.  
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1.1.3 Cystic Fibrosis Transmembrane Regulator 
The CFTR gene comprises 180,000 base pairs, is located on the long arm of 
chromosome 7 and encodes a 1,480 amino acid protein. Wild type CFTR 
glycoprotein is trafficked to the apical membrane of airway epithelial cells to allow 
the transport of chloride out of the cell. It is a member of the ATP-binding cassette 
(ABC) transporter family and consists of two homologous cytoplasmic nucleotide-
binding domains (NBD) linked to two membrane spanning domains (MSD) and 
separated by a regulatory (R) domain. CFTR is unique within the ABC family in 
that it functions as an ion channel and has a distinctive R domain and it is the 
phosphorylation of this domain by cAMP-dependent PKA which is a prerequisite 
for channel gating by ATP, see figure 1.1. Phosphorylation of the R domain alters 
its conformation and exposes an ATP hydrolysis site on the first NBD (NBD1). 
Hydrolysis of ATP at NBD1 opens the Cl
- 
pore and the NBD2 catalytic site, 
allowing dissociation of ADP from NBD2 and permitting binding of ATP. This 
binding closes NBD1 catalytic site along with its hydrolysis product ADP, 
maintaining the open channel state. Hydrolysis of ATP at NBD2 opens NBD1 
allowing release of ADP from NBD1, which then closes the channel to complete the 
cycle. Cl
-
 transport is essential in maintaining ion and fluid homeostasis in airway 
epithelial cells, and absence of CFTR at the apical membrane leads to dehydration 
of the airway surface liquid and accumulation of macromolecular secretions. 
 
 
 
 
 
 
 
 
 
Figure 1.1: Predicted topology and protein structure of CFTR, (Lubamba et al., 2012).  
Before the CFTR protein can reach the apical membrane a number of cellular 
processes must occur. Firstly the DNA is transcribed and spliced in the nucleus to 
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mRNA. This mRNA then moves from the nucleus to the ribosomes and then to the 
endoplasmic reticulum (ER) where the nascent protein is translated. Further protein 
maturation occurs in the ER lipid bilayer leading to complex folding of the CFTR 
protein (see lane 1, figure 1.4). Final CFTR processing occurs in the Golgi with a 
glycosylation step and involves conversion of mannose-enriched side chain to a 
mature complex oligosaccharide attached at the asparagine residues in the fourth 
extracellular loop within MSD2, (see figure 1.1). Western blot analysis is a 
common technique used to determine the maturation of CFTR using specific 
antibodies and by measuring the distance of migration of specific bands one can 
deduce the amount of CFTR that achieves this final step. Band C at 180-kDa 
represents a fully mature CFTR protein while the lower band B is representative of 
the less complex core-glycosylated form that has not reached the golgi. Figure 1.2 is 
an example of a western blot showing both mature and immature versions of the 
protein. This process of protein folding has been found to be highly inefficient with 
mis-folding occurring in more than one-half of wild-type CFTR, (Ward & Kopito, 
1994). Despite the low level of abundance and low expression levels in wild-type 
CFTR expression systems, the protein is fully active functionally and maintains the 
desired state of ion and fluid homeostasis. These early observations raised the 
possibility that even correction of a small number of cells could lead to wild-type-
like lung function. 
 
 
 
      
 
                                   
Figure 1.2: Western blot showing the mature band C for fully glycosylated CFTR and immature 
band B for the immature CFTR (O‟Riordan et al., 2000). 
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1.1.4 Airway Surface Liquid (ASL) regulation 
The apical surface of airway epithelium is lined with a thin fluid coating called the 
airway surface liquid (ASL). This is a two layer system that interfaces with the 
beating cilia on the epithelial surface. The upper mucus layer is composed of the 
secreted high molecular weight mucins, MUC5AC and MUC5B and functions 
primarily to trap inhaled particles. Typically this layer is composed of 1% mucins, 
1% salt and 98% water, and varies from 7-70 μm in height (Sims & Horne, 2013), 
with 7 μm being the height of the cilia (Harvey et al., 2011). The lower phase, or 
periciliary layer (PCL) is a polyionic water layer that permits interactions between 
the hydration status of the two layers (Tarran et al., 2001) and keeps the mucus 
layer at a sufficient distance from the underlying airway epithelium to optimise 
mucus clearance. Normal airway epithelia employ the epithelial sodium channel 
(ENaC), CFTR and calcium-activated chloride channels (CaCC) for the 
maintenance of PCL volume. The hydration/volume of the normal airway surface is 
maintained in the highly water permeable airway epithelia by active transport 
processes that control the mass of salt (NaCl) on airway surfaces, with water 
following by osmosis (Matsui et al., 2000). Regulation of the balance between 
absorption and secretion determines the net transport of ions across the epithelium 
and hence the mass of salt on the epithelial surface. CFTR has been shown to have 
inhibitory effects on the ENaC channel (Rubenstein et al., 2011) and the lack of 
CFTR in CF patients is thought to cause ENaC hyperactivity leading to increased 
Na
+
 absorption followed by increased water absorption out of the ASL and into the 
cell by osmosis which causes dehydration of the ASL (figure 1.3). There is some 
data demonstrating that re-hydration of ASL might be achieved by either inhibiting 
ENaC (Althaus, 2013) or by up-regulating calcium-activated chloride channels, 
however there has been no clinical benefit to date and so much attention is still 
directed towards repairing the CFTR defect. 
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Figure 1.3: Representation of normal and CF airway surface epithelia. In normal cells, Cl
- 
efflux to 
the ASL regulates the total Na
+
 influx resulting in water transport and mucus clearance. However, in 
CF epithelia which don‟t contain a functional CFTR channel, Na+ hyperabsorption leads to abnormal 
water transport, resulting in dehydrated ASL and abolition of mucus transport. Thickness of lines 
indicates the amount of ions/molecules transported across the membrane.  
 
1.1.5 CF today 
CFTR is expressed in all secretary epithelia. Thus, in CF patients where both copies 
of the gene are defective, multiple organs including the respiratory, gut, pancreas 
and reproductive systems are affected. As the old folklore saying suggests, children 
affected with the disease would die in infancy but today advances in therapy over 
the past few decades enable CF patients to survive into their late twenties and 
beyond. Today pancreatic failure is rarely life-threatening due to replacement of 
digestive enzymes with capsules (Heubi, 2007) however, disease of the lung is still 
the main cause of fatality where defective CFTR leads to dehydration of the airway 
surface liquid, leading to lung disease characterised by mucus plugging, infections 
and sustained inflammation. Treatments for the lung include; daily sessions of 
physiotherapy to allow postural drainage, DNase inhalation treatment to break up 
mucus (Shak et al., 1990) and antibiotics to treat the repeated bacterial infections. It 
is these repeat cycles of infection and inflammation which cause irreparable damage 
to the lung tissue which eventually leads to patient death (see section 1.1.7) unless a 
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lung transplant (see section 1.3.4) is possible. But none of these treatments address 
the genetic cause of the disease.  
1.1.6 Diagnosis 
Measurement of sweat electrolyte levels is the optimal diagnostic test for CF. 
Sodium and chloride concentrations are raised in patients with the disease, >60 
mmol/L is diagnostic, 40-60 mmol/L intermediate and <40 mml/l is normal. 
Another test measures the nasal potential difference (NPD) to assess altered salt 
transport. As of the 1
st
 of July 2011, newborn screening for CF is offered in Ireland 
using the Guthrie blood spot test, www.hse.ie/go/newbornscreening. It screens 
initially for raised concentrations of immunoreactive trypsinogen and positive 
results are tested for CFTR mutations. Progress in the understanding of the disease 
and better management of the condition means the predicted median for survival for 
babies born with CF in the 21
st
 century is now more than 50 years (Dodge et al., 
2007).    
1.1.7 Bacterial Infections and Inflammation 
As a consequence of changes in the ion and fluid homeostasis in the lung of CF 
patients, changes in airway microbiology also occur with age. In healthy respiratory 
systems, the upper respiratory tract is colonised by a wide variety of 
microorganisms comprising the normal flora while the lower tract is kept sterile by 
various innate host defence mechanisms. These include physical barriers and 
enodocytic/phagocytic mechanisms.  
In CF patients these defences fail and result in an increased susceptibility to 
infection from a very early age. Initially, Staphylococcus aureus (Sa) in the first 6 
months, Haemophilus influenza peaks in prevalence at 7-18 months then 
Pseudomonas aeruginosa (Pa) is usually detected and is chronic for the life-time of 
the patient. Over 30% of patients at 3 years of age and 80% of young CF adults are 
chronically infected with Pa. The long term immune responses to these chronic 
infections progressively destroy the lung and ultimately lead to respiratory failure. 
The chronic inflammation is thought to be a consequence of the mutations in CFTR. 
A number of theories have been put forward as to why the lungs of CF patients 
become so overwhelmed with infection and inflammation.  
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- “High Salt” hypothesis 
One hypothesis is that the abnormal salt composition of the ASL is a host factor 
predisposing CF patients to colonisation with Pa. In 1996, Smith et al studied the 
effects of salt concentration in the ASL on bacterial killing and found that the 
higher salt concentration in CF compared to normal reduced the bactericidal activity 
of antibacterial peptides in ASL and thus allowed colonisation of Pa (Smith et al., 
1996). 
A recent study on CFTR knock-out pigs found no changes in electrolyte 
composition of the ASL between KO and WT pigs; however, they did detect altered 
pH of the ASL suggesting a role of CFTR in HCO3
-
 secretion. They hypothesise 
that changes in pH composition of the ASL impair bacterial killing in the CF lung 
(Pezzulo et al., 2012). Inhaled bicarbonate clinical trial for CF patients has been 
completed but no results were posted (ClinicalTrials.gov: NCT00177645). 
-“Low volume” hypothesis 
The high salt theory was disputed earlier on by Matsui et al., (1998) who found no 
difference in ASL salt concentration between CF and normal airways. They 
suggested that it was the volume of the ASL that mattered and the low ASL in CF 
patients caused by the enhanced airway liquid absorption leads to impaired 
mucociliary clearance and increased bacterial growth. 
The mucociliary action is the most prominent host innate defence mechanism of the 
airway epithelium (Clarke & Pavia, 1980). Clearance relies on two features; 1) the 
ciliated apical surface and 2) a mucus layer that lines the airway lumen. The cilia 
beat synchronously, creating a steady current that continually moves the mucus 
layer upward toward the nasopharynx. The mucus layer is biphasic, consisting of an 
upper, viscous layer that can trap particles, pathogens and debris and a lower, more 
fluid layer in which the cilia beat. Normally, this clearance system traps 
microorganisms in the mucus and carries them to the nasopharynx where they are 
exacerbated and swallowed. In CF, defective CFTR decreases the height of the ASL 
in this airway lumen, meaning cilia are unable to beat as normal and the upper 
mucus layer becomes thick and stagnant, creating an attractive environment for 
pathogens. 
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These theories from the 1990s offered an explanation as to why the lungs are 
susceptible to infection but were not able to explain why the predominant pathogen 
detected in CF lungs is Pa. 
-Hypoxic mucus and Pa response 
A more recent theory is able to link mucociliary clearance, hypoxic mucus and the 
establishment of Pa in the CF lung. Worlitzsch et al. (2002) found that a steep 
oxygen gradient is present in the mucus lining the airways of CF patients caused by 
impaired mucociliary clearance leading to stagnant mucus and increased oxygen 
consumption by airway epithelia resulting in ENaC over activity. They found that 
the opportunistic Pa could penetrate this thick mucus layer and survive in the 
hypoxic environment. They also found that Pa form a biofilm under these 
conditions, leading to speculation that this might be a bacterial stress response. The 
extracellular polysaccharide matrix of which the biofilms are encased in protect 
bacteria from antibiotics which cannot penetrate this layer (Mah & O' Toole, 2001).  
-Inflammatory response 
It has been demonstrated that the inflammatory response is exaggerated in CF 
patients and that this inflammation starts early in infancy and can even be detected 
without any sign of infection (Balough et al., 1995). CF pulmonary inflammation is 
characterised by increased neutrophils, elevated interleukin (Il) -8 concentration and 
neutrophil elastase (McElvaney et al., 1992). Neutrophils provide the first line of 
defence by killing and digesting phagocytosed bacteria, however, in CF, neutrophils 
fail to eradicate infections in the lung. Up until recently it was neutrophil 
dysfunction in CF airways which was linked to neutrophil necrosis and release of 
proteolytic enzymes which had a role in destroying the tissue of the lung by 
overwhelming the antiprotease defences in the lung (McElvaney et al., 1991). 
However, now there is a shift towards emphasis on defective immune cell function 
and in particular, dysregulated neutrophil activity. Research is accumulating 
indicating functional and signalling changes in CF neutrophils that could impact 
upon clinical prognosis and lung disease severity. Micro-array analysis 
demonstrated that CF neutrophils display a distinct gene expression profile when 
compared to healthy controls, with up-regulation of genes encoding for chemokines 
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CCL17 and CCL18, interleukin receptors IL-3,-8,-10 and -12 and colony 
stimulating factors (Adib-Conquy et al., 2008). In this study, a comparison was 
made between blood and airway neutrophils with limited difference in gene 
expression observed and results suggest CF neutrophils have a perturbed 
inflammatory profile. 
Measurement of IL-6, IL-8 and IL-10 levels in normal and CF isolated HBE cells 
by Bonfield et al., (1999), revealed that normal individuals secreted IL-10 but no 
IL-8/6 whereas cells from CF patients had no detectable levels of IL-10 but did 
produce IL8/6. As IL-10 inhibits the production of anti-inflammatory cytokines, this 
non-existent to low level resulted in an imbalance in inflammatory and pro-
inflammatory cytokines and led to excessive and persistent inflammation in the CF 
airways. DiMango et al. (1995) had shown previously that gene products of Pa 
stimulated respiratory epithelial cells to secrete IL-8, and that CF cell lines 
produced four times as much compared to control cell lines. If CF patients are 
predisposed to increased inflammatory responses from birth, before infection then 
neonatal screening is of upmost importance, as the earlier the detection the earlier 
intervention can begin.    
 
1.2 CF Mutations  
1.2.1 Mutations and classification    
More than 1,900 different mutations in CFTR have been identified and can be 
divided into six main classes based on their effects on CFTR production, 
trafficking, stability and the amount of residual CFTR function (see table 1.1 and 
figure 1.4). This classification of different genotypes has been shown to be linked to 
disease severity (Hubert et al., 1996). The most common mutation, ΔF508, is the 
deletion of phenylalanine at codon 508 which accounts for ~70% of all CF alleles. 
This belongs to the class II mutation group whereby the CFTR protein is transcribed 
but is unstable and is degraded before it reaches the apical membrane. There are 
four speciﬁc mutations besides ΔF508 that reach a frequency of 1% to 3%: G551D 
(Glycine->Aspartic), W1282X (TGG->TGA), G542X (GGA->TGA), and N1303K 
(Asparagine->Lysine). Only another 20 speciﬁc mutations reach a threshold 
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frequency >0.1% (Cystic Fibrosis Genetic Analysis Consortium database, 
www.genet.sickkids.on.ca/cftr). The prominence of CF in Europe (carrier frequency 
of ~2%) is thought to be a result of the tuberculosis (TB) pandemic at the beginning 
of the 17
th
 century as CF patients and carriers have some resistance to TB (Poolman 
& Galvani, 2007). This pandemic allowed CF mutations to establish themselves and 
to reach their current levels in Europe. 
Table 1.1: List of CFTR mutation classes.  
Mutation 
Class 
Description Disease Severity 
 
Class I 
No protein is produced. The most common types 
of mutations in the group are nonsense mutations 
and frameshift mutations which result in premature 
stop codons, e.g. G542X 
Severe 
 
Class II 
Defective protein processing. Full length CFTR is 
produced but cannot exit the endoplasmic 
reticulum (ER). The most common mutation 
ΔF508 falls in this group. 
Severe 
 
 
Class III 
Block in CFTR regulation. The CFTR protein is 
produced and delivered to the apical membrane, 
However, mutations such as G55ID prevent ATP 
binding and channel gating. The corrector VX-770 
is used to treat this mutation.  
Severe 
 
Class IV 
Altered conductance. The CFTR is correctly 
inserted into the apical membrane but mutations 
prevent the channel from fully opening or from 
closing, e.g. R117H 
Mild 
 
 
Class V 
Reduced synthesis. Mutations in the promoter 
region or ribosomal binding site result in a 
reduction of protein synthesis. However, any 
CFTR protein produced is fully functional, e.g. 
2789 + 5G->A 
Mild 
 
Class VI 
Functional but unstable with decreased half life at 
the cell surface, e.g. Gln1412X  
Severe 
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1.2.2 Mutations and disease severity 
As outlined in table 1.1, mutations in the gene encoding the CFTR protein lead to 
disruption of the cellular processes mentioned in section 1.1.3 which are necessary 
for production of functional CFTR. Depending on what stage of production the 
protein reaches determines the severity of the disease. For example in class I no 
transcript is made due to nonsense mutations meaning no protein at all is produced, 
in class II the protein is incorrectly folded leading to degradation before it reaches 
the membrane and in class III the protein is made and correctly trafficked to the 
apical membrane but is unable to open to allow ion efflux making these three 
classes the most severe. The least severe classes are IV and V, in which the channel 
is functional but at a lower efficiency due to either altered conductance or reduced 
synthesis. Finally class VI mutations are the rarest and result in unstable proteins 
and are considered severe. Treatments that can restore function of the protein are 
needed and much work has been done for classes III, IV and V whereby the protein 
is at the surface but not functional. But for the more severe class, whereby no 
protein at all is made, a gene based treatment such as cDNA addition or gene repair 
would appear the only option. 
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Figure 1.4: Schematic representation of the six different CFTR mutation classes, taken from (Boyle 
& De Boeck, 2013). Normal: CFTR reached the apical membrane and allows Cl
-
 flux. Class I: A full 
length transcript is disrupted by premature stop codons, no protein is made. Class II: Protein is 
transcribed but is mis-folded and becomes trapped in the ER leading to degradation, meaning no 
protein reaches apical surface. Class III: Protein reaches the apical membrane but the channel is 
defective, allowing no Cl
-
 flux. Class IV: Channel is present at the apical membrane but has 
defective conductance allowing partial Cl
-
 movement. Class V: Channel is at the apical membrane 
but at low abundance leading to reduced total Cl
-
 flux. Class VI: Channel at apical membrane but is 
unstable leading to little Cl
-
 movement.    
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1.2.3 ΔF508 
The missense class II mutation ΔF508 is by far the most common CF-causing 
mutation, affecting 70% of all CF patients. It is caused by the deletion of a 
phenylalanine at position 508 of the CFTR protein which leads to misfolding and 
degradation before it can reach the membrane (Kerem et al., 1989). F508 resides in 
the first nucleotide binding domain (NBD) of CFTR near a predicted interface with 
the fourth intercellular loop-ICL4. Identification and assessment of positions 
statistically coupled to F508 using evolutionary sequence analysis revealed that 
both NBD1 folding and interaction with ICL4 are altered by the mutation (Mendoza 
et al., 2012). It was determined that correction of both defects is needed to restore 
CFTR function. Emerging therapies which can re-route the misfolded protein to the 
plasma membrane are of great interest as it has been shown that once the ΔF508 
CFTR protein is at the surface it exhibits suboptimal gating and activation relative 
to wild-type (Denning et al., 1992). These types of therapies are called „correctors‟. 
Once at the membrane, „potentiators‟ increase opening probability of the protein 
and increase function, making them of use to mutations like G55ID, a class III 
mutation. 
1.3 Mutation Specific Therapies 
1.3.1 Aminoglycosides for Premature Stop Codons  
Nonsense mutations occur when a single base change produces an in-frame stop 
codon producing a highly unstable transcript and no protein synthesis. For the 
~10% of patients with the nonsense mutations of class I, a possible treatment would 
be to promote read-through of the premature stop codons to enable translation of the 
entire sequence and synthesis of full length CFTR protein. It was shown that 
aminoglycoside antibiotics can interact with the small ribosomal RNA subunit-18S 
and alter normal ribosomal proofreading during protein translation in eukaryotic 
cells, (Purohit & Stern, 1994). Sometimes this interaction inserts an incorrect amino 
acid at the premature stop codon and allows production of a full length protein, 
albeit with a single incorrect amino acid, in other words it can suppress the 
premature stop codons. Two of the first aminoglycosides to be tested to read 
through such a mutation were G-418 and Gentamicin, a clinically approved 
antimicrobial. They exhibited suppressive activity in CF cell models with stop 
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mutations, and restored expression of functional CFTR, (Howard et al., 1996). 
Although a 14-day trial involving nine CF patients in 2000 provided promising 
results indicating that gentamicin applied directly to the nasal mucosa of CF 
patients with class I mutation could improve CFTR Cl
-
 transport, (Wilschanski et al. 
2000) a trial in 2007 on a larger number of patients was unable to demonstrate 
significant alteration in nasal PD following 28 days of nasally administered 
gentamicin, (Clancy et al., 2007). 
Using high-throughput screening (HTS) technology a novel compound PTC124 
(Ataluren) has been identified, a non-aminoglycoside, which is able to read through 
premature stop codons but not normal stop codons and has no evidence of renal 
toxicity. PTC124 acts by inactivating the nonsense-mediated mRNA decay pathway 
which usually degrades truncated proteins and so by disrupting this pathway, 
nonsense containing transcripts are stabilised (Welch et al., 2007). It has been 
shown to be superior to gentamicin and well tolerated in mouse studies with another 
premature stop codon disease, Duchenne muscular dystrophy, where it induced 
production of full length proteins, (Welch et al., 2007). In a CF mouse model, 
expressing the human CFTR-G542X transgene, oral administration of PTC124 
suppressed the G542X nonsense mutation and restored a significant amount of 
CFTR protein at the apical surface as seen by immunofluorescence staining and also 
CFTR function saw a restoration of 24-29 % of the average cAMP-stimulated Cl
- 
currents observed in WT following treatment, (Du et al., 2008). Phase II trials with 
PTC124 determined the drug to be well tolerated with mild side effects. However, 
the 2012 phase III trial of ataluren in 238 patients with cystic ﬁbrosis with stop 
mutations did not reach its primary endpoint of improvement in forced expiratory 
volume in 1 s (FEV1) at 48 weeks, except in a subset of individuals who were not 
simultaneously taking nebulised aminoglycoside antibiotic (ECFS meeting, 2013). 
Total absence of CFTR protein in class I mutations make it the most challenging 
defect to address and a gene therapy approach is most likely to benefit this class the 
most.  
1.3.2 Correctors 
The class II mutation ΔF508 can be rescued to the cell surface in cell cultures by 
reducing temperature to 27 °C, (Denning et al., 1992). However, this technique is 
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not practical for patients. Correctors are compounds that can enhance the productive 
trafficking of these mutated CFTR proteins. Using the HTS technique compounds 
were identified which acted as potent correctors. One such compound was VX-809. 
In pre-clinical models of CF, western blot analysis of HBE cell lysates following 
treatment showed an increase in the amount of band C correlating to an increase in 
CFTR maturation to the apical membrane. Cl
-
 secretions were also increased to 
~15% of that seen in WT HBE cells (Van Goor et al., 2011). The compound 
proceeded to phase II clinical trials in adults with CF homozygous for ΔF508 and 
was well tolerated when taken once over 28 days, with adverse effects similar to 
placebo. It reduced sweat chloride levels in a dose-dependent manner but there was 
no significant improvement in CFTR function in the nasal epithelium as measured 
by PD changes nor were there significant changes in lung function or patient report 
outcomes. No maturation of immature ΔF508 was detected in rectal biopsies, 
(Clancy et al., 2007). Despite these disappointing phase II results, VX-809 is 
entering into phase III clinical trials to be used as a combination therapy with the 
potentiator VX-770 (see 1.3.3) as it was seen in ΔF508 HBE cells, the level of VX-
809 corrected ΔF508 could be doubled by addition of VX-770, (Van Goor et al., 
2011). Another corrector entering phase III combination therapy trials with VX-770 
is the compound VX-661. Both trials are still recruiting volunteers and so results are 
pending. 
1.3.3 Potentiators 
In January 2012, a huge advance was made for people suffering from the class III 
gating mutation, G551D, which affects 4-5% of people with CF. The potentiator, 
VX-770 was approved by the FDA and was available for treatment. This small 
molecule acts by opening the CFTR channel that is already present at the apical 
membrane. It was identified following HTS of 280,000 chemically diverse drug-like 
and lead-like compounds using a cell based fluorescence membrane potential assay 
designed specifically to identify CFTR potentiators, (Van Goor et al., 2009). 
They found that VX-770 increased CFTR open probability in recombinant cell lines 
with either ΔF508-CFTR (after biosynthetic rescue at 27ºC) or G551D-CFTR 
mutations. All experimental cell lines/cultures were pre-treated with forskolin to 
activate cAMP prior to VX-770 treatment as it is not an activator. Assessment of Cl
-
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secretion in primary HBE cultures with one ΔF508 allele and one G511D allele saw 
an increase to ~50% of that observed in HBE non-CF cultures. Loss of CFTR 
function causes an increase in ENaC channel activity leading to an increase in Na
+
 
absorption and by osmotic gradient an increase in water absorption resulting in a 
dehydrated airway surface liquid. When they assessed the Na
+
 absorption in VX-
770 treated G551D/ΔF508 HBE and WT HBE cultures by measuring potential 
difference (PD), they saw a decrease in the PD compared to baseline. Likewise, 
measurement of fluid levels as determined by airway surface liquid volume 
revealed an increase to about half of that observed in WT-HBE. An increase in cilia 
beating was also observed. The effects on ΔF508-CFTR cells were only seen 
following rescue of the channel indicating that in order for the potentiator to work 
the channel needs to be at the cell surface. Also the channel needs to be activated by 
endogenous cAMP/PKA signalling pathways as seen when no positive CFTR 
function affects were seen when cells weren‟t first stimulated with forskolin. 
1.3.4 Lung tissue engineering 
Lung transplantation is the only definitive treatment for end-stage CF lung disease, 
but as limited supply of donor lungs and survival statistics for lung transplants are 
lower than other organ transplants, this makes it a last resort (Nichols et al., 2012). 
However, if successful it can be highly effective and the new lungs will be mutant 
free meaning normal ion and water transport will occur in the lungs. Other tissues 
will still be affected by CF but these effects can be well managed. 
Groups have begun to use tissue-engineering strategies to develop autologous bio-
artificial lungs that could potentially overcome the need for donors. Peterson et al., 
(2010) first generated a whole-lung scaffold by perfusion and de-cellularisation of 
adult rat lung. They then reseeded the endothelial and epithelial surfaces of the 
scaffold with new cells. Following implantation of the new lung into the rat for 
short time intervals, gas exchange occurred in the engineered lungs (Petersen et al., 
2010). By correcting CF patients own cells by gene repair ex vivo and then 
reseeding these cells onto the scaffold, a CF-free lung could be made available that 
could be transplanted back into the patient and would not be rejected. A similar 
strategy has been used previously to treat patients with severe combined immuno-
deficiency (SCID) disease. Bone marrow cells were corrected ex vivo and then re-
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introduced into the patient leading to full correction of the disease phenotype 
(Cavazzana-Calvo, et al., 2000). There is plenty of work that needs to be done 
before tissue engineering can be used in a clinical setting but if combined with gene 
repair therapies the need for donor lungs for CF patients could be made redundant.  
 
1.4 Gene Therapy for CF 
The recent drug discoveries mentioned before show great promise for CF patients 
who suffer from the relevant mutations, however, there are still 5-10% who suffer 
from mutations where no protein at all is produced, who benefit from no available 
treatment apart from traditional methods. For these patients other forms of treatment 
are needed. Gene therapy offers an alternative to these drug based methods. 
Furthermore, if one could repair the genetic mutation that gives rise to the disease, 
for example correcting the three base pair deletion in ΔF508, then the corrected 
DNA would give rise to functionally active protein for the life-time of the cell.  
1.4.1 CF: A good and bad candidate for gene therapy 
A number of factors make CF an attractive candidate for gene therapy. It is a 
monogenic disease and so only requires correction of one gene. In addition, the 
levels of full-length CFTR mRNA vary considerably in phenotypically normal 
individuals suggesting that a high level of transgene expression is not required to 
restore normal phenotype. There is some variance in studies reporting the amount of 
transcript needed to restore function. Chu et al., (1991) found when analysing the 
CFTR mRNA transcripts of freshly isolated HBEs from 12 normal adults that all 
had some CFTR mRNA transcripts with exon 9 completely deleted. They 
concluded that individuals can have up to 66% of bronchial CFTR mRNA 
transcripts that lack exon 9, a region representing 21% of the sequence coding for 
the NBD1 region of the protein, and show no symptoms of CF disease (Chu et al., 
1991). In a further study, they deduced that only between 8-16% bronchial 
epithelial cells need to express normal exon 9 CFTR mRNA to maintain normal 
phenotype as deduced from the observation that an individual with 92% of 
transcripts lacking exon 9 showed no symptoms of CF (Chu et al., 1992). Another 
group developed a PCR based method to quantify CFTR transcripts and applied this 
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to the analysis of nasal epithelium RNA of five patients with CF and the 3272-
26A>G/ΔF508 genotype. The 3272-26A>G mutation creates an alternative splice 
acceptor site in intron 17 that competes with the normal one. The use of this 
alternative splice site causes a reduction in normal transcript levels and as a 
consequence normal protein (Beck et al., 1999). They calculated that 8.2 ± 0.1% of 
the total CFTR RNA was normal full-length CFTR in these five patients. When the 
reduced number of mutant CFTR transcripts that result from the ΔF508 allele were 
also taken into account, it was calculated that these patients had only 4.7 ± 0.5% 
normal CFTR mRNA relative to normal individuals. All five patients had mild CF 
compared to ΔF508 homozygotes therefore they concluded that 5% of normal 
CFTR mRNA is enough to ameliorate the severity of the disease (Ramalho et al., 
2002). A more recent study looked at the functional effects of correcting CFTR on 
the levels of ASL. This in vitro study involved delivering CFTR cDNA in a 
parainfluenza virus to a model of the human CF ciliated surface epithelium and 
measuring the effects on mucus transport. They found that 25% of cells needed to 
be corrected to restore mucus transport rates to levels comparable to non-CF 
airways (Zhang et al., 2009).  
A lot of studies look at the Cl
-
 defect but what about the Na
+
 abnormalities seen in 
CF? It is unclear whether both Na
+
 and Cl
-
 abnormalities need to be corrected for 
clinical benefit. A study addressed this by introducing varying numbers of non-CF 
cells with CF cells and assessed the resultant degree of correction of both ion 
abnormalities. It showed that a mixture of ~ 5% of non-CF cells corrected the Cl
-
 
defect completely but nearly 100% of cells needed to be non-CF in order to restore 
Na
+
 transport (Johnson et al., 1995).  
The natural defence barriers presented by the lung to foreign particles makes 
delivery of gene therapy tools difficult. Firstly the mucociliary mechanism 
mentioned earlier can inhibit gene transfer as CF patients produce more mucus and 
increase the viscosity and penetrability of this layer. To counter viscous CF sputum, 
agents such as rhDnase and gelsolin have been used effectively to reduce viscosity 
and increase transduction efficiency (Stern et al., 1998). The host‟s innate immune 
system creates another barrier making repeat dosing with some viral vectors 
impossible, as recognition of viral coat proteins results in production of neutralising 
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antibodies (Zabner et al., 1996). Cao et al., demonstrated that transient 
immunosuppression could significantly enhance the efficiency of transgene 
expression and facilitated repeat dosing of helper-dependant (HD) adenovirus 
vectors to mouse lungs (Cao et al., 2011).  
1.4.2 Which cells/ part of the lung to target? 
The optimal cell type to target is unclear and remains a topic of debate. Some think 
the cells with maximal CFTR expression are in the submucosal glands in bronchial 
tissues notably in the serous component of the secretary tubules (Engelhardt et al., 
1992). This group used in situ hybridisation and immunochemistry to characterise 
the distribution of CFTR in cells. Another group have reported WT CFTR protein 
was localized to the apical membrane of ciliated cells within the superficial 
epithelium and gland ducts (Kreda et al., 2005). These conflicting reports make it 
difficult to ascertain which cells to target for gene therapy. Delivery via 
nebulisation would hit the surface epithelium but would not reach the submucosal 
glands. Also treating the surface epithelia, which are terminally differentiated, 
would mean gene expression would be lost with the death of the cell. The life-span 
of human epithelia is still unknown, however studies in mouse models have shown 
that ciliated airway cells have an average half-life of six months in the trachea and 
17 months in the lung (Rawlins & Hogan, 2008). Targeting stem cells of the 
respiratory tract such as basal cells, would be much more difficult to transduce but 
if successful gene transfer would be passed on to progeny cells and lead to long-
term CFTR expression. There is evidence that a number of epithelial cell types in 
the lung are slow-cycling/progenitor cells that have the capacity to proliferate in 
vivo following lung injury (Liu et al. 2009). Studies of gut epithelia which have a 
high turnover rate identified the crypt base columnar cell as the intestinal stem cell. 
As the stem cells proliferate, some become displaced from the niche and commit to 
differentiation leaving the overall stem cell number approximately conserved. The 
clone size undergoes a random sequence of expansions and contractions around the 
crypt base. Sooner or later the entire crypt base stem cell population derives from 
the last remaining clone. Targeting the stem cells of CF patients with integrating 
vectors, like AAV, could lead to long term correction. 
 21 
 
1.4.3 Efficacy is difficult to detect 
Measurements of transgene mRNA and protein levels will determine if gene 
transfer is successful. As CFTR is normally expressed at a low level in healthy 
lungs, the level of transgene mRNA and protein will be similarly low, and assays 
used to detect these levels may not be sensitive enough. Also, detection of protein 
may not always correlate to improved function, as has been seen in some previous 
clinical trials. Transmembrane potential difference (PD) is used as an end point in 
nasal trials of CF gene transfer and novel pharmacological agents (Wilschanski et 
al., 2000). More recently, tracheal and bronchial PD measurement techniques have 
been developed and used in clinical trials of liposome-mediated CFTR gene 
transfer, (Alton et al., 1999). Function can also be deduced from more downstream 
measures, like inflammation. For example, IL-6 /8 and neutrophils are increased in 
CF lungs, if there was a decrease in these levels following gene transfer one could 
infer that function has been restored. Forced expiratory volume (FEV1) is another 
measure of efficacy outcome. A number of measurements would need to be taken 
into account in order to achieve a clear picture of whether a gene therapy trial has 
clinical benefits.  
1.4.4 Animal models to study the disease 
The development of novel CF therapies has been hindered by the lack of animal 
models that recapitulate the key features of lung and other organ disease 
pathogenesis. Transgenic mice with CFTR null alleles and a variety of other 
mutations have been available since the early 1990s but as these do not 
spontaneously develop a CF lung phenotype their use has been limited. In 2008, 
two groups used AAV vectors, followed by nuclear transfer and cloning, to develop 
CF pigs (Rogers et al., 2008) and CF ferrets (Sun et al., 2010). Pigs share many 
anatomical and physiological features with humans. Newborn pigs lacking CFTR 
exhibited defective Cl
-
 transport and developed meconium ileus, exocrine and 
pancreatic destruction all of which are seen in human newborns with CF (Rogers et 
al., 2008). Like humans, null pigs‟ lungs were free of inflammation at birth but 
manifest a bacterial host defence defect without prior infection. Null ferrets develop 
multi-organ system disease and neonatal animals manifest a pulmonary host disease 
defect associated with colonisation of bacteria (Sun et al., 2010). Both of these new 
 22 
 
models of CF disease are very attractive for gene therapy studies, however, cost and 
handling procedures mean it will be several years before these models are available 
to the wider research community.  
1.4.5 CF gene therapy to date 
 
-Viral vectors 
Since cloning of the CF gene in 1989, twenty-five Phase I/II clinical trials have 
been carried out using a variety of viral and non-viral gene transfer agents, 
(Griesenbach & Alton, 2009). In this section some of the findings of these trials are 
discussed. 
The first trial in 1993 used E1-deficient adenovirus (AdV) vectors to deliver CFTR 
cDNA to the nose of three CF patients. The outcome of treatment was assessed by 
measuring PD in the nasal epithelium in response to low Cl
-
 solution. An increase in 
PD was observed in all three patients suggesting the CF Cl
-
 defect had been 
partially corrected. No detection of increased levels of CFTR mRNA or protein was 
reported. Patients suffered nasal congestion and mild rhinorrhoea but symptoms 
subsided within 24 hrs of administration of AdV-CFTR and were attributed to the 
method of delivery (Zabner at al., 1993).  
In 1994, the first clinical trial to deliver CFTR to human lung was carried out using 
AdV (Crystal et al. 1994). In this study four patients, all homozygous for ΔF508, 
were administered with a replication deficient AdV containing the 4.5 kb of CFTR 
cDNA. Approximately 5-14% of bronchial cells tested were shown to express AdV 
derived CFTR after treatment but no increase in lung function (FEV1) was detected. 
The level of CFTR positive cells was quite high and may have been a result of 
bronchial brushings being taken from the site of AdV vector delivery. This study 
demonstrated that it was safe to deliver AdV expressing CFTR to the lung over a 
1,000-fold range from 2 x 10
6
 to 2 x 10
9
 plaque forming units (PFU) with no sign of 
virus shredding or replication competent virus. However, one patient did suffer 
adverse effects having received a dose of 2 x 10
9
 which lasted 14 days post 
administration. The problem was attributed to vector-induced inflammation. No 
replication-competent or deficient virus was observed in nasal, pharyngeal, rectal, 
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blood or urine samples. There was a significant increase in IL-6 in one patient, and 
lower levels of IL-6 detected in the other three suggesting IL-6 levels were dose- 
dependent and that there was a threshold for symptomatic responses to IL-6.  
The following year a group conducted a trial on 12 CF patients, again using AdV, to 
deliver CFTR cDNA. The nasal epithelium was the site of delivery, with six 
patients receiving AdV-CFTR and six receiving control. Reverse-transcriptase (RT) 
PCR detected molecular evidence of gene transfer in 5/6 of the patients treated with 
AdV-CFTR, however, the level of epithelial cells transduced was very low (<1%) 
with no restoration of Cl
-
 conductance or normalisation of Na
+
 transport as 
determined by nasal PD. It is thought the absence of AdV tropism for surface 
columnar cells which normally express CFTR (a factor that should have been 
considered before clinical trials were started) may explain this low level. No toxic 
effect was seen at the lower doses, however, like before there was some mucosal 
inflammation in 2/3 patients at the highest dose of 2 x 10
10
 PFU meaning the 
problem of low gene transfer cannot be overcome by increasing the dose, Although 
there were no phenotypic changes detected, the safety profile of AdV as a vector 
was demonstrated (Knowles et al., 1995). 
Much attention has focused on the problem of repeat administration of AdV; as 
AdV expression is transient it would be necessary to repeatedly deliver CFTR 
cDNA for the lifetime of the patient. Zabner et al. (1996) showed that repeat 
administration was safe in a group of six patients who received increasing doses of 
up to 10
10
 infectious units with no detection of adverse effects; however, they did 
develop additional humoral immune responses. Partial correction of the Cl
-
 defect 
was observed in some subjects, but this was decreased in subsequent 
administrations thought to be because the immune response limited gene transfer. 
In a lower airway study (Harvey et al., 1999), Ad-CFTR was delivered at doses 
ranging from 3 x 10
6 
to 2 x 10
9 
PFU via an endobronchial spray in three doses over 
a nine month period to 14 CF patients. Bronchoscopic assessment was performed 3 
and 30 days post-administration. The data from this study demonstrates that; (i) the 
strategy appears to be safe; (ii) 3 days after the first administration, vector-derived 
CFTR cDNA expression was detected in the CF airway epithelium in a dose-related 
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pattern, with greater than 5% endogenous CFTR mRNA levels at the higher doses; 
(iii) expression is transient; second administration resulted in some expression that 
was not dose-related and the third administration produced no expression in any 
sample; (iv) the lack of expression with repeat dosing does not correlate with 
induction of systemic anti-Ad neutralising antibodies. Although repeat 
administration is safe, efficacy is severely compromised. As gene expression was 
not seen in patients with high pre-existing levels of antibody it is thought that the 
response may be dictated by these pre-existing titers and modified by route of 
administration but is not dose dependant (Harvey et al. 1999). 
The poor uptake of AdV vectors by apical membrane of airway epithelia may be 
explained by the lack of AdV receptors on the cell surface. The AdV fibre protein 
receptors, the Coxsackie B and Adenovirus type 2 and 5 receptor (CAR) and major 
histocompatibility complex (MHC) class 1 α-2 domain are all located on the 
basolateral surface of epithelial cells (Pickles et al., 1998). This is reinforced by the 
studies of Cohen et al., (2001), who observed that when AdV is applied to the 
basolateral surface of cells or when gap junctions are disrupted allowing access to 
the basolateral surface, the level of AdV transduction is increased. The inability of 
rAdV to replicate means it cannot infect the lung as effectively as WT AdV, which 
is commonly associated with lung infections as only a small number of WT virus 
particles are needed to initiate infection.  
Another virus vector regularly used in CF clinical trials is recombinant Adeno-
Associated virus (rAAV). Twenty-five CF patients were treated with AAV-
serotype- 2 via intranasal and endobronchial administration in a phase I clinical trial 
(Flotte et al., 2003). Doses of rAAV-CFTR vector ranged from 3 x 10
1
 to 1 x 10
9
 
replication units (RU). One serious adverse event was recorded and judged to be 
vector related. Vector shredding was minimal and serum-neutralising antibodies 
were detected after vector delivery of the highest doses. PCR was used to measure 
gene transfer and was not observed in nasal and bronchial epithelia until a dose of 1 
x10
7
 was administered. No change in nasal PD was reported. In another study by 
Moss et al., (2007), repeat administration of AAV-CFTR was investigated. In this 
study 102 CF patients received two doses AAV-CFTR or matching placebo 
administered 30 days apart via a nebuliser. In contrast to a smaller phase II trial 
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carried out previously, Moss et al., (2004) reported that there was no difference 
observed in FEV1 or IL-8 levels between groups. It did demonstrate the safety of 
AAV vector re-administration but also suggests the need to improve gene transfer 
technology to increase clinical efficacy outcome.  
These studies have shown; 
a) Both AdV and AAV viral vectors are safe delivery vehicles 
b) Repeat dosing is necessary as expression is transient 
c) Although some functions are improved following first dose, no benefit has been 
seen as subsequent dosing induces an immune response limiting gene transfer 
There have been no new studies using virus vectors for CF patients reported by 
clinicaltrials.gov since 2005. 
 
-Non-viral vectors 
An alternative to using virus vectors for gene transfer is to use non-viral or synthetic 
vectors. As mentioned above, the repeat administration of viral vectors seems to be 
limited by the production of antibodies in response to vector delivery or the 
existence of pre-existing neutralising antibodies. Non-viral vectors may be able to 
overcome these limitations. 
The majority of trials to date have used lipid-based gene transfer agents. The first 
non-viral clinical trial assessed the safety and efficacy of a single nasal dose 
delivery of plasmid DNA containing CFTR cDNA under the control of SV40 
promoter, complexed with (3β[N-(N‟,N‟-dimethylaminoethane)-carbomoyl] 
cholesterol:dioleoylphosphatidylethanolamine (DC-Chol/DOPE) liposomes. Fifteen 
CF patients were tested, with 9 receiving the CFTR cDNA and 6 receiving just 
liposome. No adverse defects were detected and there was a 20% partial correction 
of Cl
-
 defect observed in nasal PD. This was maximal at day three and had reverted 
to pre-treatment levels by day seven, (Caplen et al., 1995). Alternative formulations 
were investigated in which plasmid DNA containing the CMV promoter complexed 
with dioleoyl trimethyl ammonium propane (DOTAP) liposomes and were shown 
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to have similar effects. In one study in which eight CF patients were treated with 
pCMV-CFTR-DOTAP, transgene DNA was detected in 7/8 patients up to 7 days 
following treatment and for up to 28 days in two of these seven patients. Vector 
derived CFTR mRNA was observed in 2/7 patients at days 3 and 7 post-treatment 
(Porteous et al., 1997). Although delivery of these complexes was well tolerated 
any electrophysiological defect correction was small and variable. By studying the 
gene transfer ability of different commercially available cationic lipids to the lung 
of mice in vivo Lee et al. (1996) found that a novel lipid GL-67 in combination with 
the neutral co-lipid DOPE, could enhance gene transfer by 1,000 fold as compared 
with DNA administered alone. Co-formulation of GL67 (GL67A) with the neutral 
lipid DOPE, (which is thought to facilitate pDNA endosomal escape), along with 
small amounts of a polyethylene glycol-containing lipid, DMPE-PEG5000, was 
found to stabilise formulations at concentrations sufficient for aerosol delivery to 
the lung (Eastman et al., 1997). Delivery was safe and a single nasal dose of 
GL67A/pDNA produced vector derived mRNA expression and an overall 
correction of ~20% of the Cl
-
 defect in the nose (Zabner et al. 1997).  A double-
blind placebo-controlled trial was performed by Alton et al., (1999) on eight CF 
patients to assess the safety and efficacy of GL67-CFTR (Alton et al. 1999). The 
CFTR cDNA was under the control of the CMV promoter and the DNA-lipid was 
delivered by nebulisation to the lung. Seven of the eight patients receiving the 
active complex experienced flu-like symptoms that were resolved within 36 hrs. 
Pulmonary administration resulted in a significant degree of correction of Cl
-
 
abnormality that equated to 25% restitution towards normal values as determined by 
in vivo PD. However, no effect was seen on the increased Na
+
 absorption 
experienced by CF patients. Encouragingly bacterial adherence was decreased 
following treatment in five out of six patients. No vector specific CFTR mRNA was 
detected in any patient sample, however vector-derived DNA was detected at levels 
of 10
6
 copies or more per sample in all eight patients at day two eluding to the 
possibility that RNA integrity was compromised or there was inadequate sample.  
To overcome the initial flu-like symptoms experienced in this trial a number of 
modifications were made. Firstly, the pro-inflammatory CpG motifs were removed, 
and secondly the viral CMV promoter was exchanged for a humanised one (hybrid 
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elongation factor-1a) capable in preclinical trials of sustaining prolonged gene 
expression (Hyde et al., 2008). They showed that even a single CpG motif in the 
plasmid DNA was sufficient to elicit an inflammatory response in a mouse model. 
When this newly improved plasmid containing CFTR cDNA (pGM169) was 
complexed to GL67A, it led to > 4 week expression in murine lung model upon 
single dosing.  
This study has lead to the formation of The UK Cystic Fibrosis Gene Therapy 
Consortium and major funding to support current trials. One such trial is currently 
assessing GL67A/pGM169 in an ongoing multi-dose trial at the Royal Brompton 
Hospital in London and at the Western General Hospital and Royal Hospital for 
Sick Children in Edinburgh (www.cfgenetherapy.org.uk). An update of the trial was 
presented at the 37
th
 ECFS meeting held in Lisbon by Dr. Jane Davis. It was 
reported that the delivery by aerosol of the GL67A/pGM169 complex under the 
control of the humanised promoter showed enhanced duration when compared to 
the CMV driven complex. Reduced inflammation was observed due to removal of 
the CpGs and there was an improvement in Lung Clearance Index (LCI).    
As well as DNA-lipid complexes, some groups are using nanoparticles to deliver 
CFTR cDNA. Compacted DNA nanoparticles were delivered to the nasal 
epithelium in twelve CF patients (Konstan et al., 2004). Some Cl
-
 transport was 
observed in nasal PD and at day 14 vector PCR analysis showed a mean value in 
patients receiving the highest dose of 8.0 mg or 0.58 copies per cell. Corrections 
persisted for up to six days following gene transfer. 
1.5 Gene addition vs Gene repair 
Although millions of dollars have been spent on these studies there are still little or 
no reports of success to date in these clinical trials. As they are focusing on 
delivering CFTR cDNA in a transient manner, the limitations of repeat dosing are 
going to have to be overcome in order for patients to benefit from treatment. The 
developments of lipid-complexes which do not produce an immune response are 
promising. Viral vectors which target specific regions and cell types are being 
studied and may be of clinical benefit. Another obstacle with cDNA addition is that 
once the corrected cell dies so does the CFTR. If one could permanently correct the 
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DNA mutation in a stem/progenitor cell, rather than adding cDNA, then the correct 
DNA sequence would be passed on to daughter cells. Another advantage of such a 
gene repair strategy would be that the corrected gene would be under the control of 
the endogenous promoter and so spatiotemporal expression would be maintained 
unlike cDNA addition where the gene is under the control of an exogenous 
promoter and so expression levels are typically higher than normal.  
The field of genome editing is described in the following section. 
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1.6 Genome editing 
DNA damage is constantly occurring in cells due to both environmental and 
endogenous insults at a rate of 10
3 
- 10
6
 lesions per cell per day (Lodish et al., 
2004). A double-stranded break (DSB) is the most cytotoxic form of DNA damage. 
It can occur during the normal course of DNA replication, through exposure to by-
products of cellular metabolism like oxygen free radicals (Valko, et al., 2006) and 
ionising radiation (Jackson & Bartek, 2009). To combat threats posed by DNA 
damage, cells have evolved with mechanisms to detect DNA lesions, signal their 
presence and promote their repair (Rouse & Jackson, 2002).The ability of a cell to 
repair these breaks is critical for the preservation and faithful propagation of genetic 
information. Deficiencies in DSB repair can lead to mutations and chromosomal 
rearrangements which may ultimately result in genomic instability and 
tumourigenesis. Xeroderma pigmentosum is an autosomal recessive disease in 
which the ability of the DNA repair system to repair damage caused by exposure to 
UV light is deficient and leads to skin cancers. 
 
1.6.1 DNA repair mechanisms 
There are three major pathways used by cells to repair DSBs; the error-prone non-
homologous end joining (NHEJ) pathway (Lieber, 2008), the faithful single strand 
annealing (SSA) pathway, and homologous recombination (HR) pathway, which 
can also be referred to as homology directed repair (HDR) (San Filippo, et al., 
2008). In eukaryotes, homologous recombination is restricted to the S and G2 phase 
of the cell cycle when the sister chromatid is in close proximity (Sonoda et al., 
2006) whereas NHEJ can occur throughout the cell cycle because it does not require 
a homologous chromosome. The three pathways are described in detail below and 
the regulation of choice is discussed in the next section. 
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Figure 1.5: DSB repair pathways. The major pathway during the G1 growth phase is NHEJ shown 
in the left column. Following DSB formation the KU70:80 dimer is recruited to the free DNA ends 
and recruits DNA-PKcs. DNA-PKcs recruits the nuclease Artemis, XRCC4 and DNA ligase IV. 
XRCC4 acts as a scaffold to enhance Artemis activity which results in small deletions prior to both 
ends being joined by DNA ligase IV. The middle column demonstrates the single strand annealing 
pathway. This pathway is used to repair DSBs that occur near repeat sequences. It is initiated by the 
binding of the MRN complex to the free DNA ends. The EXO1 nuclease resects back the both sides 
of the break to create 3‟ ssDNA overhangs. RPA binds to the ssDNA. Single stranded repeat 
sequences either side of the DSB (shown on red) can bind via complementary base pairing creating 
3‟ heterologous tails which are removed by ERCC1. The final major pathway which cells employ to 
repair DSBs is the homologous recombination pathway shown in the far right column. End resection 
occurs in a similar manner to that in single strand annealing. Following recruitment of RPA to 3‟ 
ssDNA overhangs RAD51/52 is recruited to the overhangs. Interaction between RAD51/52 and 
RAD54 facilitated strand invasion of a homologous DNA duplex. DNA synthesis then occurs 
creating a D-loop which can be resolved in different ways resulting in a non-crossover or crossover 
event. (Adapted from Vasileva & Jessberger, 2005) 
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1.6.2 Homologous Recombination  
HR is an important repair mechanism in mitotic cells to correct DSBs and is 
essential during meiosis to promote pairing and segregation of chromosome 
homologs at the first meiotic division. It relies on the presence of a homologous 
template from which to repair from and this is generally the sister chromatid in 
mitotic cells or the chromosome homolog in meiosis (Mimitou & Symington, 
2009). 
HR is initiated by resection of the DNA ends at the DSB site to yield 3‟ single-
stranded DNA (ssDNA) overhangs which are capable of invading duplex DNA 
containing a homologous sequence (Mimitou & Symington, 2009). The MRN 
complex (MREII, RAD50 and NBS1) together with CtIP (Sartori et al., 2007) is 
required for the initial end processing step of HR in human cells. The 5‟-3- 
exonuclease EXO1 (Mimitou & Symington, 2008) or the combined 
helicase/nuclease activities of SGS1/DNA2 (Zhu et al., 2008) are involved in more 
extensive processing. The ssDNA is bound initially by a replication protein A 
(RPA), which removes any secondary DNA structures. RPA is displaced by 
BRCA2 which recruits the filament forming protein RAD51 via its BRC repeats 
(Yuan et al., 1999). RAD51 is a DNA-dependent ATPase that forms nucleoprotein 
filaments with DNA. Once recruited to the DSB, RAD51 catalyses strand exchange 
during which ssDNA invades homologous duplex DNA forming a displacement 
loop (D-loop). The mechanism by which strand invasion occurs is not fully 
understood, however, the DNA strand exchange activity of RAD51 is strongly 
stimulated by the helicase RAD54 which displays dsDNA-dependent ATPase 
(Petukhova et al., 1998), DNA translocase (Heyer et al., 2006) and DNA 
supercoiling and chromatin remodelling activities (Tan et al., 2003). Once formed, 
the D-loop has multiple fates (San Filippo et al., 2008). In the primary pathway in 
mitotic cells, termed synthesis-dependent strand annealing (SDSA), the 3‟ D-loop is 
extended by repair synthesis, and then the newly synthesised DNA strand 
dissociates to anneal to the other 3‟ end to complete the reaction. If the second 3‟ 
overhang is “captured” by the D-loop, a double Holliday junction forms that can 
potentially be resolved by several different proteins, GEN1 (Mimitou & Symington, 
2009) and SLX1/SLX4 (Klein & Symington, 2009). As double Holliday junction 
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resolution can occur in different ways, crossover and non-crossover products are 
possible. Crossover products play an important role in facilitating chromosome 
segregation during meiotic recombination (Cole et al., 2010). Crossovers occurring 
during mitotic recombination may have deleterious effects, including loss of 
heterozygosity (Moynahan & Jasin, 2011). However, proteins such as BLM 
suppress mitotic crossovers by disrupting Holliday junctions, thereby decreasing the 
risk of genomic instability (Chu & Hickson, 2009). 
1.6.3 Single Strand Annealing 
Another repair pathway that makes use of sequence homology, but is distinct to HR, 
is single strand annealing (SSA) (Lin et al., 1984). SSA can occur after end 
resection if sequence-repeats exist on both ends of the DSB. The complementary 
single strands formed at the repeats then re-anneal and flaps formed from the 
annealing reaction are trimmed off, resulting in loss of sequence between repeats. 
Compared to HR, SSA is far more mutagenic because it involves loss of genetic 
information. Proteins identified to promote SSA in mammalian cells include 
RAD52 (annealing), ERCC1 and RAD1/RAD10 (flap endonuclease) (Stark et al., 
2004). 
1.6.4 Non-Homologous End Joining 
NHEJ is initiated by DNA end-binding proteins Ku70 and Ku80 heterodimer, which 
rapidly associate with exposed DNA breaks. NHEJ can join DNA ends together 
with a number of different structures and as a result makes use of a number of 
processing steps that may include cleavage and gap filling prior to ligation. Artemis 
and DNA-PKcs exist as a complex within cells and binds to the Ku-DNA end 
complexes. Upon complex formation, DNA-PKcs phosphorylate Artemis, and 
Artemis acquires endonucleolytic activity on the 5‟ and 3‟ overhangs, as well as 
hairpins (Ma et al., 2002). This cleavage may result in gaps in the DNA that need to 
be filled in with polymerases. This gap filling reaction is most likely carried out by 
members of the PolX family which includes polymerases μ and λ, which interact 
with the Ku-DNA complex via BRCT domains (Ma et al., 2004). The modification 
of DNA ends prior to end joining by these processing steps can lead to deletions 
and insertions accounting for the more error-prone nature of NHEJ compared to 
HR. Ultimately, Ku/DNA-PKcs complex recruits DNA ligase IV/XRCC4 complex 
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which completes repair of the break. The XRCC4 acts as a scaffold that forms 
interactions with both Ku and DNA and both stabilises and stimulates ligase activity 
of DNA ligase IV (Grawunder et al., 1997). 
Although NHEJ is imprecise at the local sequence level, it is efficient in restoring 
chromosomal integrity that would otherwise result in the loss of hundreds of genes 
on entire chromosomal arms or segments. Vertebrates have taken advantage of the 
error prone nature of NHEJ in the generation of antigen receptors for the adaptive 
portion of the immune system. In V(D)J recombination, the imprecision at the V-to-
D and D-to-J joining sites markedly increases the amount of potential diversity that 
would otherwise be limited simply to the various combinations of V, D and J 
segments. The major disadvantage of NHEJ is the accumulation of randomly 
located mutations over time in the genome. 
1.6.5 Regulation of repair pathway choice 
In 1998, it was shown that the stage of the cell cycle is a decisive factor in the 
control of DSB repair (Takata et al., 1998). In this genetic study it was found that 
when the chicken cell line DT40 lacked Ku70, NHEJ was defective whereas when 
the cell line lacked Rad54, HR was moderately impaired. Both ΔKu70 and ΔRad54 
cell lines were more sensitive to killing by ionising radiation relative to the WT 
DT40 cell line, suggesting both pathways contribute to repair of DSBs. A phase-
specific sensitivity profile to ionising radiation clearly showed that HR and NHEJ 
are differentially employed during the cell cycle, with ΔRad54 cell lines showing 
ionising sensitivity during the S to G2 phase and the ΔKu70 showing sensitivity at 
the G1 phase. The restriction of HR to the S/G2 phases of the cell cycle makes sense 
in that the primary repair template in mammalian cells is the sister chromatid, which 
is not present in G1 cells.  
The choice between repair pathways is also governed by cyclin-dependent protein 
kinases (CDKs), with DSB resection being a major site of control, an event 
necessary for HR but not for NHEJ. In yeast, CDK activity is required for efficient 
end resection of DSBs, and hence, HR, during S/G2 (Ira et al., 2004). They reported 
that DNA damage checkpoint activation by a DSB requires CDK1 in budding yeast. 
CDK1 was also found to be required for DSB-induced HR as inhibition of CDK1 
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resulted in a compensatory increase in NHEJ. CDK1 is required for efficient 5‟ to 
3‟ resection of DSB ends and for the recruitment of RPA and Rad51 proteins. 
More recent data have identified the role of a DNA damage response protein 
53BP1. In response to DSBs, 53BP1 binds to chromatin at damaged sites and 
blocks end resection, thereby favouring repair by NHEJ (Bothmer et al., 2010). Pro-
NHEJ functions require the direct physical association of 53BP1 with DNA ends 
and the DSB-induced phosphorylation of its N-terminal ATM/ATR kinase sites 
(Bothmer et al., 2011). The DNA damage response protein RIF1 has recently been 
identified as an essential factor recruited by phosphorylated 53BP1 to promote 
NHEJ and block HR (Chapman et al., 2012).  
Many groups have attempted to manipulate the cell cycle and/or the concentrations 
of relevant proteins in order to discriminate between one pathway and another. A 
study involving the introduction of a point mutation into the αB-crystallin gene in 
one-celled mouse embryos found that by co-injection of ssDNA along with 
antibodies against Ku70/80, or by supplementing the system with hRad51/54, 
resulted in an increase of the rate of HR to enable targeted mutagenesis (Morozov & 
Wawrousek, 2008). A few studies have reported that a transient cell cycle arrest in 
the G2 phase using microtubule inhibitors vinblastine and nocodazole can increase 
targeted HR up to seven-fold (Urnov et al., 2005; Maeder et al., 2008). However, 
these compounds are highly toxic to cells and therefore would not be of use in a 
therapeutic setting. Recently, the cyclin-dependent kinase inhibitor indirubin-3‟-
monoxime has been shown to increase transduction of AAV and nuclease-mediated 
gene targeting (Rahman et al., 2013). The transient cell cycle arrest induced by 
indirubin increased AAV-mediated homology directed repair up to six-fold in 
human cell lines and ten-fold in umbilical cord-derived mesenchymal stromal cells. 
Minimal cytotoxicity was observed and so indirubin may prove useful for future 
clinical applications.  
 
1.6.6 Homology-directed repair (HDR) 
DSBs are repaired efficiently as they arise naturally during the life cycle of a cell. 
The repair process of HR using the sister chromatid as a repair template gave way 
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to the hypothesis that if artificial DNA repair templates were introduced, could they 
be used to repair mutations in the genome. That is, if you provide a donor plasmid 
containing the correct sequence of DNA and homology arms, would recombination 
be significantly increased with the generation of DSB close to the mutation locus? 
The first methods for homologous genome editing were described in yeast whereby 
a stable leu-2
-
 yeast strain was transformed to leu-2
+
 by using a chimeric ColE1 
plasmid carrying the yeast leu-2 gene (Hinnen et al., 1978). This simple method of 
genome modification demonstrated that plasmid DNA and yeast sequences could 
integrate into the yeast chromosome, not only at the intended leu-2 region, implying 
homology plays a role in the insertion event but also in several other chromosomal 
locations albeit to a lesser extent than the intended location. 
The first evidence of extrachromosomal homologous recombination in mammalian 
somatic cells was provided by Kucherlapati and colleagues (Kucherlapati et al., 
1984), thus showing that an exogenous donor sequence can be used for HR repair 
rather than relying on the sister chromatid. They demonstrated this principle using 
two plasmids, each containing a different mutation in a neomycin resistance gene 
such that either plasmid alone does not confer resistance to this drug on cells 
(human bladder carcinoma cell line), but the presence of both results in HR between 
the plasmids to create a functional neomycin resistant cDNA sequence and thereby 
confers neomycin resistance to the cells. This application of HR for the repair of 
mutations has been named homology-directed repair to distinguish it from 
endogenous HR processes.  
-Length of homology arms and sequence divergence 
Multiple groups have explored the optimal length of homology required for 
efficient HR. Thomas and Capecchi first described an exponential relationship 
between length of homology and targeting frequency in the HPRT locus (Thomas 
and Capecchi, 1987). A later study comparing the frequency of gene targeting with 
varying lengths of homology revealed that the minimum length required for HR to 
occur was 1.7 kb (Hasty et al., 1991). They found that an additional 225 bp 
increased the frequency by at least five-fold. An increase in homology from 1.9 to 
4.2 kb and from 4.2 to 6.0 kb resulted in a further 16-fold and 3-fold increase 
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respectively, with a total difference of 240-fold efficiency between 1.7 and 6 kb. Of 
note in this study, all vectors used to introduce the target site were linearised prior 
to electroporation into mouse embryonic stem (ES) cells. They determined that the 
1.3 kb vector contained only 132 bp of homology on the 5‟ end, which may be too 
little homology for efficient HR to occur. Homology arms of equal length on either 
side of the target sequence may be more efficient. A comparison of vectors with 
total arm length of 6-8 kb to vectors with arms longer than 18.4 kb revealed that 
increasing the length higher than 8 kb did not increase the efficiency of HR. Again 
all vectors were linearised prior to transfection (Lu et al., 2003). As well as 
homology arm length the degree of homology between the template sequence and 
the sequence to be repaired is also important. A study by Elliott et al., (1998) 
revealed that 1.2% sequence divergence resulted in a six-fold decrease in 
recombination (Elliott et al., 1998). This study also gave some insight into the effect 
of distance from the DSB/cut site on repair, with the majority of events (~80%) 
occurring at 58 bp or less. 
-Increasing the rate of HDR by inducing a DSB 
The rate of HR in mammalian cells typically falls in the range of 10
-5
 to 10
-6
 events 
per cell per generation, however, a DSB can stimulate HR by >1000 fold (Sun et al., 
2012). It had been shown that linear vectors could increase the level of HDR in 
cells, leading to the hypothesis that DSBs in the DNA are highly recombinogenic 
and that broken ends of DNA molecules can interact directly with homologous 
chromosomal regions (Orr-Weaver et al., 1981). However, to harness the 
recombinogenic potential of a DSB it is necessary to create a unique DSB at the 
genomic site of interest. Early studies used the homing endonuclease I-SceI from S. 
cerevisiae, which recognises a unique 18 bp nonpalindromic sequence (Colleaux et 
al., 1988) creating a DSB on average once every 7 x 10
10 
bp (4
18
). Rouet et al., 
expressed a modified I-SceI endonuclease in COS1 mammalian cells, resulting in 
cleavage and enhanced extrachromosomal recombination (Rouet et al., 1994). 
Recombination was measured by chloramphenicol acetyltransferase (CAT) activity 
which can only be expressed following successful HR. CAT activity was very low 
when the recombination substrates were transfected by themselves. However a ten-
fold increase was detected following transfection along with I-SceI. As there are 
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only a handful of homing nucleases like I-SceI and a limited number of recognition 
sequences, the chances of cleaving in a gene are virtually zero. Also the limitation 
of having to pre-insert the I-SceI site into the genome makes it unsuitable for more 
advanced gene modification experiments. Another study in the same year 
demonstrated that the non-specific nuclease domain Flavobacterium okeanokoites 
endonuclease (FokI) could be removed and retargeted to bind a different DNA 
sequence (Kim & Chandrasegaran, 1994). FokI is a type II restriction endonuclease 
that recognises a nonpalindromic sequence in duplex DNA and cleaves nine and 13 
bp away from the recognition site. They reported the presence of two distinct 
domains within this enzyme; a sequence-specific domain and a non-specific 
nuclease domain (cleavage domain). By linking the Drosophila Ultrabithorax (Ubx) 
homeodomain to the cleavage domain of FokI they were able to redirect FokI 
cleavage to the Ubx recognition site indicating that the non-specific domain could 
be used in conjuction with DNA binding proteins to target any sequence in the 
genome. As random introduction of genetic material in higher organisms can lead to 
unintended effects due to insertional mutagenesis, targeted genome modification to 
a specific location is desired. 
 
1.7 ZFN, TALEN and CRISPR/Cas-based tools for genome 
editing 
The previous section showed the importance of a DSB to induce HDR. The way 
forward is to use „programmable enzymes‟ to create specific DSBs at any desired 
location. This section describes the advances in the last 8-10 years in this area. 
1.7.1 Zinc Finger Proteins (ZFPs) 
The Cys2-His2  (C2H2) zinc-finger (ZF) domain is a type of DNA-binding motif 
found in eukaryotes and is the second most frequently encoded protein motif in the 
human genome accounting for ~2% of all genes (Beerli & Barbas, 2002). The C2H2
 
class of zinc fingers were first identified in Xenopus laevis transcription factor IIIA 
(TFIIIA) (Miller et al., 1985). TFIIIA was shown to contain nine tandem C2H2 zinc 
fingers each consisting of 30 amino acids, containing two invariant pairs of 
cysteines and histidines, the most common Zn
2+
 ligands. X-ray crystallography 
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confirmed that a ZF was composed of two beta strands and an alpha helix (Lee et 
al., 1989). The two cysteines are near a turn in the anti-parallel beta sheet, and the 
two histidine residues are in the C-terminal portion of the alpha helix. By studying 
the X-ray crystal structure of DNA complex with Zif268 (a mouse immediate early 
protein) at 2.1Å resolution, Pavletich et al., were able to show that ZFs bind to the 
major groove in a simple tandem arrangement with a semi-conserved pattern of 
interactions in which three/four amino acids from the alpha helix contact three/four 
adjacent bases in DNA (Pavletich & Pabo, 1991). The most specific amino-DNA 
interactions occur at positions -1, +3 and +6 from the alpha helix and a fourth 
interaction between the amino acid at position +2 and a base on the opposite DNA 
strand (Figure 1.6a) (Jacobs, 1992). The overall binding arrangement has the first 
(N-terminal) finger near the 3‟ end of the recognition site and the last (C-terminal) 
finger near the 5‟ end of the recognition site. Typically the amino acid residue at -1 
bind the 3
rd
 base, the +3 binds the middle base and the +6 residue binds the 5‟ base 
with the +2 residue binding the 4
th
 base on the opposite strand. 
 
 
 
 
 
 
     
 
 
 
 
Figure 1.6a: Interaction of a zinc-ﬁnger domain with 4-bp DNA target observed in the complex. In 
the complex, one-to-one interactions between all recognition amino acids and DNA bases at speciﬁc 
positions were observed for the ﬁrst time. (Adapted from Sera, 2009). 
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As it appeared that each ZF works as an individual module, it was proposed that 
fingers with different triplet specificities could be combined to create a zinc finger 
protein (ZFP) that could recognise longer DNA sequences (Miller et al., 1985). 
They were shown to be usually linked  by the short sequence TGEKP (Pellegrino & 
Berg, 1991). Studies have indicated that this linker sequence is not just a passive 
structural element but can actually stabilise the alpha helix assisting in binding the 
protein to DNA (Laity et al., 2000). The first example of ZFPs with altered binding 
specificities was described in 1992. In this study they mutagenised the amino acid at 
position three of the 2
nd
 finger of Sp1 based on a database of zinc finger sequences 
available at the time, and presented the first partial recognition code of GNG and 
GNT triplets (Desjarlais & Berg, 1992). Since these early manipulations a number 
of methods are now available to design specific ZFPs to target any sequence in the 
genome (figure 1.6b) see section 1.7.3. 
 
    
Figure 1.6b: Interaction of 3-finger ZFP with double stranded DNA. The 4 bp DNA targets are 
overlapped. (Sera, 2009) 
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1.7.2 Zinc finger nucleases: designer nucleases for HDR 
The first group to link the cleavage domain of the FokI endonuclease to two 
different ZFPs and create a zinc finger nuclease (ZFN) fusion protein showed that 
cleavage was indeed directed towards the recognition site of the ZFPs (Kim, et al., 
1996). In this study they designed and tested two ZFNs in vitro with the λ phage 
genome (~48 kb). The targeted ZFN site was successfully cleaved in a sequence-
specific manner with a cleavage efficiency of >95%. In 1998, a study determined 
that WT FokI acts as a dimer. Introduction of mutations into the nuclease domain 
interface of FokI, making it defective for dimerisation, revealed greatly impaired 
DNA cleavage (Bitinaite, et al., 1998).  It was also demonstrated in this study that 
free nuclease may interact with bound nuclease to mediate DNA cleavage when the 
nuclease is in excess. In order to cleave at a desired location two 9 bp DNA 
sequences in inverted orientation  and separated by 6-35 bp should be selected, as 
reported by Smith et al., (2000). They determined that when ZFNs bind in a tail to 
tail fashion (see figure 1.7)  the rate of DNA cleavage occurs almost to completion 
with cleavage observed at a 1:1 ratio of ZFN to DNA. No cleavage was observed 
when only one ZFN was used, however at a ratio of 5:1 some cleavage occurred in 
vitro. 
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A) 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 1.7: A) A pair of ZFNs bound to their respective sites in a tail-to-tail fashion and on opposite 
strands. This conformation enables efficient FokI nuclease domain dimerisation resulting in DSB 
formation. B) The modular assembly method uses phage display and gel mobility assays to isolate 
ZF motifs for specific target triplets. These motifs are then linked to create ZFPs with longer DNA 
recognition sequences. This method is limited to designing 3-finger ZFPs. (Adapted from Rebar & 
Miller, 2004 and Miller et al., 2007). 
 
The first report of the ability of ZFNs to create a DSB and induce homology-
directed repair was demonstrated in Xenopus laevis (Bibikova et al., 2001). The 
group microinjected plasmids containing two 1.25 kb repeats separated by ZFN 
binding sites into X. laevis oocyte nuclei along with the ZFNs. Repair of DSB 
formation by ZFNs in these cells would proceed by the single-strand annealing 
mechanism used to repair repeat sequences (see section 1.6.3). Homology-directed 
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repair was only observed when two ZFN binding sites were orientated in a tail to 
tail fashion with no repair detected with a single copy of the ZFN binding site 
indicating that conditions for cleavage in oocyte are stricter than in vitro. This study 
also looked at the effect of spacer length between the two ZFN binding sites as well 
as the length of the linker between the ZFP and FokI nuclease domain on DNA 
cleavage. Unlike the in vitro data reported previously by Smith et al., (2000) 
whereby all spacers from 6 to 35 bp were effectively cleaved when ZFN protein 
was present in modest excess (Smith et al., 2000); the effective spacer in oocytes 
was 6 to 18 bp with a 6 bp spacer being the most efficiently cleaved. The most 
effective linker between a ZFP and FokI nuclease domain was found to be between 
0 and 6 amino acids.  
A study in 2009 tested several linker sequences of different lengths with different 
spacer regions (Shimizu, et al., 2009). They used a plasmid-based single strand 
annealing (SSA) reporter assay in HEK 293 cells. Briefly, a luciferase gene was 
disrupted by a stop codon and a ZFN target site. A ZFN-induced DSB would allow 
SSA HR with an 870 bp region of homology in direct repeat orientation resulting in 
active luciferase activity. They showed that a 6 aa linker TGAAAR enhanced 
activity of ZFNs separated by a 6 bp spacer sequence and was most specific. An 
earlier study had reported highly-efficient HR in human cells using a ZFN with 4 aa 
linker on a target with a 5 bp spacer (Urnov et al., 2005). The exact spectrum of 
activities is most likely to depend on a variety of factors including cell type, assay 
used, composition and concentrations of the ZFNs and target sites. Of note, ZFs are 
not restricted to just three fingers, up to six fingers can be linked together to target a 
total of 36 bp.  
1.7.3 Zinc Finger Protein Design 
This section will look at a number of methods that have been developed to enable 
scientists to design and create their own ZFNs in the lab. Today ZFNs are readily 
available commercially from Sangamo Biosciences in partner with Sigma-Aldrich 
however pricing makes these ZFNs unattainable for some research groups who opt 
to design their own.       
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1.7.4 Modular Design 
There are 64 possible DNA triplets which can be recognised by ZFs. One design 
strategy was to identify highly specific fingers for all 64 triplets in order to establish 
a library for rapid construction of ZFPs (Pavletich & Pabo, (1991), Liu et al., 
(2002), Dreier et al., (2001, 2005)). Then via modular assembly ZFs for specific 
triplets can be linked together to recognise longer DNA sequences. 
From phage display selection and studying the Zif268 crystal structure several 
proposed codes emerged for the binding of ZFPs to DNA targets (Choo & Klug, 
1994). Screening methods based on gel mobility shift assays were used to isolate ZF 
motifs that not only bind all sixteen 5‟-GNN-3‟ triplets but were optimised to bind 
all sixteen triplets at the first, second and third position of a ZFP (Liu et al., 2002). 
Gel mobility shift assays were used to isolate ZFPs with high affinity for GNN 
triplets. Selected ZFPs were then re-tested up to five times via gel mobility shift 
assays with a degenerate oligo pool to select for ZFPs that showed both high 
specificity and high affinity. Most ZFP sequences identified matched those obtained 
by phage display in a previous study (Segal et al., 1999). Other phage display 
studies have isolated ZF motifs that bind twelve of all possible sixteen 5‟-ANN-3‟ 
(Dreier, et al., 2001) and fifteen 5‟-CNN-3‟ triplets (Dreier et al., 2005). Only a 
handful of ZF motifs that bind 5‟-TNN-3‟ triplets have been published, the best 
characterised being TGG which is the second finger of Zif268  (Pavletich & Pabo, 
1991). It is important to note that apart from the Liu et al. 2002 study in which they 
looked at the positional effect of a ZF motif on amino acid sequence, all other phage 
display methods selected ZFs for triplets at the second position. The availability of 
ZF libraries allows assembly of ZFPs that can recognise a diverse range of genomic 
targets. 
In spite of this large pool of resources, it has been reported that such designed ZFPs 
have an unexpectedly high failure rate (Ramirez et al., 2008). In this study 168 
ZFPs designed via modular assembly were tested against 104 DNA target sites in a 
bacterial 2 hybrid (B2H) assay. This system can accurately identify arrays that lack 
ZFN activity in human cells as determined by the expression of β-galactosidase. Of 
the 104 target sites tested, they did not obtain a single three finger array that scored 
positive in the B2H assay for 79 sites, (76% failure rate). The preference of ZFs for 
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guanine rich sequences was noted early (Pavletich & Pabo, 1991) and interestingly, 
when the authors grouped target sites based on number of GNN triplets present, 
they found that the number of GNN triplets had a remarkable effect on the success 
of ZFP binding efficiency. Only 41% of target sites containing three GNN triplets 
failed to bind a ZFP. This failure rate rose to 71%, 88% and 100% with 2 GNN, 1 
GNN and 0 GNN respectively. Therefore, even with three GNN triplets in the target 
site, the chance of designing an efficient pair of ZFPs is only 60%.  
1.7.5 Rational Design 
In 2002, Sera and Uranga published a non-degenerate recognition code table to 
allow rapid creation of numerous ZFPs with satisfactory binding properties. The 
table was based on a designed ZFP with three ZFs that recognise overlapping 4 bp 
sites in a 10 bp target sequence. Known and potential DNA base-amino acid 
interactions derived from X-ray crystal structures allowed identification of an amino 
acid for each position of the α-helical region (-1, 2, 3, and 6) of the ZF domain 
which contact DNA bases at specific positions in a regular fashion implicating four 
amino acids in DNA recognition (Sera & Uranga, 2002).  
 
 
Figure 1.8: Non degenerate recognition table design (Sera & Uranga, 2002). List of amino acid 
residues which make contact with the desired DNA bases at each position of a ZF recognition site.  
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For the most part, amino acids with shorter and smaller side chains were used for 
recognition of the second and fourth DNA bases and amino acids with larger and 
longer side chains were used for recognition of the first and third bases. Threonine 
was used for thymine recognition at positions -1, 2 and 6 as the methyl group of 
threonine interacts with the methyl group of thymine via hydrophobic interactions 
(Aggarwal et al., 1988) and this interaction could be strengthened by the potential 
hydrogen-bonding of the hydroxyl group of threonine and the O4 of thymine. Serine 
was used at position 3. In this study, they used the non-degenerate recognition table 
to design ten 3-finger ZFPs, five bound to their targets with high affinity and 
specificity while the other five did not. It was reported that the five successful ZFPs 
had at least three guanines at various positions in the first nine bps of DNA, 
whereas the unsuccessful ZFPs had less than two guanines in the first 9 bases 
reiterating the finding by Pavletich & Pabo, (1991) that the number of guanines in 
the DNA target has a remarkable effect on ZF binding.  
1.7.6 ZFP Oligomerised Pool Engineering “OPEN” Selection   
A potentially more effective way to generate multi-finger arrays is the OPEN 
method, however, this method is much more labour intensive compared to modular 
assembly as it requires construction and interrogation of large randomised libraries 
(typically >10
8 
constructs). Screening methods have focused on screening Zif268 
variants in which ZF1, ZF2 and ZF3 was randomised at the alpha helix positions -1, 
1, 2, 3, 5, and 6 (Maeder et al., 2008). Zif268 variants were tested against all sixteen 
GNN triplets‟ at all three positions and between 5 to 7 TNN triplets at each position 
in a B2H assay using Zif268 target sites with two Zif268 recognition triplets and the 
target triplet. Ninety-five ZFs for each triplet at each position were then pooled to 
create ZF pools. These pools were recombined to create a ZFP library consisting of 
95
3 
=8.6 x 10
5
 ZFPs which were interrogated using a B2H selection system against 
a 9 bp target site. Successful ZFPs were determined by the expression of the 
histidine synthesising gene his3B which allowed growth of bacteria on histidine 
deficient media. Selection of highly active ZFPs was achieved with a gradient of 3-
aminotriazole (3-AT), a competitive inhibitor of his3B. In order for OPEN selection 
to target any genomic sequence, 192 finger pools need to be established. However 
once established, this method yields highly active and specific ZFNs. 
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1.7.7 Context-dependent assembly (CoDA) 
CoDA is a publically available platform for engineering ZFPs using standard 
cloning techniques. Three-finger arrays are assembled using one of the 319 N-
terminal and one of the 344 C- terminal fingers that have been previously identified 
in other arrays engineered to function when positioned adjacent to one of the fixed 
18 middle fingers. In contrast to OPEN and modular assembly methods, CoDA does 
not treat the fingers as independent modules but instead accounts for context-
dependent effects between adjacent fingers, thereby, increasing the probability that 
a ZFN will function efficiently (Sander et al., 2010). Target sites for ZFPs designed 
using the CoDA method are reported to be found in diverse sequences on an 
average of every 500 bp. 
1.7.8 Transcription Activator-like effectors (TALE) 
TALE proteins are naturally occurring proteins from the plant pathogenic bacteria 
genus Xanthomonas that act as transcriptional activators in the plant cell nucleus. 
Binding to DNA is through a central domain of tandem repeats. Boch et al. (2009) 
were able to decipher the DNA recognition code that allows this binding and found 
that the DNA-binding domains consisted of a series of 33-35 amino acid repeat 
domains that recognises a single base pair of DNA (Boch et al., 2009). The 
specificity is determined by two hypervariable amino acids (aa 12 and 13), known 
as repeat-variable di-residues (RVDs). The four most common RVDs are shown in 
table 1.2 and figure 1.9a with their most frequently associated nucleotide. 
 
Repeat Variable Domain Associated nucleotide 
HD C 
NI A 
NG T 
NN G 
Table 1.2: The four most common RVDs with their associated nucleotides 
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Figure 1.9: (a) Structure of the naturally occurring TAL effector. A consensus repeat sequence is 
shown with the sequence determining variable-repeat di-residues underlined. The four most common 
RVDs are shown with their most frequently associated nucleotide. (b) Structure of a TALEN. Two 
monomeric TALENs bind DNA to allow FokI to dimerise and cleave the target site. NLS; nuclear 
localisation signal, AD; transcriptional activation domain. (Adapted from Cermak et al., 2011). 
 
Like ZFs, TALE proteins can be linked together to recognise DNA sequences and 
then fused to a cleavage domain like FokI to make a TALE nuclease (TALEN) 
(Christian et al., 2010). Each target half-site is typically constructed to bind 14-
20 bp with a spacer of 12-19 bp between binding sites. However, in contrast to 
ZFPs there is no reengineering necessary of the linkage between repeats to enable 
construction of long arrays of TALEs with the ability of targeting unique sites in a 
genome. The only targeting limitation for TALE arrays is that TALE binding sites 
should start with a T base (Boch et al., 2009). The single base recognition of TALE-
DNA binding repeats allows greater flexibility than triplet-confined ZFPs. However 
the cloning of repeat TALE arrays presents a technical challenge due to extensive 
repeat sequences. Numerous strategies have been developed to overcome this 
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challenge such as „Golden Gate‟ molecular cloning which uses a type IIS restriction 
endonuclease to cleave outside the recognition sequence to create 4 bp overhangs. 
Cloning is then expedited by digesting and ligating in the same reaction mixture as 
correct cloning eliminates the enzyme recognition site (Cermak et al., 2011). Using 
this cloning system, Kim et al. (2013) constructed a library of TALENs spanning 
the human genome by assembling TALEN plasmids for 18,740 protein-encoding 
genes (Kim et al., 2013). Several protocols are available describing rapid assembly 
of custom TALENs using publically available reagents from Addgene (Cermak et 
al., 2011). Reyon et al. (2012) recently presented the largest collection of TALENs 
to date using the fast ligation-based automatable solid-phase high-throughput 
(FLASH) system (Reyon et al., 2012), whereby DNA fragments are assembled on 
solid-phase magnetic beads rather than in solution. They assembled a total of 144 
TALEN pairs; 48 pairs were tested in a human cell-based EGFP reporter system 
and were all found to process efficient gene-modification activities, 96 pairs were 
targeted against endogenous human genes implicated in cancer regulation and 88% 
successfully cleaved their target site. 
1.7.9 CRISPR/Cas system 
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR 
associated protein Cas9 is the latest gene editing tool. It is a prokaryotic RNA-
programmable nuclease system that provides natural immunity in bacteria against 
invading viruses and plasmids (Wiedenheft et al., 2012). This defence system relies 
on small RNAs for sequence-specific detection and silencing of foreign nucleic 
acids. An in vitro study of the S. pyogenes type II CRISPR system demonstrated 
that CRISPR RNA (crRNA) fused to normally trans-encoded trans-activating 
crRNA (tracrRNA) is sufficient to direct Cas9 protein to sequence-specifically 
cleave DNA sequences matching the crRNA (Jinek et al., 2012). This raised the 
possibility that the approach could be used for targeted gene editing in vivo. The 
target sequence is specified by a 20 bp CRISPR RNA and the only constraint 
associated with this sequence is the requirement for the bases NGG, known as the 
protospacer adjacent motif (PAM), immediately following the 20 bp target 
sequence. In January 2013, it was reported that the type II CRISPR system could be 
used to reengineer the genome in human cells. A human codon optimised version of 
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Cas9 was cloned into a mammalian expression system and the human U6 
polymerase III promoter was used to express crRNA-tracrRNA fusion transcripts, 
called guide RNAs (gRNAs). The U6 promoter requires a „G‟ in order to initiate 
transcription and along with the requirement for the PAM sequence, any genomic 
site of the form GN20GG can potentially be targeted (Mali et al., 2013). A major 
advantage of this CRISPR system over ZFNs/TALENs is that in order to target a 
specific sequence a simple 20 bp oligo is designed according to GN20GG and 
cloned into the U6 expression plasmid followed by co-transfection along with the 
Cas9 protein compared to the labour intensive design and assembly methods 
described above. As depicted in figure 1.10 RNA-guided gene targeting in human 
cells involves co-expression of the Cas9 protein bearing a SV40 nuclear localisation 
signal at the C-terminus with a guide RNA expressed from the human U6 promoter. 
Cas9 unwinds the DNA duplex and cleaves both strands upon recognition of the 
target sequence by the gRNA. Another advantage of the CRISPR system is that the 
architecture of natural CRISPR loci with multiple tandem guide templates makes it 
possible to target many targets in a single experiment as was seen in a study by 
Wang et al. 2013. In this study five genes were simultaneously disrupted in 
embryonic mouse cells using the CRISPR/Cas system (Wang et al., 2013). A follow 
on study from this reported the one-step generation of mice carrying reporter 
constructs in three different genes (Yang et al., 2013). They also produced 
conditional mice by microinjecting two Mecp2-specific gRNAs, Cas9 mRNA and 
two oligos encoding loxP sites into fertilised eggs. Usually the development of a 
new mouse model for a disease involves careful breeding of multiple generations 
and can take at least a year, with CRISPR technology; a new mouse model can be 
ready for testing in a matter of weeks.  
 50 
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B) 
 
 
 
 
Figure 1.10: Schematic representation of gene editing in human cells using type II CRISPR system. 
A) Human codon optimised Cas9 under the control of the CMV promoter and NLS at the C terminal 
is co-transfected into cells with gRNA expressed from U6 promoter. B) Inside the cell, Cas9 
unwinds the DNA and gRNA binds and cleaves DNA to create a DSB. (Mali et al., 2013).  
In terms of flexibility in binding DNA sequences ZFNs still suffer from context 
effects on DNA recognition and a limited range of targetable sequences, due to the 
lack of availability of fingers for all possible DNA triplets. TALE nucleases 
(TALENS) appear to be less subject to these constraints due to greater simplicity of 
their DNA-binding domains, with one well defined module for each of the four 
bases. However, some degree of ambiguity emerged recently when it was shown 
that the module used to recognise G also binds A. To increase specificity of these G 
recognising modules it was shown that a module with a RVD NK sacrifices affinity 
to gain specificity, while modules with an NH RVD show improved biological 
activity and specificity (Cong et al., 2013). The new CRISPR/Cas system with its 
efficiency and ease of use looks set to be the most flexible out of all the gene 
editing tools in target recognition, however, the incidence of off-target events have 
still not been fully explored and the outcome of these studies will ultimately decide 
the future of this system (Pennisi, 2013). 
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1.8 Gene modifications using programmable and RNA-guided 
nucleases 
The advances made in efficient gene targeting have enabled investigators to 
manipulate many genes in a diverse range of cells and organisms. Gene disruption 
involves the use of ZFN/TALEN/CRISPR (nucleases) to target and abolish the 
function of an endogenous locus, creating a gene knockout. Nucleases delivered to a 
cell, in the absence of a donor, result in a DSB which will be repaired by NHEJ 
leading to insertions/deletions (indels) of nucleotides. If this cleavage occurs in a 
coding region of a gene, these indels will usually result in loss of gene function. 
Gene correction involves delivery of nucleases along with donor DNA which result 
in precise modification of a targeted locus. Nucleases are designed to create a DSB 
near the site of the gene mutation, and the donor DNA is used as a template to 
correct this DSB by HDR (figure 1.11). In this section I will discuss a number of 
advances made in the last decade using nuclease-induced gene modifications. 
Figure 1.11: Repair outcomes following a DSB induced by nucleases. The nuclease binds the target 
DNA and creates a DSB. If a homologous donor DNA is present repair can proceed through the HR 
pathway using the donor DNA as a template. Alternatively the break can be repaired by NHEJ 
resulting in mutations at the cleavage site (Carroll, 2011). 
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1.8.1 Gene Disruption 
This technique has been applied to the CCR5 locus of human CD4+ T cells in an 
effort to make them resistant to HIV infection. CCR5 is the major co-receptor for 
HIV-1 entry (Deng et al., 1996). It was discovered that cells with a 32 bp deletion in 
both CCR5 alleles confers resistance to HIV-1 (Samson et al., 1996) and so CCR5 
became a target for HIV therapy. ZFNs targeting the CCR5 gene resulted in non-
functional gene products that would fail to be expressed at the cell surface and so 
prevent HIV entry. These ZFNs were delivered ex vivo using Ad5/35 vector to 
primary CD4+ T cells and resulted in >50% gene disruption of transduced cells 
(Perez et al., 2008). CCR5 was also successfully disrupted in human CD34+ 
haematopoietic stem/progenitor cells at a rate of 17% of the total alleles in the 
population (Holt et al., 2010). These modified cells were then engrafted into mouse 
HIV models and when challenged with CCR5-tropic HIV-1 showed significantly 
lower (10-fold decrease) HIV-1 levels compared to controls at 6-weeks post-
infection. Clinical trials are underway using this approach with the goal to improve 
HIV positive patients‟ immune system by allowing their CD4+ T cells to survive 
longer (ClinicalTrials.gov. Trial numbers: NCT00842634, NCT01044654, and 
NCT01252641). Data from the first phase I clinical trial demonstrated improvement 
in several clinical parameters while being well tolerated (Perez-Pinera et al., 2013).  
TALENs have also been designed to target the CCR5 gene. A study in 2011 
compared the efficiency and specificity of both ZFNs and TALENs targeting this 
gene. Specificity is an important parameter of designer nucleases and will be 
discussed in more detail in section 1.9. Off-target events are very undesirable as 
they can cause mutagenesis which can result in cancer. A major off-target locus of 
the CCR5 binding nucleases is the gene CCR2 which shares a high degree of 
sequence identity with CCR5 (figure 1.12).  
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Figure 1.12: Sequences of CCR5 and CCR2 genes. Asterisks indicate the differences between the 
two target sequences. Letters in bold indicate the nucleotides affecting binding by the designer 
nucleases used in the study. Target sites are highlighted by grey shaded (TALEN) or black outlined 
boxes (ZFN). (Mussolino et al., 2011). 
 
In this study, the ZFN target site in CCR5 differed from the CCR2 site by two 
nucleotides, one in each half site. In contrast, the entire 19 bp target sequence of the 
left TALEN subunit was found in CCR2 while the right target half site varied at one 
position (Mussolino et al., 2011). Measurement of indels in the CCR2 gene 
following transfection with either ZFNs or TALENS specific to the CCR5 locus 
revealed mutations at 11% and 1% respectively. Even though gene disruption at the 
intended CCR5 target was similar with either ZFNs or TALENs the off target 
events at CCR2 were much lower with TALENs. This study was pivotal in 
demonstrating that the TALEN platform enables the design of nucleases with single 
nucleotide specificity.   
Generation of knock-out (KO) animals has been made easier and more efficient due 
to the advancements in gene editing tools. ZFNs targeting the interleukin 2 receptor 
gamma (IL2RG) were used to successfully create KO rats which were used as 
models to study X-linked severe combined immunodeficiency (X-SCID) (Mashimo 
et al., 2010). ZFNs were injected as mRNA into the pronucleus of fertilised oocytes 
and yielded genetically modified offspring at rates greater than 20% which 
processed a number of indel mutations thus disrupting the gene. These genetic 
changes were faithfully transmitted to the next generation along with the SCID 
phenotype. TALENs have been used to disrupt a number of genes in a wide variety 
of model organisms including the zebrafish. Cade et al. (2012) constructed 
TALENs to target ten different endogenous genes of the zebrafish and found that 
7/10 pairs of TALENS induce indels at the correct location with efficiencies 
ranging from 2-76% (Cade et al., 2012).  
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The latest gene editing technology CRISPR/Cas system has proven to be very 
efficient at generating mutations in multiple genes. A recent report demonstrated 
that a single CRISPR array encoding two loci separated by 119 bp could be cleaved 
simultaneously in cultured human cells at a relatively low efficiency of 1.6% (Cong 
et al., 2013). Another group tested the potential to disrupt five genes simultaneously 
in mouse ES cells. Guide RNAs targeting five genes, Tet1, Tet2, Tet3, Sry and Uty 
were designed, pooled and co-transfected with a Cas9 plasmid into ES cell. Of 96 
clones screened, 10% carried mutations in both alleles of the five genes 
demonstrating the capacity of CRISPR/Cas system as a powerful tool to efficiently 
target multiple genes in a single experiment (Wang et al., 2013). 
1.8.2 Gene Correction  
Gene correction is the precise modification of a targeted locus using custom 
nucleases and donor DNA. Following the creation of a DSB in the target locus close 
to the mutation by a nuclease, homologous recombination with the Donor DNA 
(which contains homology arms complementary to the target sequence flanking the 
mutated gene and a central region containing the correct sequence) can result in 
gene correction.  
The potential of ZFNs to create DSBs and increase the efficiency of HDR in human 
disease was highlighted in an experiment that corrected a mutation in the IL2RG 
gene in a human cell line (Urnov et al., 2005). As already stated mutations in the 
IL2RG gene give rise to X-SCID (see 1.8.1). First, to rapidly assess the potential for 
ZFN-driven editing of the genome, ZFNs were initially tested in a novel ex vivo 
EGFP repair assay. A mutated EGFP construct containing the ZFN target site was 
stably integrated into the genome of HEK293 cells. ZFNs were introduced into cells 
along with a donor plasmid containing the wild type EGFP sequence flanked by 
1.5 kb total homology arms. The level of ZFN induced HDR was assessed by flow 
cytometry. The optimised ZFNs were shown to be five times more potent at EGFP 
correction than donor only controls. To determine if ZFNs can evoke a comparable 
increase in HR frequency at the IL2RG locus, a pair of four finger ZFs were 
designed to recognise a total of 24 bp of the IL2RG sequence which were optimised 
in vitro by guided single amino-acid substitutions to yield more efficient ZFNs. The 
IL2RG donor sequence contained a point mutation which introduced a novel BsrBI 
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site into a 1.5 kb sequence homologous to wild type IL2RG to allow easy detection 
of HDR. 10% of cells underwent HDR and this was increased to 18% when cells 
were arrested in the G2/M phase for 30 hrs by addition of vinblastine, (a cell cycle 
arresting drug). These HDR events were stable for at least one month and corrected 
cells showed no signs of reduced fitness.  
A follow up study expanded on this by using the IL2RG gene as a potential „safe 
harbour‟ to insert several expression cassettes (Moehle et al., 2007). Conventional 
gene addition is widely used in gene therapy and is usually achieved via random 
integration of the transgene (Section 1.4). This presents safety concerns due to the 
possibility of insertional mutagenesis and may result in poor levels of expression 
due to chromatin-based effects on transgene expression (Kwaks & Otte, 2006). 
Moehle and colleagues achieved ZFN-mediated gene addition at a specific locus 
using a donor construct containing 1.5 kb EGFP expression cassette flanked by 
750 bp homology arms and ZFNs targeting the IL2RG gene. The EGFP cassette 
was successfully added into the IL2RG locus at a frequency of 6%. They then 
constructed a donor with 750 bp homology arms to the IL2RG gene interrupted 
with a 7,762 bp insert carrying three separate promoter-transcription units, two 
which encoded the heavy and light chains of the human IgG antibody molecule and 
the third ecoding a marker. A qualitative PCR-based assay confirmed ZFN and 
donor treated cells acquired transgene specific sequences in the X chromosome and 
measurable levels of human IgG was detected in the media harbouring cells 
exposed to ZFNs and donor construct (0.131 ng/ml) compared to donor only treated 
cells (0.012 ng/ml). 
1.8.3 Gene Correction and iPs cells 
By correcting the patients‟ own cells ex vivo and then re-introducing them back into 
the body overcomes the problems of immunological incompatibility between 
patient and donor cells. The first demonstration of a significant clinical benefit from 
conventional gene therapy was reported by Cavazzana-Calvo et al., (2000) to treat 
X-SCID in two infant patients. Bone marrow from the patients was exposed to a 
retroviral vector carrying the cDNA of the human γc gene and then returned to the 
patients. After a 10-month follow up period both patients developed normal 
numbers of T lymphocytes and natural killer cells, which showed evidence of 
 56 
 
immunologic function (Cavazzana-Calvo et al., 2000). However, some problems 
were encountered in later trials. In France, an X-SCID gene therapy trial was 
carried out on nine patients. Eight of the nine established a working immune system 
following treatment. However, four developed leukaemia due to random integration 
of the retrovirus vector and one patient subsequently died. The other three patients 
survived following chemotherapy treatment and maintained a healthy immune 
system. Following the death of a patient all X-SCID trials were stopped (Hacein-
Bey-Abina et al., 2011). Another disease which has been successfully treated using 
conventional gene therapy is β-thalassaemia. Sufferers of β-thalassaemia are 
transfusion-dependant for life as the disease results in a profound decrease in β-
globin synthesis. An adult patient with severe βE/βO-thalassaemia received a 
lentiviral β-globin gene transfer and was transfusion independent at a follow up 21 
months post-treatment (Cavazzana-Calvo et al., 2010).   
Precise editing of the genome coupled with the availability of stem cells offers a 
whole new therapeutic opportunity. The development of induced pluripotent stem 
(iPS) cells has raised prospects for patient-specific therapies (Yamanaka, 2007). 
Human iPS cells can differentiate into all somatic tissues, can grow to unlimited 
numbers and can be derived from a variety of somatic cells such as fibroblasts from 
skin biopsies (Lowry et al., 2008). This strategy was used to correct a mouse model 
of human sickle cell anaemia with iPS cells derived from autologous skin. Firstly 
fibroblasts from adult mice were reprogrammed into iPS cells by transducing the 
cells with virus vectors expressing four genes Oct4, Sox2, Klf4 and c-Myc. The β- 
globin gene was added by electroporation of cells with a target construct containing 
the human β-globin gene. Modified iPS cells were allowed to differentiate in vitro 
before being transplanted into affected donor mice after irradiation (Hanna et al., 
2007). Treated mice demonstrated stable engraftment for at least 12 weeks post- 
transplantation. An indicator of sickle cell disease activity and severity is the 
elevated level of reticulocytes in peripheral blood, which are immature red blood 
cells (RBCs), reflecting increased production of RBCs to overcome their chronic 
loss. Mice that had received corrected iPS cells showed a dramatic reduction in 
reticulocyte count indicating rescue from the disease. In 2011, this technique was 
transferred to human iPS cells containing the mutation for sickle cell anaemia. 
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Sebsatiano et al. generated iPS cell lines from fibroblasts of sickle cell anaemia 
patients and subsequently corrected the genetic disease-causing mutation using ZFN 
HDR (Sebastiano et al., 2011). They used the OPEN method to design two pairs of 
ZFNs, one pair 24 bp upstream from the sickle cell mutation and one directly at the 
mutation site. The donor repair plasmid contained 1.6 kb of the β-globin gene 
sequence centred approximately on the sickle cell causing mutation E6V. A 
puromycin resistant gene 82 bp was added downstream of the E6V mutation to 
allow drug selection of corrected clones. Two silent mutations were also introduced 
into the donor construct to prevent cleavage by the ZFNs in an attempt to increase 
repair efficiency by preventing cleavage of the repaired sequence. PCR and 
Southern blot analysis revealed successful correction of the β-globin gene with 
targeting efficiencies as high as 37.9% with no detection of off-target events, even 
in highly related DNA sequences of the δ- and γ- genes. Furthermore, the 
puromycin gene was introduced 82 bp away from one ZFN site, indicating that 
ZFNs can mediate cassette insertion even when it is nearly 100 bp away from the 
DSB. 
 By correcting a patient‟s own cells ex vivo means there is no requirement for 
immunosuppressive drugs to prevent rejection and risks associated with off target 
binding events can be screened for and controlled prior to transplantation. However, 
some genetic diseases affect organ systems in which ex vivo manipulation of target 
cells is not feasible such as the liver or the lungs. Kathy High‟s group reported an 
exciting strategy to overcome this challenge (Li et al., 2011) whereby they restored 
haemostasis in a mouse model of haemophilia using ZFNs and a donor vector 
carrying part of wild-type F9 (figure 1.13). Haemophilia B is caused by deficiency 
of blood coagulation factor IX, encoded by the F9 gene. Most disease causing 
mutations in humans are found in exons 2-8, therefore, to allow complete coverage 
of a wide spectrum of mutations they constructed a promoterless donor plasmid 
containing a partial cDNA of wild type exons 2-8 flanked by a splice acceptor and 
poly-adenylation sites and homology arms. They designed a ZFN pair to target 
intron 1 of F9 so that following successful cleavage and HR with the donor, splicing 
of wild type exon 1 with the introduced exon 2-8 would lead to expression of 
functionally active factor IX and rescue of the defect caused by most mutations. 
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Figure 1.13: Schematic representation of the gene repair strategy using a mini-gene donor to correct 
F9 gene. ZFN binding site in intron 1 creates a DSB. The donor vector contains partial F9 cDNA 
(exons 2-8), splice acceptor and polyA sites and homology arms to intron 1. HDR with the donor 
vector results in correct splicing from endogenous exon 1 into introduced exons 2-8 and production 
of F9 under the control of the endogenous liver promoter. (Li et al., 2011). 
 
 AAV8 expressing ZFNs were injected into the tail vein of mice expressing the 
human F9 mutation. Cleavage was determined to range from 34 – 47%. Mice were 
injected intraperitonealy at day 2 of life with AAV8-ZFN and AAV8-donor. DNA 
from the liver was extracted at week 10 and HDR was detected at a targeting 
efficiency range of 1-3%. Human factor IX levels in the plasma of mice treated with 
ZFN and donor averaged 166-354 ng/ml which corresponds to 3-7% of normal 
levels which was sufficient to correct the haemophilia B phenotype. This strategy 
overcomes the possibility of over-expression of a protein when introduced as a full 
length cDNA with its own promoter as is the case with most cDNA addition trials. 
Furthermore, as it is targeted to a specific location in the genome, the risks of 
oncogene activation are also reduced as was seen following viral vector delivery of 
IL2RG to bone marrow cells of X-SCID patients (Hacein-Bey-Abina et al., 2008). 
As well as ZFNs, TALENs have also been used to edit the genomes of organisms 
including the zebrafish in vivo. As well as using donor DNA plasmids as repair 
templates, recent work has shown that single-stranded DNA (ssDNA) can be an 
effective donor for HDR based genome editing at a ZFN–induced DSB (Chen et al., 
2011). Bedell et al. (2012) used TALENs and ssDNA to precisely modify sequences 
in the zebrafish genome through HDR (Bedell et al., 2012). They introduced a 
custom-designed EcoRV site and a modified loxP sequence into somatic tissue in 
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vivo and went on to show successful germline transmission of both of these 
markers. Human genes have also been successfully targeted using TALENS. Sun et 
al. (2012) optimised a pair of TALENs to target the β globin gene in human cells. 
By varying the N- and C-terminal extensions flanking the central repeat domain and 
the spacer length between each effector binding element of the DNA substrates they 
were able to increase the cleavage efficiency of the TALENs. They also discovered 
that some TALEN architects are capable of binding sequences not preceded by a 
5‟-T (Sun et al., 2012).  
CRISPR/Cas system is still in the early stages of experimentation but some groups 
have already reported efficient genome editing in zebrafish in vivo (Hwang et al., 
2013). In this study, ten gRNAs were constructed to target ten endogenous zebrafish 
genes. These gRNAs were co-injected along with the Cas9 plasmid into cell-one 
stage zebrafish embryos and the frequency of altered alleles was measured using the 
T7 endonuclease assay. High frequencies of indel formation were detected at eight 
of the ten sites in individual embryos tested with a mean of 24.1-59.4%. Two genes 
which they were unable to alter using TALENs were successfully targeted using 
their designed gRNAs.  
1.9 Off-Target activity 
The possibilities of genome editing are endless and the tools to carry out these 
changes are constantly being developed. In order for customisable nucleases to 
carry relevance for genetic analysis and clinical application, they must demonstrate 
strict specificity toward their intended DNA targets. However, complex genomes 
like ours often contain multiple copies of sequences that are identical or highly 
homologous to the intended target, leading to off-target activity and cellular 
toxicity. These off-target events can lead to mutagenesis and cancers if oncogenic 
genes are switched on. A number of adjustments have been applied to these 
nucleases in order to prevent off target cleavage and improve specificity.  
1.9.1 FokI heterodimerisation 
ZFN and TALEN cleavage requires homodimerisation of the FokI endonuclease 
which is inactive as a monomer. An advantage of this is that cleavage requires 
simultaneous binding of both ZFNs/TALENs to their respective half sites. 
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However, it also introduces a problem in that protein-protein interactions mediated 
by the WT FokI cleavage domain are not themselves selective for heterodimer 
species. Therefore, the expression of any ZFN/TALEN heterodimer (L/R) also 
yields two side product homodimers (L/L and R/R) which are of no use for gene 
modification but may limit the safety and effectiveness by cleaving off-target 
sequences. This phenomenon was demonstrated in a 2006 study whereby two out of 
three designed ZFNs exhibited toxicity due to homodimer formation of a single 
ZFN (Beumer et al., 2006). To overcome this problem, both Szczepek et al. (2007) 
and Miller et al. (2007) modified the dimer interface of FokI by substituting one 
amino acid for another to yield a progressive improvement in the specificity of 
heterodimer formation. Using in silico approaches, Szczepek et al., (2007) 
generated compatible FokI cleavage domain variants (RR:DD) by remodelling the 
dimerization interface of the native enzyme (Szczepek et al., 2007). In Miller‟s 
study, the first developmental cycle identified a variant with a glutamic acid to 
lysine mutation at position 490 (E490K) that exhibited modest preference for 
heterodimerisation with the WT FokI domain. Subsequent cycles yielded variant 
cleavage domains with the double mutation E490K:I538K and Q486E:I499L (+ 
and -) which exhibited strong preference for heterodimerisation in a GFP reporter 
assay (figure 1.14). When tested for frequency of gene correction R+/L- stimulated 
gene correction at a rate of 1.98%. Reversal of the ZFN cleavage domain pairings to 
R-/L+ yielded a 1.71% correction rate. Both modified FokI combinations were 
more efficient than WT FokI which was 1.27% (Miller et al., 2007). Another group 
sought to enhance ZFNs by integrating the Sharkey framework via directed 
evolution. Sharkey consists of two amino acid mutations, S418P and K441E, which 
were shown to increase cleavage both in vitro and in vivo (Guo et al., 2010) and in 
some cases >15 fold increase in activity compared to traditional ZFNs was 
observed.  
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Figure 1.14: FokI active domain. Left shows WT structure. Right shows introduced mutations KK 
and EL (Miller et al., 2007). 
 
1.9.2 Nickases  
The discovery that nicked DNA could stimulate HR without activating the NHEJ 
repair pathway (McConnell Smith et al., 2009) led to the development of 
ZFNickases  (Kim et al., 2012). Rather than producing a DSB, nickases cut the 
DNA on one strand only which means the chromosome is still intact so NHEJ is not 
activated. In this study, the group introduced a mutation (Asp450 to Ala) into the 
active site of the FokI domain of one ZFN so that it could no longer cleave. 
Subsequently, upon dimerisation at the intended DNA sequence only one ZFN 
would cleave to produce a single stranded break. Consequently this approach leads 
to fewer off-target events than conventional DSB induction, however, the frequency 
of HDR with nickases remains lower than those achieved with traditional ZFNs.  
In the CRISPR/Cas9 system, the Cas9 protein has been modified so that it only 
cleaves one strand of DNA and so acts like a nickase (Jinek et al., 2012). Point 
mutations were introduced into the codons of the catalytic residues of the HNH and 
RuvC-like domains of Cas9 and the plasmids were purified. Incubation of variant 
Cas9 with native plasmid DNA showed that RNA guided mutant Cas9 proteins 
yielded nicked circular plasmids whereas WT Cas9 yielded linear DNA products.  
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1.10 Aims: 
The aim of this body of work was to develop an efficient process to correct CF-
causing mutations using nuclease-directed HDR. We first set out to correct the most 
common mutation, ΔF508, using existing ZFNs, which cleave in intron 9, and 
donor plasmids made in this thesis. The rate of HDR was successful, but initially 
determined to be of relatively low efficiency, so two new approaches for correction 
were explored. First, to take advantage of the position of our ZFNs, we investigated 
the HDR of a mini-gene construct into the ZFN cut site. As a proof of principle we 
introduced a seven base pair tag into this site. Following successful incorporation of 
the tag, we sought to repair almost 80% of mutations using a mini-gene construct 
containing WT exons 10-24, splice acceptor and polyA sites and a GFP tag. 
Secondly, the ability to cleave closer to the ΔF508 mutation was determined using 
the latest gene editing tool, the CRISPR/Cas9 system. Two sites were targeted with 
CRISPR guide RNAs and used with existing donor plasmids to induce HDR.    
 
1.11 Objectives: 
Chapter 3:  
Repair the ΔF508 mutation in CFTE cells using existing ZFNs targeting intron 9 
and donor repair plasmids pITR-donor and pITR-donor-XC 
Chapter 4:  
Introduce unique seven base pair tag into the ZFN cut site to prove the principle of 
mini-gene recombination 
Design and construct a mini-gene donor containing WT exons 10-24 to correct 
>80% of CF-causing mutations 
Chapter 5:  
Design and synthesise CRISPR gRNAs to target CFTR and measure cleavage 
efficiency 
Induce HDR using CRISPR gRNAs and appropriate donor plasmids  
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2 Materials and Methods 
2.1 Cell Lines 
16HBE14o-: Human bronchial epithelial cells, endogenous wildtype CFTR (Cozens 
et al., 1994) 
 
CFTE29o-: Cystic fibrosis tracheal epithelial cells, homozygous for ΔF508 (Chastre 
et al., 1991) 
 
Cell lines were generous gifts from Prof. D. Gruenert (California Pacific Medical 
Centre Research Institute, San Francisco, CA). 
 
2.2 Cell Culture Reagents 
The following reagents were used in growth and maintenance of cell lines: 
 
2.2.1  Cell Culture Medium  
Growth medium (Epithelia) 
500 ml Eagle‟s minimum essential medium (Earle‟s salts, 25mM HEPES and 
sodium bicarbonate, without L-glutamine; Sigma-Aldrich)  
50mM Foetal calf serum (FCA; PAA Laboratories) 
5 ml Penicillin-Streptomycin (100 units/ml penicillin and 100 µg/ml Streptomycin 
final concentrations; Invitrogen) 
5 ml L-glutamine (2mM final concentration; Invitrogen) 
 
Seeding medium (Epithelia) 
500 ml Eagle‟s minimum essential medium (Earle‟s salts, 25mM HEPES and 
sodium bicarbonate, without L-glutamine; Sigma-Aldrich) 
50 ml Foetal calf serum (FCS; PAA Laboratories) 
5 ml L-glutamine (2mM final concentration; Invitrogen) 
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Transfection medium 1 
 500 ml Eagle‟s minimum essential medium (Earle‟s salts, 25mM HEPES and 
sodium bicarbonate, without L-glutamine; Sigma-Aldrich) 
5 ml L- glutamine (2mM final concentration; Invitrogen) 
50 ml Foetal calf serum (FCA; PAA Laboratories) 
 
Transfection medium 2 
500 ml Eagle‟s minimum essential medium (Earle‟s salts, 25mM HEPES and 
sodium bicarbonate, without L-glutamine; Sigma-Aldrich) 
5 ml L- glutamine (2mM final concentration; Invitrogen) 
 
2.2.2 Other reagents 
Trypsin-EDTA solution (2.5 g/L Trypsin and 0.38 g/L EDTA; Invitrogen) 
1X PBS (137mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.47 mM KH2PO4, pH of 7.4) 
 
2.3 Bacterial Strains 
All bacterial strains used in this work are listed in Table 2.1. 
Strain Genotype and Source 
DH5α 
 
 
 
 
 
XL10 
 
 
 
F
-
 φ80lacZΔM15 Δ(lacZYA-argF)U169 
recA1 ndA1 hsdR17(rk
-
, mk
+
) phoA 
supE44 thi-1 gyrA96 relA1λ-
(Invitrogen) 
 
 
Tet
rΔ (mcrA)183 Δ(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1 
gyrA1 lac The [F‟ proAB lacqZΔM15 
Tn10 (Tet
r
) Amp Cam
r
] (Stratagene)  
Table 2.1. Bacteria, genotypes and sources 
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2.4 Bacterial Growth Media and Antibiotics 
 
2.4.1 Growth Media 
 
LB Agar (Lennox L agar)                                 LB Broth (Lennox L Broth) 
 
9.14 g/L enzymatic digest of casein                 10 g/L enzymatic digest of casein 
4.57 g/L yeast extract                                         5 g/L yeast extract 
4.57 g/L sodium chloride                                   5 g/L sodium chloride 
13.72 g/L bacteriological agar 
 
Both media were prepared from tablets (Sigma-Aldrich). Each tablet was dissolved 
in 50 ml of deionised water and autoclaved (15 minutes, 121 °C, 15 psi). 
 
2.4.2 Antibiotics 
 
Ampicillin 
A 100 g/ml stock solution of ampicillin (Sigma-Aldrich) was prepared by 
dissolving 1 g of powder in 10 ml of deionised water and filter sterilising through a 
0.2 µm pore. Ampicillin was used at a final concentration of 100 µg/ml. 
 
Kanamycin 
Kanamycin (10 mg/ml; Sigma-Aldrich) was used at a final concentration of 30 
μg/ml. Prepared as per ampicillin. 
Tetracycline 
Tetracycline (5 mg/ml; Sigma-Aldrich) was used at a final concentration of 
20 μg/ml. Prepared as per ampicillin. 
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2.5 Buffers, solutions and drugs 
 
Phosphate buffered saline (PBS) 
10X PBS (138 mM NaCl, 2.7 mM KCl; Sigma-Aldrich) was diluted 1:10 with 
autoclaved deionised water under a laminar flowhood to make 1X PBS. 
 
Tris-acetate-EDTA (TAE) 
50X TAE comprised 242 g of Trizma base, 18.6 g EDTA and 57.1 ml glacial acetic 
acid made up to 1 L with deionised water and adjusted to pH 7.8. 1X TAE was 
prepared by diluting the 50X solution with deionised water. 
 
X-gal 
A 100 mg/ml stock solution of X-gal (5-bromo-4chloro-3-indolyl-beta-D-
galactopyranoside; Sigma-Aldrich) was prepared by dissolving 1 g of X-gal in 
dimethylformamide and making up to a volume of 10 ml. X-gal was used at a final 
concentration of 80 µg/ml. 
 
IPTG 
A 1 M stock solution of IPTG (Isopropyl β-D-1-thiogalactopyranoside; Sigma-
Aldrich) was prepared by dissolving 2.38 g of IPTG in autoclaved deionised water 
and making up to a volume of 10 ml. IPTG was used at a final concentration of 20 
mM. 
 
 Calcium Chloride (CaCl2) 
A 1 M stock solution of CaCl2 (Calcium Chloride-Sigma-Aldrich) was prepared by 
dissolving 147 g of CaCl2 in autoclaved deionised water and making up to a volume 
of 500 ml. CaCl2 was used at a final concentration of 0.3mM. 
 
2 X HBS  
2 X HBS (280mM NaCl, 1.5mM Na2HPO4, 50mM HEPES; Sigma Aldrich) was 
made up to a volume of 500 ml with autoclaved deionised water and pH was 
adjusted to 7.1.  
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Benzonase buffer 
Bezonase buffer (50mM Tris HCl pH 8, 1mM MgCl2; Sigma-Aldirch, 0.1 mg/ ml 
BSA; New England Biolabs was made up to a volume of 1 ml with autoclaved 
deionised water. 
Benzonase Nuclease 
Benzonase nuclease (250 units/µl; Sigma-Aldrich) was used at 50U/ml. 
 
2.6 Molecular biology reagents 
All reagents used for molecular biology are listed in table 2.2. 
 
Reagents Source 
10X buffer 1/2/3/4 for restriction digests 
10X ligation buffer 
Lambda DNA/EcoRI+HindIII marker 
MassRuler Express Reverse DNA ladder 
MassRuler Express LR Forward DNA 
ladder 
6X blue loading dye 
Tritrack 
Lipofectamine 2000 
Platinum Taq Polymerase 
Taq Polymerase 
Platinum Pfx Polymerase 
Restriction enzymes 
RNA Loading buffer 
T4 DNA Ligase 
New England Biolabs 
New England Biolabs 
Fermentas 
Fermentas 
Fermentas 
 
Fermentas 
Fermentas 
Invitrogen 
Invitrogen 
Promega 
Invitrogen 
New England Biolabs 
Sigma 
New England Biolabs 
Table 2.2. Molecular biology reagents and sources 
 
 
 
 
 68 
 
 
 
2.7 Chemical Reagents 
Chemical reagents not listed in Table 2.3. were supplied by Sigma-Aldrich 
Chemical  Sources 
Glacial acetic acid 
Trizol reagent 
Ethidium Bromide  
Boric Acid 
Saponin 
Formalin solution 
Goat serum donor herd 
BDH 
Molecular Research Centre 
Sigma- Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Table 2.3. Chemical reagents and sources 
 
2.8 Other Reagents 
Other reagents used in this work are listed in Table 2.4. All plasticware was 
supplied by Starstedt unless otherwise stated. 
 
Consumable Source 
20 ml syringes 
Disposable culture tube 12 x 75 mm 
Uvette 
Glass coverslips 
Microscope slides 
Parafilm 
Scalpels 
Syringe filters (pore size 0.2 µm) 
BD 
Fischer Scientific 
Eppendorf 
Corning 
Corning 
American Can Co. 
Swann-Morton 
Whatman 
Table 2.4. Consumables and sources 
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2.9 Plasmids 
 
2.9.1  Plasmids provided 
Commercially obtained plasmids and constructs that were not produced within this 
work are listed in Table 2.5. 
Plasmids Sources 
pGL3-Control  
phRL-CMV 
pcDNA3.1(+) 
pUC19  
pWhitescript 
pEGFP-N1 
hCas9 
hCas9 D10A 
Promega 
Promega 
Invitrogen 
Invitrogen 
Stratagene 
Clontech 
Addgene 
Addgene 
Table 2.5. Plasmids and respective sources 
 
2.9.2 Plasmids constructed 
Constructs created over the course of this project are listed in Table 2.6. 
Plasmid Details 
pITR-donor 
pITR-donor-XC  
 
pUC-donor 
pUC-donor-XC 
 
pITR-CFTE 
pITR-CFTE-NheI 
pUC-CFTE-NheI-1kb 
pUC-CFTE-NheI-1.5 
kb 
pAAV containing cftr DNA from HBE cells 
pAAV containing cftr DNA with restriction enzyme sites 
added 
pUC19 containing 4.3 kb segment of cftr 
pUC19 containing 4.3 kb segment of cftr with added 
restriction sites 
pAAV containing cftr DNA from CFTE cells 
pITR-CFTE with added NheI site 
pUC19 containing 1kb fragment of pITR-CFTE-NheI 
pUC19 containing 1.5 kb fragment of pITR-CFTE-NheI 
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pUC-mini gene 
 
pEX-A (pGuide) 
 
pCEP-CFTR 
 
CRISPR ex10 
CRISPR in9 
pUC19 containing appropriate splice acceptor, exons 10-24 
CFTR cDNA WT, T2A linker and GFP with Poly A tail.  
pEX-A plasmid containing the U6 promoter and BseRI 
sites for cloning of gRNAs  
CFTR cDNA in a pCEP backbone under the control of a 
CMV promoter 
gRNA targeting exon10 of CFTR in pGUIDE backbone  
gRNA targeting intron 9 of CFTR in pGUIDE backbone 
Table 2.6. Plasmid constructs and respective details 
 
2.10  Kits 
Kits used in this work and sources are listed below in Table 2.7. 
Kits Sources 
QIAprep Miniprep Kit 
Qiagen Plasmid Maxi Kit 
Qiagen Plasmid Plus Purification Kit 
StartaPrep DNA Gel Extraction Kit 
QuikChange XL Site-Directed Mutagenesis Kit 
Dual-Luciferase Reporter Assay System 
GoTaq PCR Core System 
Improm-II Reverse Transcription System 
Virakit 
Topo TA Cloning 
QIAquick PCR purification Kit 
Platinum Taq DNA Polymerase 
PfuTurbo polymerase 
Qiagen 
Qiagen 
Qiagen 
Stratagene 
Stratagene 
Promega 
Promega 
Promega 
Virapur 
Invitrogen 
Qiagen 
Invitrogen 
Invitrogen 
Table 2.7. Kits and Sources 
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2.11  Oligonucleotides 
Name and Purpose  
c=cloning, 
 s=sequencing, 
sdm=site-directed 
mutagenesis 
p=primer 
Underlined=restriction site 
(5‟->3‟) Sequence 
CFTR- Fwd- BstEII (c) TGACTAGGTAACCGAGCCTTTTCTTTTTCATTG 
CFTR-Rev-MluI (c) CAACGCGTAGGCCCTAACTTTCATTCTTG 
Fwd SD XhoI (sdm) GATTATGGGAGAACTCGAGCCTTCAGAGGG 
Rev SD XhoI (sdm) CCCTCTGAAGGCTCGAGTTCTCCCATAATC 
Fwd SD ClaI (sdm) GTGTTTCCTATGATGAATATCGATACAGAAGCGTCATCAAAG 
SD ClaI Rev (sdm) CTTTGATGACGCTTCTGTATCGATATTCATCATAGGAAACAC 
Fwd SDM 1 MUT (sdm) CTTGACCAGCGTGACTGCAAGCTTGATGTAGGAGAAG 
 
Rev SDM 1 MUT (sdm) CTTGACCAGCGTGACTGCAAGCTTGATGTAGGAGAAG 
Fwd SDM 4 MUT (sdm) CTCTTCTGCTTCTCCTATAATAAGCTTGCAGTCACGCTG 
 
Rev SDM 4 MUT  (sdm) CAGCGTGACTGCAAGCTTATTATAGGAGAAGCAGAAGAG 
MluI/BstEII linker f (c) CTAGAGTCAGCACGCGTGCTGTACGATGGTAACCCGGACCGTCAC
CGA 
MluI/BstEII linker r (c) 
 
AGCTTCGGTGACGGTCCGGGTTACCATCGTACAGCACGCGTGCTG
ACT 
LITR CFTR (s) TGGAGCGAACGACCTACACC 
RITR CFTR (s) TGTACTAGGAGCTGGAGATG 
RITR F1 CFTR (s) CACTAAATCGGAACCCTAAA 
RITR CF CFTR (s) 
 
TTAAGAGGAAAAGACTTCAG 
Fwd-CFTR-NHEJ  (p) ATCATGTGCCCCTTCTCTGT 
Rev CFTR-NHEJ (p) TGCTTTGATGACGCTTCTGTAT 
Fwd GAPDH (p) CGCGGGGCTCTCCAGAACATCAT 
 
Rev GAPDH (p) GCCAGCCCCAGCGTCAAAGGTG 
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Fwd RT-PCR (p) AGAACTGAAACTGACTCGGAAGG 
 
Rev RT-PCR (p) CTATATTCATCATAGGAAACACCAAAG 
 
FP-i9.1 ACTTGCTTTGCCATTAACAGA 
RP i10.1 GTCGTGTTCTAGGTATATGACC 
Donor HDR (s) CTAATGGTGATTATGGGAGAAC 
Fwd gDNA (p) ACTTGCTTTGCCATTAACAGA 
Rev gDNA (p) GCAGATCAATGCTCATTCCA 
FAM-Fpe10.2 (p) FAM-CAGTTTTCCTGGATTATGCCTGGCA 
RP i10.1 (p) AGTTGGCATGCTTTGATGACGCT 
Fwd NHEJ Probe (p) FAM-TGCATAGCAGAGTACCTGAAACA 
Rev NHEJ  (p) CAAATCACGCTCAGGATTCA 
Fwd_EcoRI  (p) GTCAGGACATATAACATATTTAAAC 
Rev_NheI (p) ATGGCAGCTAGCAAGCAGAAGTGTATATTC 
Fwd_NheI (p) CTAGTCGCTAGCAAGGATGATAATTGGGGGCAAGTG 
Rev_BtgI (p) TATCTAATCCACGGTTTGC 
Fwd_KasI (p) CTAGTCGGCGCCGTCAGTAGTATTATCTTT 
Rev_XbaI (p) ATGGCATCTAGATCACAATTTTACCCCTCTAA 
Fwd_NheI specific primer 
(p) 
ACACTTCTGCTTGCTAGC 
Rev_NheI-specific primer 
(p) 
CAATTATCATCCTTGCTAGC 
CMW_sequence primer 
(s) 
GTACGGGCCAGATATAC 
FokI_sequence primer (s) GGCAAACAACAGATGGCTGG 
 
Fwd_NheI assay primer 
(p) 
CTAGCCTGGGTGACAGAGTG 
Fwd_eGFP seq primer (s) CACTCTCGGCATGGACGAG 
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Rev_eGFP (s) CTGAAGCACTGCACGCCG 
Fwd_eGFP/pA ATCAGATCTCGTGAGCAAGGGCGAGGAGC 
Rev_eGFP/pA AGCTAGCCCACAACTAGAATGCAGTG 
Fwd_cDNA primer (c) GTTTTCCTGGATTATGCCTGGC 
Rev_cDNA primer (c) GTCACTCGAGAAGCCTTGTATCTTGCACCT 
Fwd_SA primer (c) GTCAGCTAGCCTAATAATGATGGGTTTTATTTCCAG 
Rev_SA primer (c) CTCTTCTAGTTGGCATGCTTTG 
T2A(+) (c) TCGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACG 
TGGAGGAGAATCCCGGGCCTA 
T2A(-) (c) GATCTAGGCCCGGGATTCTCCTCCACGTCACCGCAT 
GTTAGAAGACTTCCTCTGCCC 
Fwd_recombination 
primer (p) 
GTAGGCTATATGTATCTGTGAG 
Rev_ex11 primer (p) CGAGCAACTGGAGGTGAGTCAC 
Fwd_GFP_HDR_(1) 
primer (p) 
CACTGCATTCTAGTTGTGGTTTG 
Rev_in10 primer (p) GTCGTGTTCTAGGTATATGACC 
Fwd_GFP_HDR_(2) 
primer (p) 
CACATGGTCCTGCTGGAGTT 
CRISPR IN9 (+) (c) ATAATGACCTAATAATGATGT 
CRISPR IN9 (-) (c) ATCATTATTAGGTCATTATCG 
CRISPR EX10 (+) (c) GAGAACTGGAGCCTTCAGAGT 
CRISPR EX 10 (-) (c) TCTGAAGGCTCCAGTTCTCCG 
Table 2.8. Names and sequences of oligonucleotides used in this project 
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2.12 Equipment 
All equipment used in this work is listed in Table 2.9. 
Equipment Sources 
Biophotometer 
Bright-Line haemocytometer 
EasyCast gel tray (Owl) 
IX70 inverted microscope 
Luminometer 
Mastercycler Gradient 
Orbital shaker 
pH meter 
Lightcycler 
Fluorescent Microscope 
Immuno-fluorescent Microscope 
Genetic Analyser 3130 (Applied 
Biosystems). 
Zeiss Laser Scanning Microscope 510 
Eppendorf 
Sigma-Aldrich 
World Precision Instruments 
Olympus 
Berthold Technologies 
Eppendorf 
Stuart Scientific 
Hanna 
Roche 
Martina Scallan‟s Lab 
Martina Scallan‟s Lab 
Collette Hand Lab, CUH 
 
Martina Scallan‟s Lab 
Table 2.9. Equipment and sources 
 
2.13  Software 
The following software was used over the course of this project: 
Olympus analysis software 
UVIPhotoMW software 
DNASTAR Lasergene sequence analysis software 
Primer X (www.bioinformatics.org/primerx/) 
Ensembl genome browser (www.ensembl.org) 
Pubmed (http://www.ncbi.nlm.nih.gov/pubmed) 
ClustalW (http://www.genome.jp/tools/clustalw/) 
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2.14 Cell culture protocols 
 
2.14.1 Subculturing cells 
Cells were passaged when approximately 80% confluent. Cells were washed with 
1X PBS and incubated with 2 ml of 0.25 % trypsin-EDTA. Detached cells were re-
suspended in 8 ml of growth medium and transferred to a 15 ml tube and 
centrifuged at 1000 rpm for 5 minutes at room temperature. The cell pellet was re-
suspended in 6 ml of growth medium and 1 ml used to seed a new flask. Growth 
medium was added to make up a final volume of 20 ml (75 cm
2 
flask) or 25 ml (175 
cm
2 
flask). 
 
2.14.2 Cell quantification and seeding density 
10 µl of re-suspended cells was transferred to each chamber of a Bright- Line 
haemocytometer. The number of cells within each of the 25 1 mm squares in both 
chambers (50 in total) was counted under the microscope. If the number of cells in 
the 50 squares was greater than 500, the sample was diluted and recounted. The 
number of cells per millilitre of suspension was determined according to the 
formula: 
 
[Cells/ml = average count per square x dilution factor x 10
4
] 
 
For 6-well plates, 300,000 cells were seeded and the volume made up to 2 ml with 
growth medium. For 100 cm dishes, 4 x 10
6 
cells were seeded and the volume made 
up to 10 ml with growth medium. 
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2.15 Bacterial protocols 
 
2.15.1 Inoculation of LB broth 
Individual colonies were transferred from agar plates to 5 ml (for Miniprep) or 50 
ml (for Midiprep) or 150 ml (for Maxiprep) of LB broth containing the relevant 
antibiotic using a disposable inoculation loop.  
 
2.15.2 Bacterial transformation 
50 µl aliquots of DH5α competent cells were thawed on ice. 1 to 10 ng (maximum 
5 µl) of DNA was added to a 50 µl aliquot of cells and incubated on ice for 30 
minutes. The cells were incubated at 42 °C for 2 minutes, then 2 minutes on ice. 
100 µl of LB broth was added to the cells and transferred to an orbital shaker at 200 
rpm and 37 °C for 1 hour. 100 µl of the cell suspension was plated on a LB agar 
plate containing the appropriate selective antibiotic. Plates were incubated at 37 °C 
for 16-20 hours.   
 
2.16 DNA and RNA isolation 
 
2.16.1 Plasmid extraction (Qiagen Plasmid Plus Purification Kit) 
Plasmid DNA for transfection and ligations was extracted from E. coli DH5α cells 
using a Plasmid Plus Midi Kit as per the manufacturer‟s instructions. 50 ml of LB 
broth containing the appropriate antibiotic was inoculated with the transformed 
bacteria and incubated at 37 °C on an orbital shaker at 200 rpm for 16 hours. The 
culture was centrifuged at 6,000 x rpm at 4°C for 15 minutes. The pellet was re-
suspended in 4 ml of RNase Buffer P1. Four millilitres of lysis Buffer P2 was 
added, mixed by inversion and incubated at room temperature for 5 minutes. Four 
millilitres of Buffer S3 was added, mixed by inversion, and filtered through a 
QIAfilter cartridge to remove proteins and genomic DNA. The filtrate was 
transferred to a fresh 50 ml tube and 2 ml of Buffer BB was added and mixed by 
inversion. Lysate was transferred to a Midi spin column with a tube extender 
attached and solution was drawn through the column using a vacuum. DNA was 
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washed with 700 µl of Buffer ETR, followed by further washing with 700 µl of 
Buffer PE and centrifuged at 13,000 x rpm for 1 minute. DNA was eluted from the 
column by adding 200 µl of Buffer EB, incubating at room temperature for 5 
minutes and centrifuged as before. DNA obtained was stored at 4 °C.  
 
2.16.2 Plasmid extraction (Qiagen Miniprep Kit) 
Plasmid DNA for restriction analysis was obtained from individual bacterial 
colonies using a QIAprep Miniprep Kit according to the manufacturer‟s guidelines. 
Individual colonies were grown overnight in 5 ml of LB broth containing a suitable 
plasmid selective antibiotic at 37 °C on an orbital shaker at 200 rpm. 1 ml of 
bacterial suspension was centrifuged at 6,000 x rpm for 5 minutes at room 
temperature. The pellet was re-suspended in 250 µl of Buffer P1 containing RNase 
and cells lysed with 250 µl of Buffer P2. Lysis was terminated after 5 minutes with 
350 µl of Buffer N3 and mixture centrifuged at 13,000 x rpm for 10 minutes at 
room temperature. The supernatant was applied to a QIAprep spin column and 
centrifuged at 13,000 x rpm for 1 minute. 750 µl of Buffer PE was added to the 
column which was centrifuged as before. DNA was eluted from the column by 
adding 50 µl of deionised water, incubating at room temperature for 5 minutes and 
centrifuging at 13,000 x rpm for 1 minute. DNA obtained was stored at 4 °C.  
 
2.16.3  Plasmid extraction (Qiagen Maxiprep Kit) 
Plasmid DNA for virus production was obtained from individual colonies grown for 
16 hrs in 150 ml LB broth containing the appropriate antibiotic. Cells were 
centrifuged at 6000 x rpm for 15 minutes at room temperature. The supernatant was 
discarded and the cell pellet re-suspended in 10 ml of RNase Buffer P1. Cells were 
lysed with 10 ml Buffer P2. 10 ml of Buffer P3 was added after 4 minutes 
incubation at room temperature. Lysate was poured into a QIAfilter Cartridge and 
incubated at room temperature for 10 minutes. A HiSpeed Maxi Tip was 
equilibrated by adding 10 ml QBT Buffer and allowing column to empty by gravity. 
Lysate was filtered through the pre-equilibrated HiSpeed Maxi Tip. QIAGEN-Tip 
was washed with 60 ml Buffer QC and DNA eluted with 15 ml Buffer QF. DNA 
was precipitated by adding 10.5 ml room-temperature isopropanol, mixed and 
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incubated for 5 minutes at room temperature. A QIAprecipitator Maxi Module was 
attached to the outlet nozzle of a 30 ml syringe and the elute/isopropanol mixture 
added and filtered through under constant pressure. 2 ml of 70% ethanol was added 
to the syringe and filtered through to wash the DNA. The QIAprecipitator was 
attached to a 5 ml syringe and 1 ml of Buffer TE was added to the barrel. The DNA 
was eluted into a 1.5 ml collection tube and stored at 4 °C.  
 
2.16.4 Measuring DNA concentration 
The Biophotometer spectrophotometer was calibrated with a 1:10 dilution of Buffer 
TE before measuring the sample. DNA was diluted 1:10 (10 µl + 90 µl deionised 
water) and transferred to a cuvette. The dilution values were entered into the 
spectrophotometer and absorbance of the sample at 260 nm and 280 nm measured. 
An absorbance value of 1.0 at a wavelength of 260 nm indicates a DNA 
concentration of 50 µg/ml. The spectrophotometer automatically calculates 
concentration and adjusts for dilution. DNA purity was assessed by dividing 
absorbance at 260 nm by absorbance at 280 nm. A value between 1.8 and 2 
indicated an acceptable level of purity. 
 
2.16.5 RNA extraction 
Cells were washed with PBS then re-suspended/lysed with 1 ml Trizol reagent. The 
lysate was transferred to a 1.5 ml tube and incubated for 5 minutes at room 
temperature. 200 µl of chloroform was added and the tube shaken vigorously by 
hand for 15 seconds, incubated for 2.5 minutes at room temperature, then 
centrifuged at 12,000 x g for 15 minutes. The clear upper phase was removed to a 
fresh 1.5 ml tube, and the RNA precipitated with the addition of 750 µl of 
isopropanol. After 10 minutes incubation, the tube was centrifuged at 12,000 x g for 
10 minutes and the supernatant discarded. 1 ml of 75 % ethanol was added and the 
tube centrifuged at 7,600 x g for 5 minutes. The supernatant was discarded and the 
RNA pellet allowed to air- dry for 5 minutes. RNase free water was added and the 
RNA re-suspended by heating at 55 °C for 5 minutes. RNA was stored at -80 °C. 
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2.16.6 Measuring RNA concentration 
The Biophotometer spectrophotometer was calibrated with 100 µl of deionised 
water before measuring the sample. RNA was diluted 1:10 (10 µl RNA + 90 µl 
deionised water) and transferred to a cuvette. The dilution values were entered into 
the spectrophotometer and absorbance of the sample at 260 nm and 280 nm 
measured. An absorbance value of 1.0 at a wavelength of 260 nm indicates an RNA 
concentration of 40 ng/ml. The spectrophotometer automatically calculates 
concentration and adjusts it for dilution. RNA purity was assessed by dividing 
absorbance at 260 nm by absorbance at 280 nm. A value between 1.8 and 2 
indicated an acceptable level of purity. 
 
2.17 DNA and RNA manipulation 
 
2.17.1 Restriction digests 
In a typical digest, 1 µg of plasmid DNA was cleaved by combining it with 5-10 
units of each required enzyme, 2 µl of the appropriate 10X buffer and deionised 
water to a final volume of 20 µl in a 0.5 ml tube. The digest was incubated at 37 °C 
for 1-2 hours. 
 
2.17.2 Preparing DNA agarose gels 
To prepare 1 % agarose gels, 1 g of agarose was mixed with 100 ml of 1X TAE 
buffer in a conical flask and heated in a microwave until the agarose had completely 
dissolved. When the flask was cool to touch, 8 µl of 10 mg/ml ethidium bromide 
was added and the agarose was poured into an EasyCast gel tray containing a comb 
to form wells and allowed to set for 20 minutes. The comb was removed, the tray 
placed in the electrophoresis chamber and 1 X TAE added to cover the gel. 
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2.17.3 Loading and running agarose gels 
Up to 20 µl of DNA was mixed with 6X Tritrack loading dye (20 µl DNA + 4 µl 
dye). The electrophoresis chamber was attached to a power supply which was set at 
120 Volts. When the yellow band reached the end of the gel, the tray was removed 
from the electrophoresis chamber and the bands viewed using a gel documentation 
system. Images were acquired using UVIPhotoMW software. 
 
2.17.4 RNA gel 
1 % TAE gels were prepared as previously described in section 2.17.2, 15 µl of 
RNA was mixed with 5 µl of RNA loading buffer and heated at 65 °C for 15 
minutes. The sample was then cooled for 10 minutes on ice and loaded onto the gel. 
The gel was run and photographed using a gel documentation system as described 
in section 2.17.3. 
 
2.17.5 Gel purification 
The agarose gel was viewed on top of an ultraviolet transilluminator and the band of 
interest excised with a scalpel blade and transferred to a 1.5 ml tube. A StrataPrep 
DNA Gel Extraction Kit was used to isolate the DNA according to the 
manufacturer‟s guidelines. 300 µl of DNA extraction buffer was added for every 
100 µg of gel slice and the sample heated at 50 °C for 10 minutes. The melted gel 
was transferred to a microspin cup and centrifuged at 13,000 x rpm for 1 minute at 
room temperature. DNA remained bound to the fibre matrix within the cup while 
the waste solution passed through the matrix to a receptacle tube and was discarded. 
The microspin cup was washed with 750 µl of wash buffer and centrifuged as 
before. The flow-through was discarded, the microspin cup centrifuged again to 
remove any trace of ethanol and transferred to a fresh receptacle tube. 50 µl of 
deionised water was added to the fibre matrix and incubated for 5 minutes. The 
DNA solution was collected by centrifugation at 13,000 x rpm for 1 minute at room 
temperature.  
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2.17.6 Annealing oligonucleotides 
5 µl each of sense and anti-sense single stranded oligonucloetides (1 µg/µl) were 
added to 85 µl of DEPC and 5 µl of ligase buffer, heated at 95 °C for 5 minutes and 
allowed to cool to room temperature. 
 
2.17.7 Ligation 
Digested plasmid and insert DNA were mixed at different ratios to a total volume of 
8 µl (1:3, 1:1, 3:1). 2 µl of 10 X ligation buffer and 1 µl (400 units) of T4 DNA 
ligase were added to each and the reaction incubated at room temperature for 15 
minutes. 
2.17.8 De-phosphorylation 
Following digestion of plasmid, it was sometimes necessary to de-phosphorylate the 
backbone prior to ligation. 16 µl of plasmid backbone was added to 2 µl Antarctic 
phosphatase buffer and 2 µl Antarctic phosphatase and incubated at 37 °C for 30 
mins followed by 20 mins at 65 °C to inactivate the enzyme. 
2.17.9 Golden gate cloning 
Plasmid pEX-A and CRISPR gRNA oligos were digested and ligated 
simultaneously in one reaction. 150 ng of plasmid was mixed with 15/150 ng 
CRISPR gRNA oligo, 1 μl BseRI, 1 μl T4 ligase, 2 μl ligase buffer and dH2O to a 
total volume of 20 μl. The reaction was incubated at 37 °C for 5 min, then 16 °C for 
10 min for 10 cycles, followed by 30 mins at 37 °C and finally 20 mins at 80 °C to 
heat inactivate the enzymes. XL-Blue bugs were transformed with 2 μl of the 
reaction. 
 
2.17.10  Site-directed mutagenesis 
Mutations were introduced into plasmid DNA using the QuikChange XL Site-
Directed Mutagenesis Kit. All primers were designed using PrimerX and ordered 
online from MWG Biotech (www.mwg-biotech.com) The reaction components 
were mixed together in thin-walled PCR tubes in the following order: 5 µl 10X 
reaction buffer, 1 µl template DNA, 1.25 µl primer 1, 1.25 µl primer 2, 1 µl dNTP 
mix and autoclaved deionised water to a final volume of 49 µl. 1 µl of PfuTurbo 
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polymerase (2.5 units) was added, and the tubes transferred to a Mastercycler 
Gradient thermalcycler programmed as shown in table 2.10. 
 
Cycles Temperature Time 
1 95 °C 1 minute 
12 
 
95 °C 
55 °C 
30 seconds 
1 min/kb plasmid length 
1 68 °C 
 
5 minutes 
Table 2.10. Thermalcycler guidelines for site-directed mutagenesis 
 
DNA was digested by adding 1 µl of Dpn I and incubating at 37 °C for 1 hour. 
Forty-five micro-litres of XL-10 ultracompetent E.coli cells were thawed on ice and 
treated with 2 µl of β-mercaptoethanol. After adding 1 µl of DNA, the cells were 
incubated on ice for 30 minutes. The cells were heat-shocked in a 42 °C heat block 
for 2 minutes and then incubated on ice for 2 minutes. 450 µl of pre-heated LB 
broth was added and the tubes places on an orbital shaker in an incubator at 200 
rpm and 37 °C for 1 hour. The transformed bacteria were spread on LB agar plates 
containing the appropriate selective antibiotic.  
A control mutagenesis supplied with the kit allowed for the determination of 
reaction efficiency. Re-activation of the β-galactosidase gene in pWhitescript 
through site-directed mutagenesis using the supplied primers, could be screened for 
by growing transformed cells on LB containing X-gal and IPTG. Colonies 
containing the corrected β-galactosidase gene appear blue as β-galactosidase 
cleaves X-gal resulting in an insoluble blue product.  Colonies containing the 
original pWhitescript will appear white. Comparing numbers of blue and white 
colonies gives an indicator of the efficiency of the mutagenesis.  
 
2.17.11  Reverse Transcription 
Reverse transcription of mRNA was performed using the ImProm-II Reverse 
Transcription System. 1 µg of RNA extract and 1 µl of Oligo(dT)15 (0.5 µg) primer 
were mixed and heated at 70 °C  for 5 minutes and incubated on ice for 5 minutes. 
The remaining components (4 µl 5X reaction buffer, 3.2 µl MgCl2 (25mM stock), 1 
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µl dNTPs (40 mM stock), 1 µl reverse transcriptase) were added to a final volume 
of 20 µl. The reaction was incubated at 42 °C for 1 hour. The reverse transcriptase 
was inactivated by heating at 70 °C for 15 minutes. This product then served as 
template for PCR.  
 
2.17.12  Polymerase chain reaction 
PCR was carried out using the GoTaq PCR Core System. Template DNA (5 µl in 
the case of RT product) was mixed with reaction components (10 µl 5X Colourless 
GoTaq Flexi buffer, 4 µl MgCl2 (25 mM stock), 1 µl dNTPs (40 mM stock), 1 µl 
forward primer (50 mM stock), 1 µl reverse primer (50 mM stock), 0.25 µl (5 units) 
GoTaq DNA polymerase, autoclaved deionised water to a final volume of 50 µl) in 
a thin-walled PCR tube. Samples were loaded into Mastercycler Gradient 
thermacycler. 
 
2.17.13  High Fidelity Polymerase Chain Reaction 
High fidelity PCR was carried out using the Platinum pfx polymerase. Template 
DNA (100 ng for genomic DNA, and 10 ng for plasmid DNA) was mixed with 
reaction components (10 µl 10x PCR Buffer, 1.5 µl of 10 mM dNTP mix, 1 µl of 
50mM MgSO4, 1.5 µl of each primer, 0.5 µl of Platinum pfx polymerase, and 
deionised water up to 50 µl) in a thin walled PCR tube. 
 
2.17.14  PCR purification 
PCR products were purified as per manufacturer‟s instructions. Five volumes of 
Buffer PB was added to 1 volume of PCR reaction and mixed. If the colour of the 
reaction was orange or violet, then 10 µl of 3 M sodium acetate, pH 5.0 was added 
and mixed and colour of mixture turns yellow. A QIAquick column was placed in a 
2 ml collection tube. Sample was applied to QIAquick column and centrifuged for 1 
min at 13,000 rpm to bind DNA. Flow-through was discarded. To wash DNA, 0.75 
ml of Buffer PE was added to column and centrifuged as before. DNA was eluted 
from the column by adding 50 µl deionised water or EB buffer, incubating at room 
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temperature for 5 min and centrifuging as before. DNA was stored at 4 °C until 
needed.  
 
2.17.15  Cel-1 (Surveyor) Nuclease Assay 
30 µl of PCR product was incubated in a heat block at 95 °C for 5 minutes. The heat 
block was removed and left to cool to room temperature allowing heteroduplex 
formation. 16 µl of the heteroduplex solution was incubated with 2 µl of surveyor 
nuclease and 2 µl of enhancer solution at 42 °C for 20 min. The surveyor nuclease 
was inactivated by adding 2 µl stop solution. 
 
2.17.16  T7E1 assay 
Two hundred nanograms of purified PCR product was added to 2 µl NEB buffer 2 
and deionised water to a total of 19 µl volume. Solution was incubated in a heat 
block at 95°C for 5 min. Heat block was removed from and left to cool to room 
temperature facilitating heteroduplex formation. 1 µl (10U) T7E1 was added to 
heteroduplex solution and incubated at 37°C for 15 min. Two microlitres of 0.5 M 
EDTA was added following incubation. 
 
2.17.17   In vitro transcription translation reaction 
In vitro transcription translation (IVTT) reactions were carried out according to 
manufacturer‟s specifications. 2 µg of T7 expression plasmid was incubated with 1 
mM methione and 1X IVTT reaction mix in a 50 µl reaction. All reactions were 
incubated at 30°C for 2 hours. A Renilla luciferase expression plasmid (pHRL) was 
used as a positive control. Renilla protein concentrations were determined by a 
luciferase assay with 100,000 relative light units (RLU) corresponding to 1 ng of 
Renilla protein. ZFN protein concentrations were approximated to the Renilla 
values after accounting for differences in peptide length.  
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2.18 Transfection 
2.18.1 Transfection of cell lines 
Cells were transfected with 4 µg of DNA and 10 µl of Lipofectamine 2000. Cells 
were plated in transfection media 1, 24 hours in advance of transfection as 
described in section 2.14. Plasmid DNA and Lipofectamine 2000 were each mixed 
separately with transfection medium 2, combined, and incubated at room 
temperature for 20 minutes.  Mixture was transferred to cells and incubated at 37 °C 
and 5 % CO2. 
 
2.19 Fluorescence Microscopy 
Cells were transfected with pEGFP and incubated for 24 hours to allow for 
enhanced green fluorescent protein (EGFP) expression. Cells were washed with 1 x 
PBS. Cells were viewed on an Olympus 1x70 inverted microscope equipped with a 
green fluorescent filter set (500±10 nm excitation and 535±15 nm emission). 
Images were acquired using Olympus analysis software. 
2.20 Flow Cytometry 
Cells were harvested with 500 µl of trypsin. 500 μl of media was added and the 
cells suspension was centrifuged at 1200 rpm for 5 mins. The cell pellet was 
washed with 1 ml of cold 1XPBS and centrifuged again at 1200 rpm. The cell pellet 
was re-suspended in 1 ml PBS plus FCS. Cells were sorted and GFP positive cells 
were detected using a green fluorescent protein filter set (500±10 nm excitation and 
535±15 nm emission). 
2.21 Genotyping 
Twelve microlitres of formalin and 0.5 µl of a known marker were added to 1 µl 
PCR sample and heated to 95 °C for 5 mins and cooled for 10 mins. The sample 
was transferred to a 96-well plate and the proportion of PCR product at 101 and 103 
bp was analysed using a Genetic Analyser 3130 (Applied Biosystems). 
2.22 Immuno-staining 
Cells were grown on 13 mm coverslips for 72 hrs at a density of 2 x 10
5
 cells/well 
in a 12-well plate. Following washing with 1 X PBS, cells were fixed with 300 μl of 
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4% paraformaldehyde for 10 mins. Cells were washed thoroughly and 
permeabilised with 300 μl of 0.1% Saponin for 30 mins. Cells were washed and 
blocked with 300 μl of 1% bovine serum albumin and 5% goat serum for 1 hr. Cells 
were washed. Primary CFTR 596 antibody was added at 1:1000 and incubated for 1 
hr at room temperature. Cells were washed. A secondary antibody, goat anti-mouse 
IgG Cy3 (abcam), was added at 1:5000 as well as the nuclear stain DAPI (1mg/ml) 
at 1:500 in a dark room and incubated for 1 hr. A single drop of mounting media 
was added to glass slides and sterilised forceps were used to position the coverslip 
upside down onto the mounting media making sure to avoid air bubbles. Slides 
were incubated in the dark at room temperature until ready to view.   
2.23 Enrichment of GFP positive cells 
Cells were initially transfected in a 6-well plate. In wells containing GFP positive 
cells, one-hundred micro-litres of the cell suspension was re-seeded 7-days post-
transfection into a new 6-well plate. At day 12, the complete cell population of GFP 
positive cell containing wells was transferred evenly onto a 96-well plate in an 
attempt to decrease the surface growth area and increase GFP positive cell growth. 
Again the complete cell population of any GFP containing wells in the 96-well plate 
was transferred into its own 96-well plate at day 14. 
To increase growth, the concentration of foetal calf serum (FCS) was increased by 
5% and cells were seeded into a new 96-well plate at day 21. Cells were transferred 
to a single well of a 24-well plate. The cell population from this single well was 
then transferred to three new wells of a 24-well plate. Serum starvation was applied 
to cells to induce a stress response which would lead to increased GFP positive cell 
survival. The concentration of FCS was altered with cells receiving 0, 5 or 10% 
total FCS for 24 hours. At day 22 the FCS was increased to 4% in well with 0% 
FCS. At day 23, each of the three wells was re-seeded into three new wells 
increasing the number of wells to nine, with each set of three supplemented with 
varying concentrations of FCS, either 1, 2, 5 or 10%. Cells kept in 1% FCS showed 
the highest increase in GFP from 4 cells at day 26 to 10 on day 27. At day 29 no 
further increase was detected and a yeast infection determined the end of the 
enrichment. 
 87 
 
2.24 Next Generation Sequencing 
Next generation sequencing (NGS) was performed by Eurofins MWG. PCR 
samples were amplified using labelled For-CFTR-NHEJ and Rev-CFTR-NHEJ 
primers shown in table 2.11. PCR products of 452 bp were pooled together into a 
single eppendorf at a final concentration of 100 ng per sample.  
Sample Labelled Primer 
Untransfected A CGTAGACTAGATCATGTGCCCCTTCTCTGT 
Untransfected B TACGAGTATGTGCTTTGATGACGCTTCTGTAT 
CFi9-L
EL
/CFi9-R
KK
 A TACTCTCGTGATCATGTGCCCCTTCTCTGT 
CFi9-L
EL
/CFi9-R
KK
 B TAGAGACGAGTGCTTTGATGACGCTTCTGTAT 
CFi9-L
EL
/CFi9-R
KK
 Donor-XC A TCGTCGCTCGATCATGTGCCCCTTCTCTGT 
CFi9-L
EL
/CFi9-R
KK
 Donor-XC B ACATACGCGTTGCTTTGATGACGCTTCTGTAT 
CFi9-L
EL
/CFi9-R
KK
 Mini-gene A ACGCGAGTATATCATGTGCCCCTTCTCTGT 
CFi9-L
EL
/CFi9-R
KK
 Mini-gene B ACTACTATGTTGCTTTGATGACGCTTCTGTAT 
CFi9-L
EL
/CFi9-R
KK
 Donor-NheI1.5 kbA ACTGTACAGTATCATGTGCCCCTTCTCTGT 
CFi9-L
EL
/CFi9-R
KK
 Donor-NheI1.5 kb B AGACTATACTTGCTTTGATGACGCTTCTGTAT 
CRISPR In9 A AGCGTCGTCTATCATGTGCCCCTTCTCTGT 
CRISPR In9 B AGTACGCTATTGCTTTGATGACGCTTCTGTAT 
CRISPR In9 Mini-gene A ATAGAGTACTATCATGTGCCCCTTCTCTGT 
CRISPR In9 Mini-gene B CGCTACGTTGCTTTGATGACGCTTCTGTAT 
CRISPR Ex10 A CAGTAGACGTATCATGTGCCCCTTCTCTGT 
CRISPR Ex10 B CGACGTGACTTGCTTTGATGACGCTTCTGTAT 
CRISPR Ex10 Donor- XC A TACACACACTATCATGTGCCCCTTCTCTGT 
CRISPR Ex10 Donor- XC B TACACGTGATTGCTTTGATGACGCTTCTGTAT 
Table 2.11: List of primers used for NGS. Underlined sequence indicates sequencing label used to 
identify samples. A: forward sequence, B: reverse sequence. 
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2.25 Miscellaneous methods 
 
2.25.1 Dual-luciferase reporter assay 
Luciferase assays were performed using the Dual-Luciferase Reporter Assay 
System according to manufacturer‟s guidelines. Cells were transfected 24 hours 
prior to assaying with separate plasmids containing genes for firefly and Renilla 
luciferase. Cells were washed with 1X PBS, then 500 µl of passive lysis buffer was 
added and the dishes placed on an orbital shaker for 15 minutes at 100 rpm. 20 µl of 
lysate was transferred to a borosilicate glass tube and 100 µl of Luciferase Assay 
Reagent was added to this and mixed by pipetting. The tube was placed in a single-
sample luminometer and the firefly luminescence measured for 10 seconds. 100 µl 
of Stop & Glo Reagent was added and the tube briefly vortexed. Renilla 
luminescence was measured for 10 seconds. Luminescence ratio was calculated 
according to: 
    
      [Luminescence ratio = Firefly luminescence/Renilla luminescence] 
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3 Design and construction of pITR-donor and pITR-
donor-XC donor repair plasmids, and correction of 
ΔF508 mutation in the CFTE cell line 
3.1 Aims: 
The aim of this chapter was to design donor repair plasmids for use with exisitng 
CFi9-L
EL
/CFi9-R
KK
 ZFNs to correct the ΔF508 mutation in the CFTR gene. These 
ZFNs cleave the CFTR gene to create a double stranded break (DSB) 203 bp 
upstream of the CTT deletion (Lee et al., 2012). To test if AAV-ITR sequences 
affect HDR and to facilitate downstream use of AAV as delivery vectors, donor 
sequences were flanked by AAV-ITRs. 
 
3.2 Objectives: 
 Amplify a 4.3 kb region of the CFTR gene, and clone it into a plasmid 
flanked by inverted terminal repeats (ITRs) from Adeno-Associated virus 
(AAV) to make pITR-donor 
 Introduce two unique restriction sites into pITR-donor, to help detect HDR 
events, using site directed mutagenesis to make pITR-donor-XC 
 Transfect CFTE cells with donor plasmids and the CFi9-LEL/CFi9-RKK 
ZFNs to effect HDR 
 Detect repair using an RT-PCR based assay 
 Measure the level of repair using restriction digests and genotype analysis 
3.3 Design and construction of pITR-donor and pITR-donor-XC 
3.3.1 Cloning of CFTR into AAV backbone 
To create the pITR-donor donor plasmid, a 4,343 bp PCR product was generated 
from genomic DNA from HBE cells using high fidelity PCR and the primers 
CFTR-Fwd-BstEII and CFTR-Rev-MluI, which introduce a unique BstEII site at the 
5‟end and a MluI site at the 3‟ end. This PCR product contains wild type exon 10 
and 4.3 kb of homology to the flanking intronic regions.  
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Optimal temperature conditions for the PCR were identified as seen in figure 3.1. 
The 4,343 bp band was extracted from the gel and purified for cloning. This WT 
CFTR sequence from the HBE cell line differs from the mutant CFTE cell line 
sequence by a well characterised single nucleotide polymorphism (SNP) A/G 
rs213950 in exon 10 as well as the CTT. 
                
 
 
 
       
 
Fig 3.1: Temperature optimisation of CFTR-Fwd-BstEII and CFTR-Rev-MluI primers. Lane 1: 
EcoRI/HindIII lambda ladder, band sizes 2027 and 4973 bp indicated by arrows. Lanes 2-5: 20µl 
PCR product of genomic HBE DNA at 51.6, 56.8, 54, 60 °C.   
 
 
The PCR product in lane 2 was gel extracted, purified then cleaved with BstEII and 
MluI and ligated into the BstEII/MluI backbone of the pAAV-IRES-GFP vector as 
depicted in figure 3.2.  
Following transformation, two potential clones were analysed by restriction analysis 
using EcoRI, a successful clone would yield a single band of 7,251 bp. As seen in 
figure 3.3 both clones were correct and subsequent sequencing of ITRs and exon 
10, confirmed successful cloning. 
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Figure 3.2 Schematic representation of pAAV-IRES-GFP and pITR-donor constructs. Location of 
BstEII and MluI restriction sites used to clone CFTR insert are indicated. 
 
 
 
 
 
Figure 3.3 Analysis of two potential pITR-donor clones. Lane 1 contains lambda DNA 
EcoRI/HindIII marker, band sizes 5148 and 21,226 bp indicated by arrows. Lane 2 and 3 contain 
potential pITR-donor digested with EcoRI. 
 
Use of the CFi9-L
EL
/CFi9-R
KK
 ZFNs and this donor plasmid containing exon 10 
derived from HBE cells should be able to correct the CTT deletion, and would also 
introduce the G variant of the well characterised SNP, both these changes occur 
within exon 10 so would be incorporated into the CFTR mRNA, see section 3.5. 
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3.3.2 Site-Directed Mutagenesis on pITR-donor to yield pITR-donorXC  
To make detection of HDR easier, a donor containing XhoI and ClaI restriction sites 
was constructed (pITR-donor-XC) by site-directed mutagenesis. The XhoI site was 
92 bp upstream of the CTT and the ClaI site was 21 bp downstream of the CTT 
sequence (see figure 3.5).  To verify successful introduction of both sites, 5 clones 
were digested with XhoI and ClaI independently as seen in figure 3.4. Clone 3 was 
positive for both restriction sites as seen in lanes 7 and 8 of figure 3.4 and these 
were further confirmed by sequencing.  
Following successful repair with this donor plasmid, these unique restriction sites 
will be incorporated into the genome of CFTE cells and cleavage of PCR products 
using these enzymes will allow a quantification of repair. 
 
Figure 3.4: Clones digested with enzymes XhoI and ClaI. Lane 1: Mass Ruler Express Reverse 
DNA Ladder. Lane 2: Uncut clone; negative control. Lanes 3,5,7,9 and 11 were digested with XhoI, 
lanes 4, 6,8,10 and 12 with ClaI. Clone 3 was positive for both restriction sites.  
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3.4 Development of a wild type specific RT-PCR assay to detect 
homology directed repair with pITR-donor 
If HDR is successful it should correct the CTT in exon 10 and add CUU in the 
mRNA. To detect repair, an RT-PCR assay previously established in the lab to 
generate a product using a primer pair that can only bind the corrected mRNA was 
used (Lee et al., 2011). Successful amplification via WT specific RT-PCR should 
yield a 675 bp band. 
 
3.5 CFi9-LEL/CFi9-RKK ZFNs mediate HDR in the presence of 
pITR-donor or pITR-donor-XC 
To test the hypothesis that HDR using our donor plasmids and ZFNs can correct the 
genetic mutation in CF cells, CFTE cells were transfected with CFi9-L
EL
 and CFi9-
R
KK
 and pITR-donor or pITR-donor-XC as outlined in table 3.1. 
             Assay 
Plasmid (µg) 
1 2 3 4 5 6 
CFi9-L
EL
 0 1 0 0 1 1 
CFi9-R
KK
 0 1 0 0 1 1 
pITR-donor 0 0 2 0 2 0 
pITR-donor-XC 0 0 0 2 0 2 
pcDNA3.1 4 2 2 2 0 0 
Table 3.1: Amount of plasmids transfected for CFi9-L
EL
/CFi9-R
KK
 HDR assays with pITR-donor or 
pITR-donor-XC 
 
RT-PCR was performed on total RNA extracted 72 hrs post-transfection using 
forward and reverse RT-PCR primers, GAPDH primers were used as a positive 
control.  
                         
.  
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Figure 3.6:  Upper panel: Results from WT specific RT-PCR assay. Lane 1: Mass Ruler Express 
Reverse DNA Ladder. Lanes 2-7 contain samples 1-6 from table 3.1. Lower panel: GAPDH RT-
PCR reactions of same samples. 
 
The presence of a 675 bp band in lanes 6 and 7 in figure 3.6 indicates repair when 
either pITR-donor or pITR-donor-XC donor plasmids are used with the ZFNs. (The 
band at 1100bp seen in lanes 4-7 transfected with donor plasmids is an artefact that 
was also observed in PCR optimisation). Cells transfected with the donor should 
contain the CTT and G SNP. Cells transfected with pITR-donor-XC should also 
contain the introduced XhoI and ClaI sites. The 675 bp band in lane 7 from the gel 
in figure 3.6 was extracted and cloned into a TOPO vector and sequenced. As the 
RT-PCR was performed using a reverse primer which binds the CTT at the 3‟end, 
one would expect to see this sequence in all products, therefore the G SNP and 
restriction enzyme sites were used as indicators of homologous recombination. 
Figure 3.7 shows the presence of the XhoI site and G SNP which are 92bp and 103 
bp upstream of the CTT deletion respectively in one of the sequenced clones. As 
this sequence can only be derived from an mRNA molecule that has been 
synthesised from ZFN-HDR corrected genomic DNA, this data confirms that CFTR 
gene repair can occur. 
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Figure 3.7: Alignment of part of exon 10 of CFTR cDNA from CFTE cells transfected with pCFi9-
L
EL
/pCFi9-R
KK
 and pITR-donorXC (bottom) versus mock transfected CFTE cells (top). The 
corrected sequence contains both the G SNP and the complete XhoI site, whereas the wild-type has 
the A SNP and an incomplete XhoI site. 
 
However, of 16 clones sequenced, the remainder showed no incorporation of the 
SNP or XhoI but the CTT was present, suggesting the possibility of mis-priming. 
There is a faint band of 675 bp in lane 2 of figure 3.6 containing sample transfected 
with CFi9-L
EL
/CFi9-R
KK
 ZFN only. This may be due to mis-priming of the Rev-
RT-PCR primer with the mutant ΔF508 sequence, as the sequence to which the 
primer binds is almost an exact match regardless of the absence of the CTT triplet 
in the wild type sequence as seen in figure 3.8. The second base A at the 3‟ end is 
the only mismatch in the mutant ΔF508 sequence when compared to the wild type 
sequence. 
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Figure 3.8: Diagram demonstrating the possibility of mis-priming occurring between the CTT 
specific reverse primer and the mutant sequence. 
 
3.6 Quantification of the level of repair 
3.6.1 XhoI/ClaI digests: 
Having shown that CFTR gene correction was possible it was necessary to 
determine the level of repair. The pITR-donor-XC donor provides a potentially easy 
method for quantification of repair as detection of either restriction site by digest 
analysis on the DNA from corrected cells indicates that HDR has occurred. 
Previous studies using this approach could detect as low as 2.6% (Urnov et al., 
2005). Seventy-two hours post-transfection of CFTE cells with ZFNs and pITR-
donor-XC donor, genomic DNA was extracted, and a 2.6 kb PCR product was 
generated using a forward primer in intron 9 FP-i9.1 (outside donor plasmid region 
to eliminate plasmid carry-over) and reverse primer, RP i10.1, in intron 10 located 
approximately 490 bp downstream of the CTT site. The 2.6 kb product was gel 
extracted and purified for cloning into the TOPO TA vector system. Following 
transformation 96 clones were cultured and digested with either XhoI or ClaI. No 
clones were successfully digested, suggesting that the level of repair was below 1%. 
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3.6.2 Genotyping 
A potentially more sensitive assay was developed involving a two-step fluorescence 
PCR-based assay to quantify the percentage of cells in which this ZFN-mediated 
HDR had occurred. Using this method a 101 bp product represents uncorrected 
DNA whereas a 104 bp product indicates gene correction. The percentage of 
products that are 104 bp will indicate the percentage of cells in which at least one 
ΔF508 CFTR allele has been corrected. To determine the level of detection of the 
assay, different amounts of PCR amplicons derived from HBE and CFTE cells, 
corresponding to corrected and uncorrected sequences respectively, were mixed at a 
number of different ratios and screened using a Genetic Analyser 3130 (Applied 
Biosystems). As seen in figure 3.9B, at 50% HBE to 50% CFTE, corrected: 
uncorrected, the system was able to detect the corrected PCR product. At 1% HBE 
to 99% CFTE, a corrected product is still detectable. However, at 0.5% there was no 
detection, indicating the limit of detection using this method was approximately 
1%. 
Having verified the assay to detect correction of genomic DNA, we used it to 
analyse DNA treated with ZFNs and/or the donor, extracted 72 hrs post-
transfection. A 2.6 kb PCR product (PCR#1) was generated using forward primer 
FP-i9.1 and reverse primer RP i10.1, see figure 3.9A and then a second PCR 
(PCR#2) amplified using primers, FAM-FPe10.2 (FAM labelled) and RP e10.2, 
both within exon 10, was performed on these 2.6 kb products.  
No PCR#2-WT product was detected in genotyping analysis of mock transfected 
CFTE cells, CFTE cells transfected with ZFNs
 
alone, or pITR-donor/pITR-donor-
XC only. No PCR#2-WT product was detected with ZFNs and pITR-donor-XC 
(figure 3.9C) suggesting that the level of repair is below 1%. We know that repair 
has occurred as seen by PCR and sequencing data but the level is below the 
detection limit of the Genetic Analyser 3130. We can conclude from these results 
that repair of the CTT deletion in CFTE cell line is possible using ZFN and donor 
plasmids; however, the efficiency of repair is low. 
 
 99 
 
Figure 3.9 Two-step fluorescence-based assay to detect HDR. (A) PCR#1 should amplify a 2.6-kb 
region of genomic DNA without creating a product from pITR-donor-XC. Using the 2.6-kb product 
as a template, the second PCR (PCR#2) should generate a 101-bp uncorrected amplicon (A: ΔCTT) 
in the absence of ZFN-HDR, or a 104-bp amplicon  if the ΔCTT has been repaired; this corrected 
amplicon should also contain XhoI and ClaI restriction sites (G X+ CTT C). (B) Relative levels of 
uncorrected and corrected PCR#2 amplicons generated from genomic DNA from HBE and CFTE 
cells mixed at percentages shown. (C) Relative levels of uncorrected and corrected PCR#2 
amplicons generated from genomic DNA from CFTE cells transfected as shown. HDR, homology 
directed repair. 
 
3.6.3 Next generation sequencing (NGS) data 
Shortly before submission of this thesis, the opportunity to perform a small-scale 
deep sequencing analysis arose. NGS was performed on a single sample obtained 
from cells transfected with ZFNs and pITR-donor-XC. Data was obtained from 629 
sequences, of these, 12 had the correct CTT, G->C (XhoI) and A->C (ClaI). Figure 
3.10 below displays some of the sequence data. The arrows indicate the base pair 
changes that occur following HDR with pITR-donor-XC. As already seen in section 
3.5 our ZFNs can mediate HDR with our donor plasmids but the level of repair as 
determined by digest and genotyping analysis was <1%. However, in this one 
 100 
 
sample the level of repair was 2% suggesting the sensitivity of our detection assays 
is such that they cannot measure the level of repair. More samples will need to be 
analysed to obtain a more accurate value but the data clearly shows that HDR is 
occurring in these cells.  
Figure 3.10: Sample sequences of 629 PCR products from CFTE cells transfected with ZFNs and 
pITR-donor-XC confirming incorporation of XhoI, CTT and ClaI sites from donor into genome. The 
arrows indicate the base pair changes following HDR with pITR-donor-XC. G->C for XhoI site, 
CTT addition and A->C for ClaI site. 
 
3.7 Conclusions 
The aim of this chapter was to correct the ΔF508 mutation present in the CFTE cell 
line using a pair of ZFNs made previously in the host lab and donor plasmids 
described in this chapter containing the correct sequence. 
Evidence of precise repair in cells was initially detected using an RT-PCR based 
assay three days post-transfection with ZFNs and pITR-donor/pITR-donor-XC, 
(figure 3.6, lanes 6 and 7). Subsequent sequencing data of clones derived from the 
DNA in lane 7 confirmed successful repair by homologous recombination with the 
pITR-donor-XC plasmid by detection of the G SNP and the XhoI restriction site 
(figure 3.7).  
Further study to quantitate repair efficiency indicated it was below 1%. This low 
level of repair, despite cleavage efficiency by ZFNs at 7%, may be due to the 
distance of the CTT deletion from the ZFN target cut site which is 203bp 
downstream. To date, efficient ZFN-HDR has only been reported at or within a few 
base pairs of the ZFN-induced DSB (Urnov et al., 2005) (Maeder et al., 2008).  It 
has been shown previously (Elliott et al., 1998) that the distance between the repair 
site and cut site is proportional to the level of repair. It was shown that 80% of 
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gene-targeting events extended no further than 45 bp from the DSB, although gene 
repair tracts did extend as far as 228 bp in 8% of corrected clones. In the same 
study, even a low level of heterology (1.2%) between donor and target was shown 
to decrease the level of repair by approximately six fold. Therefore, we concluded 
that the 203bp might be too far for efficient correction at the CTT target site and the 
various differences between pITR-donor-XC sequence and the target region (i.e. a 
SNP, two base pair changes to create XhoI and ClaI sites, and the 3 bp CTT 
insertion) may also contribute to the low level of HDR. 
Nonetheless, this initial observation showed for the first time correction of the 
endogenous CFTR gene in the CFTE cell line following transfection with our ZFNs 
targeting intron 9 and donor plasmids. Correction of CFTR using ZFN-HDR has not 
previously been reported, although a pair of ZFNs which can cleave human CFTR 
in 1.2 % of cells has been described using the OPEN method of ZFN construction 
(Maeder et al., 2008), and a pair of ZFNs which can cleave mouse cftr in vitro only 
have also been reported (Mani et al., 2005).  
As shown in section 3.6.3, the efficiency is potentially higher than originally 
envisaged at 2% by NGS. Still, the overall efficiency of repair was found to be low 
and needs to be improved if this technology is ever to be of potential clinical use. 
An obvious next step would be to design a new pair of ZFNs closer to the CTT 
deletion as distance was determined to be a limiting factor. However, this would be 
time consuming and ZFN design has been shown to have a low success rate.  
In this thesis, two different options were subsequently explored:  
1) to take advantage of the position of the ZFNs in intron 9 and use this site for 
insertion of a mini-gene construct comprising exons 10-24 from CFTR cDNA (with 
appropriate splice acceptor and poly A sites) to allow production of full length 
corrected CFTR mRNA. This approach has been used successfully in cells to 
correct the IL2RG locus (Lombardo et al., 2007) and in vivo to correct human F9 in 
a murine model of haemophilia that subsequently restored haemostasis (Li et al., 
2011). This strategy would enable the correction of a much wider range of CF 
causing mutations and will be described in chapter 4. 
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2) Use other gene-editing tools, more amenable to changing location, such as the 
CRISPR/Cas9 system, as described in chapter 5. 
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4 Mini-gene Repair Strategy using ZFNs 
4.1 Aims: 
The data from chapter three showed that our ZFNs effectively cleave intron 9 of the 
CFTR gene in 7% of cells. Genotyping data initially suggested CFTR gene repair 
by HDR occurred, but in less than 1% of treated cells, though a follow-up deep 
sequencing study showed nearly 2% could be obtained. Some groups have reported 
HDR levels of up to 20%, but only when the cut site and HDR site coincide; thus, it 
seemed plausible that this low level could be a result of the distance from our ZFN 
cut site to the CTT site of repair (~203 bp) which is perhaps too far for really 
efficient HDR to occur. Rather than design a new pair of ZFNs closer to CTT it was 
decided to take advantage of the efficient cleavage activity of our ZFNs and use 
them to explore an alternative strategy whereby they would be used to recombine a 
partial cDNA cassette (exons 10-24) with appropriate splice acceptor and poly-A 
sites into the ZFN cut site (intron 9) which should result in a full length WT CFTR 
transcript following correct splicing. Firstly, to test whether repair is possible at the 
cleavage site, a new donor plasmid was designed which targets a seven base pair tag 
containing a unique NheI restriction site to intron 9 where the ZFNs cleave. 
Successful recombination with this donor would indicate that mini-gene 
recombination would be feasible at this location. The donor would then be modified 
to incorporate the partial cDNA, splice acceptor, poly-A site and a GFP tag (for 
identification of corrected cells). If this could be recombined in at this location, this 
would correct all cystic fibrosis-causing mutations occurring in exons 10-24 which 
accounts for ~80% of all known mutations (Cystic Fibrosis Mutation Database). 
4.2 Objectives: 
 Design and construct four new donor plasmids; 
 
- pITR-CFTE, (4.3 kb region of CFTR gene amplified from CFTE gDNA                 
and cloned into pITR-IRES-GFP) 
            - pITR-CFTE-NheI, (two step PCR to introduce unique NheI site into pITR-                                                                              
           CFTE) 
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 - pUC-CFTE-NheI-1 kb, (1 kb of homology to CFTR gene centered on NheI    
in a pUC vector) 
 - pUC-CFTE-NheI-1.5 kb, (1.5 kb of homology to CFTR gene centered on 
NheI in a pUC vector) 
 Detect recombination of NheI into ZFN cut site by PCR and digest analysis 
and identify the most suitable donor for mini-gene repair 
 Construct mini-gene donor plasmid 
 Detect recombination of mini-gene by PCR 
 Assess GFP expression from mini-gene 
 
4.3 Design and construction of three NheI donor plasmids with 
homology arms of 4.3, 1.5 and 1 kb. 
Three NheI plasmids were constructed to determine which length of homology 
would be optimal for the mini-gene donor.  As sequence divergence between donor 
DNA and genomic DNA has been shown to lower the efficiency of repair (Elliott et 
al., 1998) all new plasmids were derived from CFTE genomic DNA to avoid any 
sequence discrepancies such as SNPs which exist between the CFTR sequences 
from HBE and CFTE cell lines. A schematic outlining the cloning plan is shown in 
figure 4.1. 
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Figure 4.1: Schematic representation of the construction of the new NheI plasmids. Backbone and 
length of homology is shown. PCR on CFTE gDNA to create pITR-CFTE. Introduce NheI site by 
two-step PCR to create pITR-CFTE-NheI. Subclone part of pITR-CFTE-NheI into pUC backbone to 
create pUC-CFTE-NheI-1kb. PCR a region of pITR-CFTE-NheI to create pUC-CFTE-NheI 1.5kb. 
 
4.3.1 pITR-CFTE and pITR-CFTE-NheI 
The plasmid pITR-CFTE was created in the same manner as pITR-donor in section 
3.3, except the 4.3 kb region of genomic DNA was amplified from CFTE genomic 
DNA rather than from HBE DNA. This 4.3 kb fragment was then cloned into the 
pITR-IRES-GFP plasmid backbone using restriction sites MluI and BstEII.  
This plasmid was then modified by introducing a unique tag sequence, 5‟-
GCTAGCA-3‟, containing a restriction site for easy detection, into the spacer 
region of the ZFN target site in pITR-CFTE. Inserting the sequence here will 
disrupt the ZFN target site in the plasmid and thereby prevent cleavage of repaired 
alleles. The restriction enzyme NheI (underlined) was chosen as it is unique to 
pITR-CFTE. To introduce this tag sequence at the ZFN cut site in the pITR-CFTE 
plasmid site-directed mutagenesis was initially performed; however after several 
unsuccessful attempts a PCR strategy was used instead. Four primers were designed 
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which amplify short regions of DNA and incorporate the NheI unique site and also 
restriction sites EcoRI and BtgI needed for cloning into pITR-CFTE plasmid. Figure 
4.2A shows temperature optimisation of both PCR products using the pITR-CFTE 
plasmid as a template (see figure 4.1). PCR 1 at 544 bp in lane 2 was produced 
using the primers Fwd_EcoRI   and Rev_NheI and PCR 2 at 1178 bp in lanes 5-7 
were amplified using Fwd_NheI and Rev_BtgI. The bands of correct size were gel 
extracted and purified. 
 
 
 
 
 
 
Figure 4.2A: Temperature optimisation of PCR 1 with primer Fwd_ EcoRI and Rev_ NheI. and PCR 
2 with primers Fwd_NheI and Rev_BtgI. Lane 1: Mass ruler express reverse DNA ladder. Lanes 2-4: 
20 µl PCR product 1 at 55, 60.6, 65.9 °C. Lanes 5-7: 20 µl PCR product 2 at 55, 60.6, 65.9 °C 
 
To create the ITR backbone, pITR-CFTE was digested with EcoRI and BtgI, (see 
Figure 4.2B), and the band at 5581 bp was extracted and purified.  
 
 
 
 
 
 
Figure 4.2B: pITR-CFTE digested with EcoRI and BtgI. Lane 1: Mass ruler express reverse DNA 
ladder. Lane 2: pITR-CFTE digested producing two bands at 5581 bp and 1567 bp. 
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A three-way ligation was performed with the PCR products 1 and 2 from Figure 
4.2A and the ITR backbone from Figure 4.2B to create the pITR-CFTE-NheI 
plasmid. Four potential clones were tested for the introduced NheI site by restriction 
digest with HindIII and NheI, figure 4.3. Positive clones should result in 3 bands at 
5049, 1766 and 441 bp. Digest analysis revealed three of the four clones contained 
the NheI site.  
 
 
 
 
 
 
Figure 4.3: Restriction enzyme analysis to identify clones containing the NheI site. Lane1: Mass 
ruler express reverse ladder. Lanes 2, 4, 6 and 8: Uncut samples. Lanes 3,5,7 and 9: samples digested 
with HindIII and NheI. Bands at 5049, 1766 and 441 are positive for the NheI site. Lanes 3, 7 and 9 
display the correct banding pattern. 
 
DNA sequencing was used to confirm the introduction of the NheI site.  
 
4.3.2 Construction of pUC-CFTE-NheI-1 kb and pUC-CFTE-NheI-1.5 kb 
donors 
To test whether the length of homology arms has an effect on the rate of HDR, two 
smaller donor plasmids containing the NheI site were constructed using pUC19 as a 
backbone, one with roughly 1 kb homology and the other with 1.5 kb homology to 
the target region of CFTR.  
Construction of pUC-CFTE-NheI-1 kb donor plasmid was straightforward by 
subcloning the 1 kb EcoRI/HindIII insert of pITR-CFTE-NheI into pUC19 (see 
figure 4.1). Cloning using these endogenous enzyme sites resulted in a right 
homology arm of 435 bp and a left homology arm of 544 bp. Following sequential 
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digest (figure 4.4) the band of correct size in lane 5 was extracted and purified and 
cloned into the pUC plasmid backbone from lane 3.  
 
 
 
 
 
 
Figure 4.4: Lane 1: EcoRI/HindIII lambda ladder. Lanes 2 and 4 contain uncut pUC 19 and pITR-
CFTE-NheI plasmids respectively. Sequential digestion with EcoRI and HindIII of pUC19 and 
pITR-CFTE-NheI results in the banding pattern shown in lanes 3 and 5. As there are two HindIII 
sites in pITR-CFTE-NheI, three bands are expected at 4536, 1761 and 979 bp. The 979 bp band has 
the desired sequence and NheI site. The arrows indicate which bands were extracted for cloning.  
 
Construction of pUC-CFTE-NheI-1.5 kb donor required amplification of a 1.5 kb 
fragment of pITR-CFTE-NheI with primers Fwd_KasI and Rev_XbaI (which 
introduce KasI and XbaI restriction sites) cloned into pUC19 vector. This cloning 
strategy produces homology arms of exactly 750 bp either side of the NheI site.  
Digest analysis of 8 clones with HindIII and NheI, which should give a banding 
pattern of 3216, 435 and 334 bp, revealed 8/8 clones contained the correct insert, 
figure 4.5. Sequencing data confirmed the correct location of NheI. 
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Figure 4.5: Digest analysis of 8 potential clones for NheI insert. Lane 1:  Mass ruler express reverse 
ladder, Lanes 2, 7 and 11 are uncut plasmid controls. Lanes 3, 4, 5, 6, 8, 9, 10 and 12 were digested 
with NheI and HindIII. All show the expected banding pattern of 3216, 435 and 334 bp. 
 
4.4 Development of detection assays to determine if NheI is 
introduced into the genome following ZFN mediated HDR 
with NheI donor plasmids 
If HDR with any of the NheI donor plasmids occurs, the unique seven base pair 
sequence should be introduced into the genomic DNA within the spacer region of 
the ZFN cut site. A problem experienced in chapter 3 when detecting the CTT 
sequence in corrected cells was the occurrence of mis-priming which was explained 
in section 3.5. The new donor plasmids constructed in this chapter have an 
advantage in that the sequence to be detected is seven base pairs making the chance 
of mis-priming very unlikely. Also the fact that a unique restriction site was 
incorporated into the seven base pairs should enable quantification of repair through 
digest analysis, as was attempted with the XhoI and ClaI sites in section 3.6.1. A 
further advantage with these new donors is that both a positive (pITR-CFTE-NheI) 
and negative control (pITR-CFTE) were available to optimise the detection assays. 
Two detection assays were developed; firstly, a PCR assay with a NheI-specific 
reverse primer and secondly to quantify HDR events a NheI digest assay. 
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4.4.1 NheI-specific primer reaction 
A NheI-specific PCR using genomic DNA as template should produce a band of 
564 bp if successful recombination has occurred with the NheI donor plasmids as 
shown in figure 4.6. 
 
 
Figure 4.6: Schematic representation of PCR strategy used to detect introduction of NheI site 
(yellow box) with NheI specific reverse primer to give a band of 564 bp. 
 
The Fwd_EcoRI primer and Rev_NheI-specific primer were temperature optimised 
using proof-reading polymerase Pfx and the plasmids pITR-CFTE and pITR-CFTE-
NheI as templates. A band of 564 bp indicates that NheI is present in the DNA 
sample. As seen in Figure 4.7, at 59.5 °C there was a band in both the negative and 
positive controls. At a higher temperature of 62 °C there was only a band in the 
positive control therefore this was the temperature used for all NheI specific PCRs. 
 
 
 
 
 
 
Figure 4.7: Temperature optimisation of NheI specific PCR. Lane 1: Mass ruler express reverse 
ladder. Lane 2 and 4: Negative control plasmid pITR-CFTE used as a template at 59.5 and 62 °C. 
Lanes 3 and 5: Positive control plasmid pITR-NheI used as a template at 59.5 and 62 °C. 
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4.4.2 NheI quantification assay 
To quantify the level of recombination with the NheI donor plasmids a digest 
detection assay was used. A 2.6 kb PCR was generated from gDNA and 
subsequently digested with NheI. Comparing the intensity of the two bands 
produced against the remaining undigested 2.6 kb band would give an indication of 
the level of recombination.  
Figure 4.8: Schematic representation of NheI digest quantification assay. PCR on gDNA produces a 
band of 2.6 kb. Successful NheI digest produces two bands of 1900 and 700 bp. 
 
As the NheI product above does not occur in nature, the plasmids pITR-CFTE and 
pITR-CFTE-NheI were used in order to determine the level of detection by NheI 
digest. Different amounts of pITR-CFTE and pITR-CFTE-NheI were mixed 
together and made up to a total of 10 ng and analysed. PCR was performed using 
the primers Fwd_EcoRI and Rev_BtgI and go Taq polymerase. Following PCR, 
products were purified and digested with NheI and ran on a 5% polyacrylamide gel. 
This PCR should produce a product of 1729 bp and following successful digest with 
NheI should produce two bands of 1180 and 549 bp. In figure 4.9, pITR-CFTE-
NheI was mixed at 50, 20, 10, 5, 2, and 1% of pITR-CFTE. The limit of detection 
was taken to be 1% as the bands in lane 7 are very weak meaning at ratios below 
1% it would be difficult to ascertain whether digest was successful.  
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Figure 4.9: NheI digestion assay to determine the level of detection. Lane 1: Mass ruler express 
reverse ladder. Lanes 2-7: pITR-CFTE-NheI at 50, 20, 10, 5, 2 and 1% of pITR-CFTE. Arrows 
indicate expected bands following successful digestion.  
 
When using this quantification assay to analyse DNA from cells transfected with 
the NheI donor plasmids it was necessary to use different primers Fwd_gDNA and 
Rev_gDNA to avoid false positive results from donor plasmid carry-over in DNA 
extracts. This PCR product of 2.6 kb upon NheI digestion will produce two bands of 
1900 and 700 bp as shown in figure 4.8. 
 
4.5 Successful incorporation of NheI tag into CFTR using CFi9-
L
EL
/CFi9-R
KK
 ZFNs and pUC-CFTE-NheI-1.5 kb donor 
To test the hypothesis that HDR can occur at the ZFN cut site using our NheI donor 
plasmids and ZFNs, CFTE cells were transfected with ZFNs CFi9-L
EL
 and CFi9-
R
KK 
and the various donors as shown in table 4.1.  
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Assay 
Plasmid (µg) 
1 2 3 4 5 6 
CFi9-L
EL
 0 1 0 0 1 1 
CFi9-R
KK
 0 1 0 0 1 1 
pITR-CFTE-NheI 
(4.3 kb) 
0 0 0 2 0 2 
pUC-CFTE-NheI-1.5 
kb 
0 0 2 0 2 0 
pcDNA3.1 4 2 2 2 0 0 
Table 4.1: Amount of plasmids transfected for CFi9-L
EL
/CFi9-R
KK
 HDR assays with pITR-CFTE-
NheI or pUC-CFTE-NheI-1.5 kb. 
 
Seventy-two hours post-transfection, a two-step PCR was performed on total DNA 
to eliminate false positives from donor plasmid carry over. In step one, high-fidelity 
PCR with primers Fwd_gDNA (binds outside plasmid) and Rev_gDNA produced a 
2.6 kb product (figure 4.10a). This product was purified and used as template for 
step two.  
 
Figure 4.10a: Step one: 2.6 kb PCR product from samples described in table 4.1. M = Mass ruler 
express reverse ladder. Lanes 1-6 contain samples 1-6 from table 4.1. 
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In step two, PCR was performed using primers Fwd_EcoRI primer and Rev_NheI-
specific primer. A band of 564 bp should only be produced if successful 
recombination has occurred. Plasmids pITR-CFTE-NheI and pITR-CFTE were used 
as positive and negative controls respectively for the NheI specific PCR, (figure 
4.10b). 
Figure 4.10b: Step two: NheI specific PCR. M = Mass ruler express reverse ladder. +ve = positive 
control, -ve = negative control, lanes 1-6 contains samples 1-6 from table 4.1. White arrow in sample 
5 indicates correct band of 564 bp. 
 
The absence of a 564 bp band in sample 6 indicates that the combination of ZFNs 
and pITR-CFTE-NheI donor did not induce a detectable level of HDR. No band was 
present in samples treated with ZFNs and pUC-CFTE-NheI 1 kb donor either (data 
not shown). 
However, the presence of a 564 bp band in sample 5 indicates that HDR has 
occurred in cells transfected with ZFNs
 
and pUC-CFTE-NheI-1.5 kb. This shows 
that it is possible to insert a unique seven base tag into the ZFN site in exon 10 of 
CFTR genomic DNA. 
To determine the level of recombination a quantification assay was performed as 
described earlier in section 4.4.2. Several attempts were made to quantify 
recombination but no detectable cleavage was observed (data not shown). Based on 
the data from the sensitivity assay (figure 4.9), it was initially deduced that the level 
of HDR at the ZFN cut site was below 1%. 
However, NGS performed on a single sample obtained from cells transfected with 
ZFNs and pUC-NheI-1.5 kb revealed the level of HDR to be ~2.7% implying that 
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the efficiency of repair at the ZFN cut site is higher than previously thought. This 
indicates that the detection limit of the sensitivity assay when using genomic DNA 
is >3%. Figure 4.11 shows an alignment of two DNA sequences obtained by deep 
sequencing.  
 
Figure 4.11: Sample sequences of 7,303 PCR products from CFTE cells transfected with ZFNs and 
pUC-CFTE-NheI 1.5 kb confirming incorporation of NheI site from donor into genome. 
 
4.6 Design and construction of mini-gene construct to correct 
>80% of CF-causing mutations by ZFN mediated HDR 
Having proved the principle that it is possible to add a unique seven base pair 
sequence into the ZFN cut site, the possibility of recombining in a mini-gene donor 
was explored. It was decided to use the pUC-CFTE-NheI-1.5 kb plasmid as the 
backbone for the construct as this length of homology gave the only positive result. 
 
4.6.1 Design of mini-gene donor 
The aim was to construct a donor repair plasmid containing partial CFTR WT 
cDNA exons (10-24) with appropriate splice acceptor and poly-A sites, and also a 
GFP tag to allow visualisation of corrected cells. A T2A linker was used to link the 
CFTR cDNA and GFP sequences. The diagram in figure 4.12 depicts the hypothesis 
under test. Following HDR at the ZFN site in intron 9 with this mini-gene donor, 
endogenous exon 9 should be spliced together with the introduced WT exons10-24. 
If this occurs as planned, then splicing will result in a full length CFTR transcript 
that is under the control of the endogenous promoter thereby maintaining normal 
tissue-specific expression levels. The transcript should then be translated into a fully 
functional CFTR protein which can be trafficked to the apical membrane and allow 
correct Cl
-
 flux. 
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The T2A linker is positioned such that production of GFP should only occur if 
CFTR mRNA is produced first. This GFP protein should be present in all corrected 
cells and so should make detection of corrected cells easier. This experiment was 
based on the design used in Li et al. (2011) where they used a similar cDNA 
construct to target WT exons 2-8 to intron 1 of the F.IX gene (Li et al., 2011). 
 
Figure 4.12:  Schematic representation of what is expected to occur in the cell following HDR with 
mini-gene donor mediated by ZFN cleavage. Mini-gene donor is shown with cDNA exons 10-24 in 
blue, splice acceptor (SA) in red, T2A linker in orange, GFP in fluorescent green and 750 bp 
homology arms left and right (HAL, HAR) in green. Upon ZFN cleavage in intron 9 (purple box), 
homologous recombination should occur with the mini-gene donor to repair the DSB. This HR will 
result in recombination of the entire mini-gene construct into intron 9 of the CFTR gene. During 
mRNA production exons will be spliced together, exon 9 will splice into the WT cDNA of the mini-
gene due to the presence of the correct splice acceptor to produce a full length and functional CFTR 
protein. The T2A linker allows production of GFP mRNA only following production of CFTR 
mRNA. If no CFTR is made then no GFP will be made. The final products are two separate proteins, 
CFTR and GFP.  
4.6.2 Construction of mini-gene donor 
Construction of the mini-gene donor required a number of cloning steps. Firstly, a 
synthetic polylinker was designed containing all necessary restriction enzymes for 
mini-gene assembly and cloned into the MCS of pUC19 to form pUC-linker. Then 
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each of the four parts of the mini-gene was amplified from the relevant 
DNA/plasmid using appropriate primers with added restriction sites. Cloning was 
carried out in “reverse” order with the GFP-pA fragment cloned first followed by 
T2A, partial cDNA and finally the SA fragment into the linker region of pUC. 
When all fragments were correctly assembled the entire mini-gene construct was 
excised from the pUC-linker plasmid and cloned into the NheI site of pUC-CFTE-
NheI-1.5  kb which provides the 1.5 kb homology arms. This section will briefly 
describe each cloning step performed. 
-Step 1: Cloning of pUC-Linker 
Two 76 bp oligos, containing the nine restriction sites necessary for cloning and the 
extra bases needed for efficient binding of enzymes, were designed and synthesised. 
The oligos were annealed and cloned into sites XbaI and HindIII of pUC19. Figure 
4.13 shows the sequence of one strand of the linker oligo with restriction sites 
underlined and relevant fragments to be cloned in bold above the sequence. 
Figure 4.13: One strand of the linker oligo designed to clone the four mini-gene donor fragments. 
Restriction sites are underlined and mini-gene donor fragments are above the sequence in bold. SA: 
Splice Acceptor; cDNA: exons 10-24 of CFTR; T2A: linker; EGFP/pA: GFP sequence and polyA 
site. 
-Step 2: Cloning of GFP and poly-A site into pUC-linker to create pUC-
GFP/pA 
As the BglII restriction site necessary for cloning the eGFP/pA fragment was 
present in the cDNA sequence it was necessary to clone the GFP and poly-A site 
into pUC-linker first so as to avoid later disruption of the cDNA fragment. The 
plasmid eGFP-N1 was used as a template to create the eGFP/pA fragment and was 
amplified by primers Fwd_eGFP/pA and Rev_eGFP/pA which introduced BglII and 
NheI restriction sites to the 5‟ and 3‟ ends of the 955 bp fragment respectively. The 
eGFP/pA fragment was then cloned into the AvrII and BglII sites of pUC-linker. 
AvrII and NheI produce the same overhangs, which allow ligation to be performed 
without disrupting downstream cloning steps which will need to use the NheI site.  
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-Step 3: Cloning of T2A linker into pUC-GFP/pA to create pUC-T2A-GFP/pA 
The 57 bp T2A linker was designed and assembled from two single stranded oligos 
with restriction site compatible overhangs, XhoI at the 5‟ end and BglII at the 3‟ 
end, as shown in figure 4.14. 
 
Figure 4.14: T2A linker sequence. Restriction site compatible ends are underlined. 
 
This linker should allow production of the GFP mRNA following transcription of 
CFTR mRNA. The plasmid pUC-GFP/pA was digested with the same enzymes to 
produce the backbone to be used for ligation with the T2A insert.                                
-Step 4: Cloning of WT cDNA exons 10-24 and Splice Acceptor (SA) into pUC-
T2A-GFP/pA to create pUC-SA-cDNA-T2A-GFP/pA 
The strategy to assemble a splice acceptor (SA) sequence with exons 10-24 cDNA 
sequences is shown in figure 4.15a.  It was decided to use the endogenous intron SA 
sequence. A ~ 200 bp sequence containing the SA and first ~175 base pairs of exon 
10, including a SphI site, was amplified from genomic HBE DNA to produce 
SA/ex10. Wild-type exons 10-24 were amplified as a ~4136 bp fragment from the 
pCEP-CFTR plasmid as shown. Relevant restriction sites were added to the 
fragments during PCR and used to clone the cDNA exons 10-24 and SA/ex10 
fragments into pUC-T2A-GFP/pA. Both fragments are shown in figure 4.15b. 
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HBE DNA                                                                                     pCEP-CFTR 
 
Figure 4.15a: Schematic representation of cloning strategy to clone SA/ex10 in-frame with exons 
10-24. SA in red is amplified from HBE DNA with primers that add a NheI restriction site to the 5‟ 
end and include the endogenous SphI site in exon 10. Exons 10-24 are amplified from the pCEP-
CFTR plasmid starting within exon 10 close to the SphI site. Following digest with indicated 
enzymes, the overhangs produced allow ligation of the SA and cDNA fragments so that they are in-
frame and will allow correct splicing of CFTR exons.  
 
                 
Figure 4.15b: cDNA and SA/ex10 fragments for mini-gene cassette. Lane 1: Mass ruler express 
reverse ladder with relevant bands indicated with black arrows. Lane 2: cDNA fragment amplified 
from the pCEP-CFTR plasmid. Lane 3: SA/ex10 fragment amplified from HBE genomic DNA. Both 
bands were gel extracted and purified. 
The cDNA fragment, (figure 4.15b, lane 2) following purification and digestion, 
was ligated into the SphI and XhoI sites of the linker region of pUC-T2A-GFP/pA 
to create pUC-cDNA-T2A-GFP/pA.  
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pUC-cDNA-T2A-GFP/pA was digested with SpeI and SphI to create a backbone 
into which the SA/ex10 fragment was ligated using the NheI (same overhang as 
SpeI) and SphI sites. Sequencing data and digest analysis confirmed insertion of the 
cDNA and SA fragments thus completing the mini-gene cassette and yielding pUC-
SA-cDNA-T2A-GFP/pA. 
-Step 5: Cloning of SA-cDNA-T2A-GFP/pA mini-gene cassette into pUC-
CFTE-NheI-1.5 kb 
The entire mini-gene cassette was excised from of the pUC backbone as a 4091 bp 
NheI fragment. The pUC-CFTE-NheI-1.5kb plasmid was also digested with NheI to 
yield a backbone of 4001 bp and de-phosphorylated to avoid self-ligation before 
insertion of the mini-gene cassette. HindIII was used to analyse clones derived from 
the reaction. Bands at 5048, 1898, 829 and 334 bp indicate that the mini-gene 
cassette has been successfully cloned into the pUC-CFTE-NheI-1.5kb plasmid to 
yield the complete mini-gene donor. Figure 4.16 shows the correct banding pattern 
in lane 3. 
                                     
Figure.4.16: Digest analysis of potential clones derived from ligation of mini-gene cassette and 
pUC-CFTE-NheI-1.5 kb. Lane 1: Mass ruler express reverse ladder with relevant bands indicated 
with black arrows. Lane 2: Uncut control of sample in lane 3. Lane 3: Sample derived from ligation 
digested with HindIII which yields the expected banding pattern of 5048, 1898, 829 and 334 bp. 
Lane 4: pUC-CFTE-NheI-1.5 kb digested with HindIII to show banding pattern if mini-gene cassette 
has not been inserted correctly. There are two HindIII sites present in this plasmid yielding two 
bands of 3667 and 334 bp.  
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The final plasmid pUC-SA-cDNA-T2A-GFP/pA (pUC-mini-gene) contains the 
entire mini-gene cassette described in section 4.6 flanked by 750 bp homology arms 
in a pUC backbone. This plasmid will be used to test the hypothesis that our ZFNs 
can induce HDR of exons 10-24 of the CFTR gene in the CFTE cell line. 
4.7 Detection of HDR with CFi9-LEL/CFi9-RKK ZFNs and pUC-
mini-gene donor. 
As discussed in previous chapters PCR based screening methods had been 
successfully used to determine if repair had occurred, but had not been successful in 
accurately quantifying the level of repair. The design of the mini-gene donor 
construct means that GFP should only be produced if CFTR is corrected by HDR. If 
a cell is corrected it should produce both CFTR and GFP, allowing an indirect 
measurement of HDR. Thus, measuring the % of GFP positive cells would give an 
estimate of the level of repair. Furthermore, this marker allows parameters of 
transfection such as the ratio of ZFN:donor plasmid or use of histone deacetylase 
inhibitor drugs like SAHA, to be varied and any subsequent changes in GFP easily 
monitored. In addition, cells could be enriched by FACs to perform functional 
assays to determine if CFTR in corrected cells was trafficked to the apical 
membrane rather than trapped in the ER. 
In this section I will discuss attempts to detect HDR of the mini-gene.  
4.7.1 Transfection with ZFNs and mini-gene donor produce GFP positive cells. 
The hypothesis is based on the design of the mini-gene donor and is that GFP 
positive cells indicate that HDR has occurred. Firstly, following transfection, cells 
were analysed by fluorescent microscopy. However, it is important to rule out false 
positive results, not just with ZFN only or donor only treated samples but for ZFN 
and donor treated samples also. Ultimately, HDR will need to be confirmed by PCR 
and sequencing results.  
CFTE cells were typically transfected with CFi9-L
EL
 and CFi9-R
KK
 and mini-gene 
donor as outlined in table 4.2. The ratio of ZFN:donor was varied to test which ratio 
gives rise to GFP positive cells. 
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         Assay 
Plasmid 
 (µg) 
1 2 3 4 5 6 
Ratio 
ZFN:Donor 
 
N/A 
 
N/A 
 
N/A 
 
1:1 
 
1:3 
 
3:1 
CFi9-L
EL
 0  1.5  0  1  0.5  1.5  
CFi9-R
KK
 0  1.5  0  1  0.5  1.5  
pUC-mini-gene 
donor 
0  0  3  2  3  1  
eGFP 3  0  0  0  0  0  
pcDNA 3.1 1  1  1  0  0  0  
Table 4.2: Amount of plasmids transfected for CFi9-L
EL
/CFi9-R
KK
 HDR assays with mini-gene 
donor. 
 
Fluorescent microscopy was used to visualise transfected cells 3, 6, 14, 21 and 33 
days post-transfection. GFP positive cells were detected in all wells transfected with 
ZFNs and mini-gene donor, with the highest amount seen at a ratio of 1:3 
ZFN:donor. This ratio was used for the remainder of experiments, see figure 4.17. 
GFP was only detected in cells transfected with both ZFNs and donor, no GFP was 
observed in ZFN only or donor only transfected cells. The visualisation of GFP 
implied that correction has occurred and the CFTR protein was also being 
produced. However, as this observation could also be explained if the mini-gene 
had integrated in a random manner close to a promoter, it was necessary to confirm 
the recombination events by PCR. Prior to using PCR-based assays to verify, it was 
decided to try and enrich the GFP positive population.  
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Figure 4.17: Fluorescent images of treated cells as outlined in table 4.2. GFP positive control: cells 
transfected with eGFP plasmid only, (table 4.2, assay 1). Images of cells taken at various time points, 
transfected with ZFN and mini-gene donor at a ratio of 1:3. 
 
4.7.2 Enrichment of GFP positive cells 
Several attempts were made to enrich GFP positive cells with the view to increase 
the potential readout for PCR and FACs analysis. In order to enrich corrected cells, 
the overall density of cells was decreased by transferring treated cells into culture 
plates with a smaller surface area/well to promote growth. Cells were subjected to 
serum starvation in order to induce a stress response to promote corrected cell 
growth over uncorrected cells (section 2.23). 
Although there was a slight increase in GFP positive cell number following 
enrichment, it could not be further increased or maintained. Furthermore, 
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throughout the enrichment process the brightness of GFP was notably fainter than 
pEGFP control transfected cells. We hypothesised that following correct HDR the 
GFP protein will be under the control of the naturally weak endogenous CFTR 
promoter and this may be the reason for the weak GFP signal which may be 
difficult to detect using a conventional fluorescent microscope. The observation that 
GFP is detected up to 29 days post-transfection is consistent with the long-term 
correction known to occur following mini-gene HDR (Li et al., 2011).  
 
4.7.3 Fluorescent Activated Cell Sorting (FACs) analysis 
FACs was used to detect an increase in GFP expression in a treated population of 
cells. A shift in GFP above that seen in mock transfected cells would give an 
indication of the number of cells that had been corrected by HDR. Typically 500 µl 
of total cells were trypsinised and DNA extracted three days post-transfection and 
used for FACs analysis as described in section 2.20. Data obtained is provided table 
4.3B below.  
 
 
A) 
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B) 
Sample % GFP positive cells 
Mock transfected 0.3 ± 0.2 
ZFNs and donor (1:1) 0.4 ± 0.3 
ZFNs and donor (1:3) 0.8 ± 0.6 
ZFNs and donor (3:1) 0.1 ± 0.1 
Table 4.3: A) Representative sample FACs traces. B) Average percentage of GFP positive cells ± 
SEM obtained from FACs analysis performed on 70,000 cells. N=3  
As stated above, if the mini-gene had correctly recombined, GFP would be expected 
to be expressed at low levels. Thus, the fluorescence was not expected to be much 
above background. As shown in table 4.3, cells transfected with ZFNs and donor at 
a ratio of 1:3 did contain a greater number of GFP positive cells than mock 
transfected population. Indeed, a simple analysis of the data in table 4.3B suggests 
0.5% of cells express GFP which is roughly the level of HDR that might be 
expected. However, given the low level of green fluorescence detected, it was 
decided to try and increase the level of GFP expression to see if it was possible to 
improve the signal to noise ratio (see below).  
 
4.7.4 Does addition of SAHA increase HDR as determined by FACs analysis? 
The US FDA approved Histone Deacetylase (HDAC) inhibitor, SAHA, has been 
shown to increase stabilisation, trafficking and activity of ΔF508 CFTR by 
decreasing the expression of HDAC7. As a consequence SAHA was shown to 
increase the yield of CFTR trafficking as well as increase CFTR mRNA (Hutt et al., 
2010). It was hypothesised that addition of SAHA would increase the expression 
levels of CFTR mRNA and in turn GFP mRNA, thus increasing signal to noise 
ratio, which should improve the accuracy of the FACs analysis. SAHA was added 
24 hrs post-transfection at a concentration of 5 μM and removed either 24 or 72 hrs 
later. Cells incubated with SAHA for longer than 72 hrs all underwent apoptosis 
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(data not shown). Cells incubated for the shorter time of 24 hrs survived and GFP 
expression was measured by FACs. A shift in GFP was observed in cells treated 
with SAHA compared to untreated cells, however, there was no difference in GFP 
levels in SAHA treated-mock transfected cells compared to SAHA treated-ZFN and 
mini-gene donor transfected cells (data not shown). 
These observations, along with problems experienced in enrichment suggested the 
possibility that the GFP signal may not be a consequence of mini-gene HDR as 
proposed in figure 4.12, rather it may be a consequence of low level random 
integration. 
 
4.7.5 PCR-based assays to determine if HDR occurred at the correct location 
A convincing readout from GFP experiments described above was not obtained, so 
it was decided to perform PCR to detect the presence of the mini-gene construct at 
the ZFN cut site in the CFTR gene. If HDR had occurred as predicted, then WT 
exons 10-24 would have been inserted into the ZFN cut site in intron 9. Figure 4.18 
shows where the four sets of primers used to try and detect this bind. 
Figure 4.18: Four sets of primers were used to produce a PCR product that would confirm whether 
HDR with the MG donor had occurred at the correct location. Firstly detection of recombination was 
investigated at the 5‟ end of the construct using primer sets 1 (Fwd_gDNA and Rev_ex11) and 2 
(Fwd_recombination and Rev_ex11). When these proved unsuccessful, the 3‟ end was investigated 
using primer sets 3 (Fwd_GFP_HR_1 and Rev_ex10) and 4 (Fwd_GFP_HR_2 and Rev_ex10). 
 
Repeated attempts with the four primer sets failed to reveal evidence of HDR. The 
inability to obtain a PCR product to show correct recombination of the mini-gene 
donor into the ZFN cut site, strongly suggested that mini-gene HDR had not 
occurred as predicted and that any GFP expression was most likely a consequence 
of low level random integration. 
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4.7.6 Next Generation Sequencing sheds light on mini-gene HDR 
One round of deep-sequencing was carried out on a DNA sample extracted from 
cells transfected with ZFNs and mini-gene donor (1:3). If recombination has been 
successful at the ZFN cut site the sequence should now contain a 7 bp tag, 
GCTAGCT (underlined T is from the linker described in fig. 4.13), followed by a 
Δ32 bp due to the way the mini-gene donor construct was cloned into the NheI site 
of pUC-CFTE-NheI-1.5 kb. This would be followed by corrected CTT, mini-gene 
exons 10-24 and GFP. Deep-sequencing data obtained from a single sample is 
shown in figure 4.20. 
 
Figure 4.20: Sample sequences of PCR products from CFTE cells transfected with ZFNs and pUC-
mini-gene confirming incorporation of 7 bp tag and 32 bp deletion from donor into genome. 
Approximately 1% of sequences had this sequence. Lower case indicates intronic sequence and 
higher case indicates exon 10. SA sequence and position of CTT addition is indicated.  
The sequencing data clearly shows the expected 7 bp tag and 32 bp deletion 
following HDR with the mini-gene donor. However, from this data it can be seen 
that recombination only occurred at this site as no CTT was detected in these altered 
sequences. If the DSB had been repaired fully with the mini-gene donor the CTT 
sequence should be in this data but it is not present. 
It was originally hypothesised that recombination would occur as depicted in figure 
4.12. However evidence to support this has not been obtained in this body of work.  
However, as discussed below, this has allowed the design of an alternative strategy. 
 
4.8 Conclusions 
The aim of this chapter was to explore one of the two alternative strategies 
generated from results obtained in chapter three. Thus, rather than design a new pair 
of ZFNs closer to CTT it was decided in this chapter to take advantage of the 
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efficient cleavage activity of our ZFNs and use them to explore an alternative 
strategy using a CFTR cDNA mini-gene. 
Firstly, to test that HDR could occur at the cut site and to determine what length of 
homology arm was optimal, three new NheI donor plasmids were constructed 
containing different lengths of homology. HDR was detected when cells were 
transfected with ZFNs and pUC-CFTE-NheI-1.5 kb as shown by the 564 bp NheI-
specific PCR product (section 4.5). Several attempts were made to quantify the 
level of HDR by in-house detection assays with no success. It was thought that 
either the detection system was not sensitive enough, as was seen previously in 
chapter three, or else the level of HDR was below the limit of detection estimated 
for these methods.  
When samples were subject to NGS analysis, it was confirmed that the 7 bp tag had 
been added and occurred at a level of ~2.7%. This value is slightly higher than the 
2% HDR value for CTT correction using the same ZFNs. However, as it was only 
possible to perform both NGS experiments on DNA from a single transfection, it 
was not possible to determine the significance of this difference. Likewise, whilst 
tempting to speculate the increased value of HDR in this experiment is because the 
NheI tag is recombined at the ZFN cut site, compared with the CTT recombination 
some 203 bp downstream of the cut site, more experiments would be needed to 
confirm this. Also, a formal comparison of homology arm length and the role of 
AAV-ITRs would require additional experiments to be performed. Regardless, the 
NheI specific PCR successfully detected NheI in genomic DNA from cells 
transfected with ZFNs and pUC-CFTE-NheI-1.5 kb which proved the principal that 
a unique sequence can be introduced into the ZFN cut site in our cell line. 
Having shown that HDR occurs at the cut site, the second aim of this chapter was to 
correct CF-causing mutations using our ZFNs and mini-gene construct. To date, 
only two groups have successfully reported mini-gene recombination (Lombardo et 
al., (2007) and Li et al., (2011)). The strategy described herein required a more 
complex donor than these previously described and involved a number of intricate 
steps. Following transfection with ZFNs and pUC-mini-gene, GFP was detected 
using fluorescent microscopy up to 33 days post-transfection. The hypothesis based 
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on our mini-gene design is that GFP production would indicate that HDR had 
occurred, and that WT CFTR was being produced. However, the difficulties 
experienced when attempts were made to enrich the GFP positive cells, pre-treat 
with SAHA to increase expression or test for HDR by FACs, and failure of PCR to 
generate a product providing evidence of HDR as predicted indicated a problem in 
the design strategy and suggested that the GFP visualised may be an artefact. The 
lack of HDR as fully predicted was confirmed by data obtained from deep 
sequencing of a sample treated with ZFNs and pUC-mini-gene.   
However, this NGS data generated very valuable insight regarding what was 
happening following DNA cleavage by the ZFNs and also helped explain why we 
never detected a PCR product from our GFP positive samples. It also confirmed that 
the GFP detected in FACs and fluorescent microscopy was an artefact. If HDR with 
the mini-gene occurs there will be: 1) a 7 bp tag followed by a deletion of ~32 bp 
due to the mini-gene disrupting the sequence as it is cloned into the NheI site of 
pUC-CFTE-NheI-1.5 kb and 2) CTT will be present in exon 10. The NGS data did 
confirm that HDR had occurred between our donor plasmid and CFTR sequence, as 
seen from the 7 bp tag and Δ32 bp; however, homologous recombination did not 
incorporate the entire donor construct as deduced from the absence of CTT in exon 
10. 
The design of our construct may be the limiting factor here as a number of features 
of the construct may actually be preventing the HDR process as required. Firstly, 
the SA fragment contains the exact same sequence as the endogenous SA in CFTE 
cells. Secondly, the left homology arm contains mutant exon 10 which together with 
the SA fragment may provide enough homology to repair the break without using 
the right homology arm. Figure 4.21 depicts what is thought to be happening with 
our mini-gene construct. The dashed red lines show the possible homology arms 
being used to repair the ZFN induced DSB. The overlap of sequence in the 
construct with sequence in the right homology arm could be the reason why HDR 
does not extend to include the entire mini-gene. However, HDR did occur as shown 
in our sequencing data by the introduction of the 7 bp tag and 32 bp deletion, 
section 4.7.6. 
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Figure 4.21: Schematic representation of HDR theory following ZFN mediated HDR with pUC-
mini-gene. Red dashed lines indicate what homology is being used to repair ZFN induced DSB. 
Following this method of HDR, there will be a 32 bp deletion before the SA sequence. 
 
To overcome this problem in the future, a SA fragment will be designed to contain 
the essential splice machinery sequence but different intervening sequences so as to 
avoid homology overlap. Also the cut site will be moved further upstream in intron 
9 to avoid any overlapping homology arms, i.e. exon 10 coding sequence. NGS will 
be used to confirm correct recombination with the whole mini-gene. This new cut 
site will be CRISPR based or possibly double nickase based (see final discussion).  
Another issue that will have to be examined is the extent of donor sequence 
incorporated at the target. This depends on a number of factors; 1) the extent of 
synthesis after strand invasion, 2) whether the invading 3‟ end had been resected 
and 3) the direction of mismatch repair in the heteroduplex formed by annealing 
(Carroll, 2011). These factors still remain largely unknown however the lengths of 
conversion tracts have been measured and were found to be quite long in 
Drosophila where several kilobases of donor was incorporated (Nassif et al.,1994), 
whereas in mammalian cells only short tracts of between 100 and 200 bp from the 
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break were incorporated after repair (Elliott et al., 1998). To test this, new donor 
plasmids could be constructed containing multiple restriction site markers at various 
distances from the cut site, much like the pITR-donor-XC plasmid. Co-transfection 
of these plasmids with ZFNs and analysis by NGS would then give an idea of the 
effects of distance on HDR efficiency. To avoid too much sequence divergence, 
multiple plasmids with one restriction site marker in each could be used. If only 
100-200 bp is the limit for repair it implies our mini-gene may not be fully 
incorporated as it is over 200 bp. However, the study by Li et al., (2011) on which 
we based our design, showed successful incorporation of their mini-gene donor and 
production of the desired protein, factor IX (Li et al., 2011) which suggests much 
longer tracts can be incorporated when using mini-genes. Indeed, up to 8 kb can be 
incorporated (Moehle et al., 2007). Of note, the homology arms to incorporate F.IX 
targeted an intronic region. This further suggests that we need to target further 
upstream in intron 9 to exclude exon 10.  
To summarise, successful HDR was achieved using the NheI donor, proving the 
principle that recombination can occur at the ZFN cut site. Data from the mini-gene 
experiments indicate that an intron target will be more likely to succeed and this 
will require CRISPR gRNAs, which will be described in chapter five. 
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5 CRISPR/Cas9/gRNA system as an alternative to ZFNs 
to mediate HDR in the presence of donor plasmids 
5.1 Aims: 
From the conclusions drawn in chapter three it was hypothesised that distance from 
the cut site to the mutation may be a limiting factor determining the level of HDR. 
Therefore, the second option to be explored was to use other gene-editing tools, 
more amenable to changing location, such as the CRISPR/Cas9/gRNA system. This 
system is the latest tool for genome editing and as described in section 1.7.9, there 
are very simple guidelines to follow in order to create a CRISPR gRNA to target a 
specific sequence. Two new sequences were chosen to be cleaved and were of the 
form GN20GG, one in exon 10, 85 bp upstream of the CTT deletion and one in 
intron 9 close to the original ZFN target site (see figure 5.1). CRISPR ex10 will be 
used in conjunction with the original ΔF508 donors, pITR-donor and pITR-donor-
XC, while CRISPR in9 will be used with pUC-mini-gene donor to mediate HDR. 
 
5.2 Objectives: 
 Design and construct two CRISPR guide RNAs to target CFTR 
 Determine the level of cleavage/NHEJ repair at the target sites 
 Detect HDR events using CRISPR/Cas9/gRNA system and donor plasmids 
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5.3 Design of two CRISPR gRNAs to target and cleave CFTR 
In order to target a specific sequence a simple 20 bp oligo is designed according to 
GN20GG and cloned into the U6 expression plasmid followed by co-transfection 
along with the Cas9 protein. Two sites were chosen within the CFTR gene (see 
figure 5.1). The G‟s necessary for gRNA binding are provided by the sequence 
being targeted and so are not included in the 20 bp oligo. 
 
Figure 5.1: Schematic representation of a section of the CFTR sequence displaying the position of 
the target sites for the ZFNs, intron 9 gRNA and exon 10 gRNA and the location of the CTT deletion 
 
For cloning into the U6-expressing plasmid, BseRI overhangs were added to the 20 
bp oligos (see figure 5.2). 
 
Figure 5.2: Two 20 bp sequences for the two CRISPR gRNAs are shown with the added bases 
necessary for BseRI cloning underlined. 
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Figure 5.3: pEX-A plasmid. U6 promoter is in grey, CRISPR cloning site in orange and gRNA 
scaffold is in blue.  
 
5.3.1 One-step cloning of CRISPR IN9 and CRISPR EX10 
A plasmid was designed to provide the gRNA scaffold and promoter necessary for 
CRISPR gRNA expression. A 474 bp sequence was designed, synthesised and 
cloned into the NotI sites of the pEX-A plasmid. This sequence consisted of the U6 
promoter, gRNA scaffold and BseRI restriction sites necessary for CRISPR gRNA 
cloning (see figure 5.3). 
The two short single stranded oligos (figure 5.2) were annealed and cloned into the 
BseRI sites of the pEX-A plasmid by the golden-gate method. Potential clones were 
digested with XhoI and BseRI. Successful ligation results in the BseRI sites being 
destroyed and so only XhoI will cleave to produce a single band. Figure 5.4 shows 
the results of digestion. 
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Figure 5.4: Digest analysis of clones derived from golden gate cloning of CRISPR gRNAs into 
pEXA. Lane 1: Low range Ladder. Lanes 2-11: Potential clones derived from CRISPR in9 ligation. 
Lanes 12-20: Potential clones derived from CRISPR ex10 ligation. Successful cloning produces a 
single band as seen in lane 11 and in all lanes except 14 in lanes 12-20. 
 
One out of ten clones were successful for CRISPR in9, while eight out of nine was 
successful for CRISPR ex10.  
 
5.4 Determination of cleavage efficiency of CRISPR IN9 and 
CRISPR EX10 
The CRISPR/Cas system can be implemented in mammalian cells by co-expressing 
the bacterial Cas9 nuclease along with the guide RNA. Cells were transfected with 
ZFNs, CRISPR in9/hCas9, CRISPR ex10/hCas9 or CRISPR ex10/hCas9D10A (see 
table 5.1). The mutant Cas9 cleaves only one strand of DNA and so acts as a 
nickase which have been shown to increase the rate of HR by decreasing NHEJ.  
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Assay 
Plasmid (μg) 
1 2 3 4 
CRISPR in9 0.0  0.0  0.5  0.0  
CRISPR ex10 0.5  0.0  0.0  0.5  
hCas9 0.5  0.0  0.5  0.0  
hCas9 D10A 0.0        0.0  0.0  0.5  
CFi9-L
EL
 0.0  0.5  0.0  0.0  
CFi9-R
KK
 0.0  0.5  0.0  0.0  
pcDNA3.1 3.0  3.0  3.0  3.0  
Table 5.1: Amounts of plasmids used in transfection of CFTE cells 
 
Proof-reading PCR using Pfx and CFTR-NHEJ primers was performed on total 
DNA extracted 72 hrs post-transfection and NHEJ events were detected using the 
T7E1 assay. Samples were run on a 5% polyacrylamide gel. Results obtained are 
shown in figure 5.5. Successful cleavage of DNA with CRISPR ex10 should 
produce bands at ~450, 290 and 140 bp. CRISPR in9 should produce bands of 
~430, 230 and 200 bp while ZFNs produce bands of ~430, 250 and 180 bp. 
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Figure 5.5: T7E1 assay results on a 5% polyacrylamide gel. M: Mass ruler express reverse ladder. 
UT: samples untreated with T7E1. EX10: CRISPR gRNA ex10/hCas9 treated with T7E1. IN9: 
CRISPR gRNA in9/ hCas9 treated with T7E1. EX10/hCasD10A: CRISPR gRNA ex10/ hCasD10A 
treated with T7EI 
 
Results from the T7E1 assay in figure 5.5 show that both CRISPR gRNAs are able 
to recognise the CFTR gene and cleave DNA to produce a DSB as indicated by the 
desired banding pattern (shown by white arrows) when co-transfected with 
hCas9/hCas9D10A plasmid. Densitometry analysis of the relevant bands was used 
to determine the level of cleavage of the two gRNAs. CRISPR ex10 with hCas9 
cleaved at 16%, ZFNs at 3%, CRISPR in9 at 5% and CRISPR ex10 with hCas9 
D10A at 3% which is lower than CRISPR ex10 and hCas9 as expected.  
 
5.4.1 NGS data for CRISPR cleavage 
NGS data on DNA treated with CRISPR ex10/Cas9 and CRISPR in9/Cas9 provided 
further evidence that cleavage had occurred. The data shows that following 
cleavage, a mix of deletions and insertions are produced by NHEJ. Below in figure 
5.6 is some of the deep sequencing data obtained from DNA treated with CRISPR 
ex10/hCas9. The level of NHEJ for this particular sample was 15.5%. This value 
correlates closely to the value obtained using the T7E1 assay. To determine if this 
correlation is reproducible more experiments will need to be performed. 
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Figure 5.6: Sample sequences of 1,346 PCR products from CFTE cells transfected with CRISPR 
ex10 and Cas9 confirming cleavage of the genome. Deletions and insertions indicate successful 
cleavage of CRISPR and Cas9 plasmids at the desired location. Sequence for CRISPR ex10 target 
site indicated. 
 
The CRISPR in9 gRNA also showed evidence of gene targeting as seen in figure 
5.7. Large deletions and some small insertions are evident in the deep sequencing 
data obtained from a single sample. The level of cleavage in this sample was 2.3%. 
Figure 5.7: Sample sequences of 1,609 PCR products from CFTE cells transfected with CRISPR in9 
and Cas9 confirming cleavage of the genome. Deletions and insertions indicate successful cleavage 
of CRISPR and Cas9 plasmids at the desired location. Sequence for CRISPR in9 target site 
indicated. 
 
Of note both CRISPR create indels approximately 3-4 bases upstream of the PAM 
sequence as reported by Mali et al. (2013). This is the first evidence of CFTR gene 
targeting with CRISPR gRNAs and the levels of NHEJ detected are comparable to 
levels reported by other groups targeting other genes.  
 
5.5 CRISPR/Cas9 system can mediate HDR in the presence of 
appropriate donor plasmids. 
Having shown that both CRISPR gRNAs were able to efficiently cleave DNA, the 
ability of CRISPR gRNA-induced DSBs to mediate HDR with donor plasmids was 
investigated. 
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5.5.1 CRISPR EX10 can mediate HDR with pITR-donor-XC 
CRISPR ex10 cleaves roughly 85 bp upstream of the CTT deletion (see figure 5.1) 
and so was co-transfected with pITR-donor-XC. A typical transfection of CFTE 
cells is outlined in table 5.2. 
 
 
 
 
 
 
 
 
 
Table 5.2: Amount of plasmids transfected for CRISPR EX10 HDR assays with pITR-donor-XC 
 
Total DNA was extracted and analysed for HDR using essentially the same PCR-
based method described in section 3.6.1. Briefly, a 2.6 kb PCR was generated to 
exclude plasmid carry over using Fwd and Rev_gDNA primers. PCR products are 
shown in figure 5.8. 
 
 
Assay 
Plasmid ( μg) 
1 2 3 4 
CRISPR ex10 0.5 0.0 0.5 0.5 
hCas9 0.0 0.0 0.5 0.0 
hCas9D10A 0.5 0.0 0.0 0.5 
pITR-donor-XC 0.0 3.0 3.0 3.0 
pcDNA3.1 3.0 1.0 0.0 0.0 
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Figure 5.8: 2.6 kb PCR products generated from DNA samples outlined in table 5.2. Lane 1: 
EcoRI/HindIII lambda ladder. Lanes 2-5: 40 μl of PCR product generated from samples 1-4 in table 
5.3 respectively. The entire PCR product was extracted to obtain a high yield for digest analysis. 
 
The PCR products in figure 5.8 were extracted and purified, then digested with 
XhoI and ClaI. Following digest, as well as the original 2.6 kb band, some PCR 
products should be cleaved to produce bands; 2040 and 606 bp for XhoI digests or 
2157 and 489 bp for ClaI digests if HDR has been successful. As a positive control 
to show that PCR products can be successfully digested following purification, a 
432 bp fragment was amplified using pITR-donor-XC as a template across the 
region containing the two restriction sites. The expected two bands of 290 and 140 
bp were produced following XhoI digest and bands of 411 and 23 bp following ClaI 
digest. 
Figure 5.9: Digest analysis of 2.6 kb PCR products in figure 5.8. Lane M1: EcoRI/HindIII lambda 
ladder. M2: Low range ladder. +ve: Positive control digested with XhoI. 1-4: Samples 1-4 as in table 
5.2 digested with XhoI. +ve: Positive control digested with ClaI. Lanes 1-4: Samples 1-4 as in table 
5.2 digested with ClaI. 
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Figure 5.9 shows the results from these digests. All 2.6 kb PCR products remained 
undigested. Based on data from chapter 3, the inability to detect digestion suggested 
HDR, if occurring was <3%. 
5.5.2 NGS data for CRISPR ex10 and pITR-donor-XC 
Although HDR could not be detected by the PCR-based method above, it was 
decided to analyse a sample of CRISPR ex10/hCas9/pITR-donor-XC treated cells to 
see if HDR could be detected by NGS. A 432 bp PCR product was generated and 
analysed. A sample of the data obtained is shown in figure 5.10. 
Figure 5.10: Sample sequences of 3,244 PCR products from CFTE cells transfected with CRISPR 
ex10/hCas9 and pITR-donor-XC confirming incorporation of XhoI, CTT and ClaI sites from donor 
into genome. The arrows indicate the base pair changes following HDR with pITR-donor-XC. G->C 
for XhoI site, CTT addition and A->C for ClaI site. 
 
The data in figure 5.10 shows that CRISPR ex10 did mediate HDR with pITR-
donor-XC. The black arrows indicate the base changes, G->C for XhoI, addition of 
CTT and A->C for ClaI. The overall level of HDR was determined to be 1% in this 
sample. Interestingly, it was found that some sequences contained the CTT addition 
and the ClaI site but no XhoI. This is odd as the XhoI site is located at the CRISPR 
ex10 cut site. Perhaps strand invasion during repair excluded the XhoI site in the 
donor. The sequence data for this particular sample is evidence that HDR has 
definitely occurred and shows that the CRISPR/Cas9/gRNA system can mediate 
repair. This is the first evidence that CRISPR gRNAs can mediate HDR in a CF cell 
line. 
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5.5.3 CRISPR IN9 gRNA HDR with the pUC-mini-gene donor 
CRISPR in9 cleaves 40 bp downstream of the ZFN cut site (see figure 5.1) and so 
was co-transfected with the mini-gene donor plasmid. A typical transfection of 
CFTE cells with CRISPR in9 gRNA, hCas9 (WT/nickase) and pUC-mini-gene is 
outlined in table 5.3. ZFNs were used as controls. 
Assay 
Plasmid (μg) 
1 2 3 4 5 6 
CRISPR in9 0.0 0.5 0.0 0.0 0.5 0.5 
hCas9 0.0 0.5 0.0 0.0 0.5 0.0 
hCasD10A 0.0 0.0 0.0 0.0 0.0 0.5 
CFi9-L
EL
 0.0 0.0 0.0 0.5 0.0 0.0 
CFi9-R
KK
 0.0 0.0 0.0 0.5 0.0 0.0 
pUC-mini-gene 0.0 0.0 3.0 3.0 3.0 3.0 
eGFP N1 3.0 0.0 0.0 0.0 0.0 0.0 
pcDNA 3.1 1.0 3.0 1.0 0.0 0.0 0.0 
Table 5.3: Amounts of plasmids used in transfection of CFTE cells 
These experiments were performed before full analysis of the ZFN and mini-gene 
experiment described in chapter 4 was completed. As before, a low level of GFP 
could be observed in transfections with CRISPR gRNAs, Cas9 and donor but not 
with donor only (data not shown). However, as shown in chapter 4, repeated 
attempts to generate a PCR product to confirm correct recombination could not be 
obtained; leading to the conclusion that HDR had not occurred completely as 
originally planned. However, when the DNA from cells treated with CRISPR IN9 
gRNA, hCas9D10A and mini-gene donor was used for deep sequence analysis, both 
the GCTAGCT tag and expected deletion of ~32 bp were detected, but no HDR 
occurred far enough to incorporate the WT cDNA.  
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The data gathered demonstrates the ability of both our CRISPR/Cas9 gRNAs to 
mediate HDR, and confirms independently our conclusion that HDR with this 
existing mini-gene will need to be re-designed. However, the fact that two CRISPR 
gRNAs were designed so easily and shown to work efficiently to mediate both 
NHEJ and HDR (in the presence of a donor plasmid), even without full 
optimisation, is very encouraging for this study. 
5.6 Conclusions: 
The aim of chapter five was to establish the latest gene editing tool, CRISPR/Cas9 
as a cheap and efficient alternative to our ZFNs to enable relocation of the cut site 
as distance was determined to be a limiting factor for HDR in chapter three. 
CRISPR gRNAs are easily designed and can be constructed within one week, 
compared to the costly design methods involved in making ZFNs.  
Here, we designed two gRNAs targeting intron 9 and exon 10 of CFTR. Both 
CRISPR gRNAs were able to efficiently cleave the desired DNA sequence as 
determined by T7E1 data (section 5.4) and deep sequencing results (section 5.4.1). 
The overall cleavage efficiency of CRISPR in9 was found to be ~2-3% while 
CRISPR ex10 cleaved at a rate of ~15-16%.  
When these CRISPR gRNAs were co-transfected with the necessary hCas9 plasmid 
and the relevant donor, HDR events were observed. CRISPR ex10 used in 
conjunction with pITR-donor-XC resulted in HDR at a rate of 1% as determined by 
deep sequencing of a single sample. Again no HDR was detected when using our 
PCR and digest analysis assays showing that these assays are not sensitive enough 
to measure HDR and so new assays will need to be developed in the future.  
The CRISPR in9 gRNA performed precise HDR by incorporating a 7 bp tag and 32 
bp deletion at an efficiency of ~1%. 
This data shows that HDR does occur in CFTE cells when transfected with our 
CRISPR/Cas gRNAs and donor plasmids.   
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For future work the obvious next step is to re-design the repair strategy so as to 
avoid any exon 10 in the homology arms of the mini-gene and to target an intronic 
region further upstream of the original ZFN cut site which will be made much easier 
using CRISPR/Cas technology. As discussed in chapter four, we initially created 
the mini-gene construct with the homology arms described because our ZFNs 
cleave close to exon 10 and so to include enough homology it was necessary to 
include this sequence. It is now possible to target a much wider range of sequences 
of the form GN20GG using CRISPR gRNAs and so we will target one of the 161 
sites of this form in the intron 9 sequence further upstream of exon 10 so as to avoid 
any crossover of homology with construct sequence. Then following cleavage, 
HDR should occur with the mini-gene cassette which will be incorporated into the 
intronic region to produce full length CFTR protein following correct splicing. 
The CRISPR/Cas system can also be used for the repair strategy using obligate 
ligation-gated recombination discussed in detail in the final discussion. This 
strategy involves adding identical CRISPR gRNA sites to the 5‟ and 3‟ end of the 
mini-gene cassette without homology arms. Then following CRISPR gRNA 
cleavage of the genome (same sequence as mini-gene gRNAs) and the mini-gene 
plasmid, the resulting overhangs should be compatible and so the mini-gene cassette 
should be inserted into intron 9 of CFTR by ligation and rely on the NHEJ repair 
pathway which is six times more efficient than HR. This strategy was used 
successfully to insert a 15 kb gene cassette into human cell lines earlier this year 
(Maresca et al., 2013). 
The data presented in this chapter clearly demonstrates the ability of our 
CRISPR/Cas gRNAs to mediate HDR in a CF cell line to correct CF-causing 
mutations. 
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6 Discussion: 
 Cystic Fibrosis (CF) is caused by mutations in the CFTR gene which leads to 
defective chloride and bicarbonate transport and dysregulation of sodium transport 
via loss of epithelium sodium channel (ENaC) inhibition by CFTR protein. The 
most serious manifestation of CF is reduced mucociliary clearance in the lung. This 
results in the development of viscous hypoxic mucus which promotes recurrent     
P. aeruginosa infections and concomitant loss of lung function. Damage to the lung 
architecture occurs from both P. aeruginosa virulence factors and increased 
neutrophil mediated necrosis resulting in inflammation.  
CF presents as a target for novel therapeutics due to reports that low level correction 
of CFTR transcript levels (5-10%) (Ramalho et al., 2002) or of defective cells 
(25%) (Zhang et al., 2009) may be sufficient to restore a normal phenotype. It is one 
of the most common monogenic diseases and since the CFTR gene was cloned in 
1989 many research efforts have been made worldwide to understand and correct 
this disease. All CFTR mutants produce mRNA transcript and aside from class I 
mutations, all other CFTR mutants produce CFTR protein. Both the transcript and 
the protein have been targeted by novel drugs such as PTC124, VX-770 and VX-
809. 
VX-770 offers help to a small subset of CF patients (4-5%) that have the G551D 
class III mutation and proved the principles that direct targeting of CF at its root 
cause and restoring CFTR protein function can be clinically beneficial (Van Goor et 
al., 2009). Interestingly, there are reports of increased efficacy of this drug in 
homozygous patients versus heterozygotes for G551D (Harrison et al., 2013). 
However, the drug is of no benefit to the majority of CF patients who have 
mutations from the other classes. Other novel compounds targeted to a subset of 
class I mutants (PTC124) and class II mutants (VX-809) have shown promise in 
small scale studies but results from large scale studies were disappointing and did 
not meet target endpoints. A combination therapy with VX-770 and VX-809 is 
currently entering phase III clinical trials. Another compound VX-661 is also under 
trial in combination with VX-770 and results released in April, 2013 from a phase II 
trial involving 128 ΔF508 homozygote CF patients showed significant 
improvements in lung function in those who received the highest dose of treatment 
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(cff.org). Development of CF drugs is a main interest of major pharmaceutical 
companies at present and given the proof-of-principle from VX-770, other drug 
companies such as Pfizer, Genzyme and Novartis are all striving to find new drugs 
to treat the disease. This interest offers new hope for CF patients.    
In contrast to development of small molecules, gene therapy trials have attempted to 
complement the defective endogenous CFTR gene with a WT cDNA copy. This 
method, if successful, would benefit all CF patients since it would restore functional 
CFTR protein to all treated cells. It would however, require repeat dosing for the 
lifetime of the CF patient. Despite numerous clinical trials over the last 20 years in 
CF patients no clinical breakthrough has been observed. The early trials did 
demonstrate that viral delivery of transgenes to patients could be achieved. 
However, the AAV and AdV vector used did not effectively deliver the CFTR 
transgene to a significant number of cells, nor was the response sustainable with 
repeat dosing. The low level of transduction of these viral vectors was attributed to 
the lack of specific AdV/AAV receptors on the apical surface of the cell and the 
onset of an immune response to these virus vectors made repeat dosing difficult. To 
avoid repeat dosing an option would be to target progenitor cells since the corrected 
cells at the lung surface will be lost quickly, this would allow long term correction. 
Recently, a study has shown that both rAAV1 and rAAV5 are capable of 
preferentially transducing conducting airway epithelial progenitor cells that had the 
ability to clonally expand in vivo following lung injury in a mouse model (Liu et al., 
2009).  
Non-viral vectors are being explored as an alternative delivery method to viral 
vectors. The UK CF gene therapy consortium is continuously conducting CF gene 
therapy clinical trials and has developed a CFTR-expressing plasmid complexed 
with a cationic lipid. GL67A was the most effective agent, and the CFTR 
expression vector has been modified to induce prolonged expression (up to at least 
2 months) and rendered CpG free to avoid an immune response. A current phase 
IIB clinical trial is assessing the clinical benefit of repeat dosing of nebulised CFTR 
gene therapy over a 12 month period (Alton et al., 2013). 
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An alternative approach to cDNA addition is to try and correct the endogenous 
defective gene in the affected tissue using nuclease-mediated homology directed 
repair (HDR). Designer nucleases, such as zinc finger nucleases (ZFNs) and the 
RNA-guided CRISPR/Cas9 system, can be used to create site-specific double-
stranded breaks (DSB). This DSB can then be repaired using the cells own repair 
machinery, (homologous recombination) and a donor DNA sequence to result in the 
incorporation of the correct sequence into the genome. This method will still require 
efficient delivery of the nucleases and donor DNA sequence to progenitor cells to 
provide long term correction of the lung. However, once the endogenous gene of a 
progenitor cell is corrected it is permanent for the lifetime of that cell, meaning 
there is no requirement for repeat administration to that particular cell making it an 
attractive alternative to cDNA addition. The repair of an endogenous locus also 
conserves tissue specific and temporal control of expression as well as expression of 
natural splice variants.  
This body of work provides the first clear evidence that ZFNs and CRISPR gRNAs 
can successfully induce HDR between a donor repair plasmid and genomic DNA in 
a CF cell line. In chapter three, correction of the most common CF causing 
mutation, ΔF508, was achieved using our ZFNs and pITR-donors at a level of ~2% 
of transfected cells. This level of HDR was relatively successful for a first attempt 
and an obvious next step was to design a new pair of ZFNs closer to the CTT 
deletion to improve on this level as distance was determined to be a limiting factor. 
However, as this would be time consuming and ZFN design has a low success rate 
two different options were subsequently explored in this thesis:  
1) the position of the ZFNs in intron 9 was exploited and used as a site for 
recombination of a mini-gene construct comprising exons 10-24 from CFTR 
cDNA (with appropriate splice acceptor and poly A sites) to allow 
production of full length corrected CFTR mRNA and enable the correction 
of a much wider range of CF-causing mutations as described in chapter 4. 
2) Another gene-editing tool, CRISPR/Cas9 RNA-guided system, which is 
more amenable to changing location, was explored as described in chapter 5. 
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The principle of recombination at the ZFN cut site was established by successfully 
introducing a 7 bp tag into this site in chapter four. NGS data from subsequent 
transfections with the ZFNs and mini-gene donor showed that some HDR had 
occurred with the mini-gene donor as determined from introduction of the 7 bp tag 
and 32 bp deletion as predicted but CTT remained uncorrected suggesting that HR 
had not extended far enough to incorporate the entire construct. We know now from 
this data that in order for our mini-gene strategy to be successful, the cut site needs 
to be moved further into intron 9 see figure 6.1.  
 
Figure 6.1: Schematic representation of new mini-gene repair strategy.  
This new mini-gene construct will be designed to contain homology arms to intron 
9 only and a new cut site will be introduced using CRISPR gRNAs. The ease of 
design and use of CRISPR/Cas was displayed in chapter five whereby two new 
target sites were successfully cleaved and used with existing donor repair plasmids 
to induce HDR to repair the ΔF508 mutation in the CF cell line. This is the very 
first evidence of successful use of the CRISPR/Cas9 system to correct the ΔF508 
mutation in a CF cell line. 
As an alternative to the strategy above, in future studies the use of the so-called 
ObLiGaRe strategy to integrate the mini-gene into the target site by NHEJ will be 
explored. This method takes advantage of the overhangs produced following 
cleavage. If each end of the mini-gene contains the same CRISPR gRNA target 
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sequence to that in the genome then upon successful cleavage of all three sites by 
CRISPR/Cas9, complementary overhangs will be produced allowing direct ligation 
of the mini-gene into the cut site. Using this strategy eliminates the need for 
homology arms and relies on the NHEJ pathway which occurs six times more 
frequently than the HR pathway. 
To determine whether distance from cut site is a limiting factor in HDR, new 
donors could be constructed containing multiple restriction site markers at various 
distances from the cut site, much like the pITR-donor-XC plasmid. Co-transfection 
of these plasmids with ZFNs and analysis by NGS would then give an idea of the 
effects of distance on HDR efficiency. To avoid too much sequence divergence, 
multiple plasmids with one restriction site marker in each could be used.  
To be of future clinical benefit, the possibility of off-target events will need to be 
assessed. As discussed in section 1.9, off-target cleavage can lead to mutagenesis 
and cancers. Similar sequences, differing from one or more base pairs, to the one 
being targeted are potential off-target sites, therefore a number of modifications 
have been developed to try and prevent the FokI domain of ZFNs and TALENs 
from off-target cutting. The FokI domain of the ZFNs used in this project were 
modified by a former colleague in such a way so that they can only cleave as 
heterodimers and a subsequent toxicity assay showed them to be non-toxic in cells 
(Lee et al., 2012). It will be necessary in the future to look at the incidence of off-
target sites induced by our ZFNs. A number of methods have been developed to do 
this. An in vitro cleavage site selection assay was developed by Pattanayak et al., 
(2011) to identify sequences from a large partially degenerate library, based on 
intended target DNA sites that can be cleaved by ZFNs targeting the CCR5 gene. 
They identified 36 potential off-target sites and analysis of these sites in the human 
genome revealed that nine off-target sites were cleaved (Pattanayak et al., 2011). 
Another method exploits the incorporation of integrase-deficient lentivirus DNAs 
into nuclease-induced DSBs to map ZFN cleavage sites in human cells. Gabriel et 
al., (2011) applied this approach to the same CCR5-targeted ZFNs characterised in 
the Pattanayak study and identified four off-target genomic sites (Gabriel et al., 
2011). Only one site was common in both of these studies suggesting that neither 
method can identify all possible off-target sites. A recent study has shown the in 
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silico method to provide an improved approach to screen the genome for potential 
off-target sites. Looking at the same ZFNs as the previous two groups, they 
identified the previously described sites as well as dozens of additional sites (Sander 
et al., 2013). Therefore, it may take a combination of methods in order to identify 
all possible sites. 
As for the new CRISPR/Cas9 system, there have been varying reports regarding 
specificity. A recent study suggests that CRISPR gRNAs can be highly active even 
at imperfectly matched DNA interfaces (Fu et al., 2013). If these nucleases are to be 
of clinical benefit in the future then the specificity will need to be improved. An 
obvious approach would be to increase the length of the target site; however, studies 
have shown that increasing the guide sequence mediates similar levels of 
modification and does not improve targeting specificity (Ran et al., 2013). The 
same group went on to explore the potential of Cas9 nickases to increase specificity. 
They reasoned that two Cas9-nicking enzymes directed by a pair of gRNAs 
targeting the opposite strands of a target locus could mediate DSBs and reduce off-
target activity. The double nickase technique was able to generate similar levels of 
on-target modifications as produced with the WT Cas9. However, when they looked 
at the same sites which had been cleaved off-target by WT Cas9 they found that 
double nickase did not generate detectable cleavage, suggesting that this technique 
can potentially reduce off-target events. Our future studies on CF will explore the 
use of the double nickase technique. 
In our approach to correct CF causing mutations, the use of positive selection was 
avoided so that the donor plasmids would only contain the correct sequence of the 
genomic DNA being corrected. This makes enrichment and screening of cells that 
have been corrected difficult, hence one reason why the mini-gene was tagged with 
a GFP sequence. If patients‟ own cells were to be treated ex vivo then a selection 
cassette could be useful in order to target and enrich corrected cells. Conventional 
selection cassettes such as antibiotic resistance genes are flanked by loxP or 
Flp/FRT sites so that upon correction these cassettes can be excised from the 
genome. This presents its own problems in that small ectopic sequences that remain 
can interfere with the transcriptional regulatory elements of surrounding genes 
(Meier et al., 2010). A recent study combined ZFNs and piggyBac technology to 
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correct a point mutation in human iPS cells. PiggyBac works by converting 
selection cassettes into transposons and so enables the removal of cassettes flanked 
by PiggyBac inverted repeats without leaving any residual sequences (Yusa et al., 
2011). One could speculate that the same could be done using CRISPR gRNAs. 
Having shown that ZFN and CRISPR-mediated HDR repair of ΔF508 is possible, 
there are a few experiments which appear to be the next obvious step. First of all, 
treated cells should be probed to see if the corrected CFTR is expressed at the apical 
cell surface. Antibody staining followed by Z-stacking multiple microscopic images 
can determine whether CFTR has translocated to the cell surface, something that 
ΔF508 CFTR cannot do. Some preliminary studies were performed using CFTR 
expressing plasmids and GFP to ascertain whether our CFTR antibodies work and 
whether it can be detected at the apical membrane, (see appendix). The next step 
would be to validate the activity of corrected CFTR using functional assays to 
measure: 1) Cl
-
 flux by patch clamp analysis to directly measure channel activity in 
individual cells and Ussing chambers to measure changes in short circuit current on 
a population of corrected cells and 2) ASL height using confocal microscopy. Both 
the Ussing chamber and ASL assays could be used to determine the minimum 
number of cells which need to be corrected to reach normal values. 
Having shown herein that our nuclease-mediated HDR method can correct CFTR at 
the genomic level, the data gathered from the assays above will validate that this 
correction can restore normal Cl- flux to CF cells. The ability to restore normal Cl
- 
flux is crucial for establishing normal mucociliary clearance in the CF lung. This 
will ultimately decide whether this approach can be of clinical benefit. Correction 
of the underlying genetic defect in CFTR via nuclease-mediated HDR presents a 
significant first step towards achieving a realistic alternative to gene 
complementation.   
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8  Appendix: 
8.1 Functional Assay: Immunofluorescence for detection of CFTR 
protein trafficking 
The CFTE cell line is homozygous for the ΔF508 mutation which causes CFTR to 
become trapped in the ER and degraded before reaching the apical membrane. We 
know from chapters 3-5 that our ZFNs and CRISPR gRNAs can mediate HDR with 
the appropriate donor plasmids but it remains to be formally established if this 
genetic repair leads to functional CFTR protein trafficking from the ER to the apical 
membrane that will allow normal ion flux and restore ASL. 
To monitor CFTR trafficking we sought to stain the protein with appropriate 
antibodies and visualise its expression in cells using confocal microscopy. As a 
large population of cells would need to be screened with only a few being corrected 
given that the HDR rate is at 1-2%, it would be quite difficult and labour intensive 
to identify corrected cells, which is in part why we developed the mini-gene donor. 
Originally it was thought that using our mini-gene donor which contains the GFP 
tag would allow easier detection of CFTR corrected cells as GFP will be made 
following CFTR production and so a green cell should contain corrected CFTR at 
the apical membrane. However, the deep sequencing results revealed that the GFP 
signal detected in this instance was an artefact, and so could not be used. 
Nonetheless, attempts were made to establish the assay using the pCEP-CFTR 
plasmid, (which persists in cells and contains the CFTR cDNA under the control of 
a CMV promoter), transfected in CFTE cells homozygous for the ΔF508 mutation. 
pCEP-CFTR was co-transfected with pEGFP, the idea being that if a cell took up 
the EGFP plasmid then it most likely took up the pCEP-CFTR plasmid also and so 
green cells should show some CFTR at the apical membrane.  
CFTR antibodies have a reputation for being difficult to use and distinguishing real 
versus background signal can be problematic. The naturally low abundance of WT 
CFTR can also make it difficult to detect. This section describes our attempts to 
establish a CFTR trafficking assay using the CFTR 596 antibody, obtained from 
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Jack Riordan‟s lab in North Carolina, to be used for future functional studies and 
some of the problems encountered. 
8.2  Transfection of CFTE cells with pCEP-CFTR and pEGFP 
CFTE cells were seeded on 13mm coverslips and transfected with 2 μg of pCEP-
CFTR and 2 μg of pEGFP. Following 72 hrs incubation, cells were stained for 
CFTR using primary CFTR 596 antibody and the goat anti-mouse IgG Cy3 
secondary antibody. 
CFTE cells which take up pCEP-CFTR plasmid should now express full length 
CFTR which should be trafficked correctly to the apical membrane of the cell. Cells 
transfected with both pCEP-CFTR and pEGFP should contain some cells which 
express both plasmids and so a green cell will should also contain CFTR at the 
apical membrane. Cells transfected with both pEGFP and pCEP-CFTR were used to 
represent what is expected to be observed if the mini-gene donor was correctly 
recombined into the genome to produce functional CFTR and also GFP due to the 
T2A linker. It is highly likely that the GFP positive cells also contain pCEP-CFTR.  
 In order to visually ascertain which cells contain WT CFTR, the distribution of the 
protein was used as a marker. The idea was that mutant CFTR will be trapped in the 
ER and so should be located close to the nucleus whereas corrected/pCEP-CFTR 
derived CFTR should be more spread out in the cell and mainly located at the apical 
membrane. 
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Figure 8.1: CFTE cells stained for CFTR (red), nucleus (blue) and GFP. Top image shows cells 
stained for CFTR and DAPI only. Bottom image shows same cells with GFP fluorescence added. 
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The images in figure 8.1 represent CFTE cells transfected as outlined above. The 
secondary Cy3 stains CFTR red and can be seen in all transfected cells as expected. 
DAPI stains the nucleus blue, while GFP fluoresces under the correct UV light.  In 
the top image, where only CFTR and nuclei are stained, there is evidence of CFTR 
trapping in some cells whereby there is an abundance of CFTR stained in close 
proximity to the nucleus. In the bottom image, four GFP positive cells can be seen 
in the centre of the image. When these four cells are compared to the same four 
cells in the top image there seems to be a different distribution of CFTR. Rather 
than being packed tightly close to the nucleus, it now appears to be more spread out 
throughout the cell. This implies that these cells contain both pEGFP and pCEP-
CFTR and so WT CFTR is being trafficked to the apical membrane. However, there 
are some cells where the signal is ambiguous with a similar appearance to the GFP 
positive cells but contain no GFP. 
It was hoped that the visual difference in distribution of CFTR would be used as a 
marker when searching for corrected cells in a population and the GFP tag in the 
newly designed mini-gene construct will allow rapid and accurate identification of 
repair. This work is not conclusive and further analysis needs to be done before it 
can be used as a functional assay, however, it does confirm that the CFTR antibody 
works and can be used to stain for CFTR in our CFTE cell line. 
To improve the assay further, polarised cells could be used and a tight junction 
staining for ZO-1 applied in order to locate the apical membrane and determine how 
much CFTR is present. Z-stacking of multiple microscopic images would give a 3D 
view of the cell and allow better visualisation of the CFTR at the membrane. As the 
number of corrected cells will be low, the GFP tag in the mini-gene donor will 
greatly aid detecting and monitoring the trafficking of CFTR. 
If time allowed I would like to explore an alternative assay for CFTR functional 
studies, that of measuring ASL (see section 1.1.4). By measuring the height of ASL, 
one could determine whether CFTR is functional at the apical membrane. WT 
CFTR allows correct movement of Cl
-
 ions and by osmosis water through the 
membrane both which determine the ASL height. Following transfection with our 
nucleases and donor plasmids the ASL could be monitored for height changes by 
 175 
 
immune-staining. Alternatively, by adding a dye like phenol red into the apical 
compartment and monitoring changes in the O.D. reading of the fluid could give an 
indication of whether more fluid is in the ASL following transfection due to 
nuclease induced HDR. 
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